Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2225709,plasma half-life,"However, the plasma half-life of demethyldiazepam was longer in poor metabolizers than in extensive metabolizers of mephenytoin (mean +/- SD: 161 +/- 37 and 116 +/- 29 hours, respectively; p less than 0.02).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,161,402,DB00829,Diazepam
,2225709,plasma half-life,"However, the plasma half-life of demethyldiazepam was longer in poor metabolizers than in extensive metabolizers of mephenytoin (mean +/- SD: 161 +/- 37 and 116 +/- 29 hours, respectively; p less than 0.02).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,116,403,DB00829,Diazepam
,2225709,plasma half-life,"The mean plasma half-life values of diazepam in Chinese extensive metabolizers (85.1 hours) and poor metabolizers (88.3 hours) were very similar to those in white subjects who were poor metabolizers (88.3 hours), and more than twice those in white subjects who were extensive metabolizers (40.8 hours).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,85.1,404,DB00829,Diazepam
,2225709,plasma half-life,"The mean plasma half-life values of diazepam in Chinese extensive metabolizers (85.1 hours) and poor metabolizers (88.3 hours) were very similar to those in white subjects who were poor metabolizers (88.3 hours), and more than twice those in white subjects who were extensive metabolizers (40.8 hours).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,88.3,405,DB00829,Diazepam
,2225709,plasma half-life,"The mean plasma half-life values of diazepam in Chinese extensive metabolizers (85.1 hours) and poor metabolizers (88.3 hours) were very similar to those in white subjects who were poor metabolizers (88.3 hours), and more than twice those in white subjects who were extensive metabolizers (40.8 hours).",Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225709/),h,40.8,406,DB00829,Diazepam
,27481567,flow rate,"The analyte and internal standard were extracted by acetone and then separated on a polar 2-ethylpyridine phase column (100 mm × 3 mm, 1.7 μm) at a flow rate of 1.0 mL/min using CO2 (≥99.99%) and methanol (95:5, v/v) as the mobile phase.",Supercritical fluid chromatography with tandem mass spectrometry combined with postcolumn compensation and one-step acetone protein precipitation to evaluate the bioavailability of probucol solid dispersion tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27481567/),[ml] / [min],1.0,1004,DB00829,Diazepam
,27481567,m/z,"The mass transition ion-pair was m/z 515.6→236.2 and 285.2→193.1 for probucol and internal standard, respectively.",Supercritical fluid chromatography with tandem mass spectrometry combined with postcolumn compensation and one-step acetone protein precipitation to evaluate the bioavailability of probucol solid dispersion tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27481567/),,515.6,1005,DB00829,Diazepam
,27481567,m/z,"The mass transition ion-pair was m/z 515.6→236.2 and 285.2→193.1 for probucol and internal standard, respectively.",Supercritical fluid chromatography with tandem mass spectrometry combined with postcolumn compensation and one-step acetone protein precipitation to evaluate the bioavailability of probucol solid dispersion tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27481567/),,236.2,1006,DB00829,Diazepam
,27481567,m/z,"The mass transition ion-pair was m/z 515.6→236.2 and 285.2→193.1 for probucol and internal standard, respectively.",Supercritical fluid chromatography with tandem mass spectrometry combined with postcolumn compensation and one-step acetone protein precipitation to evaluate the bioavailability of probucol solid dispersion tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27481567/),,285.2,1007,DB00829,Diazepam
,2866097,spectral dissociation constant (Ks),"Cimetidine induced binding changes with a spectral dissociation constant (Ks) of 0.87 mM, whereas famotidine produced no measurable spectral alteration in concentrations up to 4 mM.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),mM,0.87,1804,DB00829,Diazepam
,2866097,elimination half-life (t1/2,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,45.6,1805,DB00829,Diazepam
,2866097,total plasma clearance (CL,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [kg·min],0.28,1806,DB00829,Diazepam
,2866097,t1/2,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,39.0,1807,DB00829,Diazepam
,2866097,CL,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [kg·min],0.31,1808,DB00829,Diazepam
,2866097,t1/2,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,2.9,1809,DB00829,Diazepam
,2866097,t1/2,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,3.0,1810,DB00829,Diazepam
,2866097,renal clearance (CLR),"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],436,1811,DB00829,Diazepam
,2866097,renal clearance (CLR),"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],443,1812,DB00829,Diazepam
,2866097,CLR,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],195,1813,DB00829,Diazepam
,2866097,CLR,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],212,1814,DB00829,Diazepam
,10707114,elimination half life,There was a significant (p < 0.05) increase in mean elimination half life (2.39 +/- 0.42 to 3.59 +/- 0.35 h) following ibuprofen and diazepam administration compared to ibuprofen alone administered at 22.00 hours.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),h,2.39,4552,DB00829,Diazepam
,10707114,elimination half life,There was a significant (p < 0.05) increase in mean elimination half life (2.39 +/- 0.42 to 3.59 +/- 0.35 h) following ibuprofen and diazepam administration compared to ibuprofen alone administered at 22.00 hours.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),h,3.59,4553,DB00829,Diazepam
,10707114,clearance,The mean clearance of ibuprofen was therefore lowered from 62.7 +/- 8.9 to 41.7 +/- 2.6 ml/h/kg under the influence of diazepam during the night.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),[ml] / [h·kg],62.7,4554,DB00829,Diazepam
,10707114,clearance,The mean clearance of ibuprofen was therefore lowered from 62.7 +/- 8.9 to 41.7 +/- 2.6 ml/h/kg under the influence of diazepam during the night.,Time dependent influence of diazepam on the pharmacokinetics of ibuprofen in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707114/),[ml] / [h·kg],41.7,4555,DB00829,Diazepam
,7550984,detection limit,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),[ng] / [ml],2,6147,DB00829,Diazepam
,7550984,signal-to-noise ratio,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),,3,6148,DB00829,Diazepam
>,7550984,Recoveries,Recoveries of the analytes and the internal standard (prazepam) were > 82%.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,82,6149,DB00829,Diazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,3.9,6150,DB00829,Diazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,6.6,6151,DB00829,Diazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,2.8,6152,DB00829,Diazepam
,22819204,m/,"The quantification was performed using the transitions of m/z 309.1/185.0 for 1-acetoxy-6α-hydroxyeriolanolide, m/z 249.0/231.1 for 1β-hydroxyalantolactone and ivangustin and m/z 285.0/193.0 for diazepam, respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),,309.1,6690,DB00829,Diazepam
,22819204,m/,"The quantification was performed using the transitions of m/z 309.1/185.0 for 1-acetoxy-6α-hydroxyeriolanolide, m/z 249.0/231.1 for 1β-hydroxyalantolactone and ivangustin and m/z 285.0/193.0 for diazepam, respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),,185.0,6691,DB00829,Diazepam
,22819204,m/z,"The quantification was performed using the transitions of m/z 309.1/185.0 for 1-acetoxy-6α-hydroxyeriolanolide, m/z 249.0/231.1 for 1β-hydroxyalantolactone and ivangustin and m/z 285.0/193.0 for diazepam, respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),,249.0,6692,DB00829,Diazepam
,22819204,m/z,"The quantification was performed using the transitions of m/z 309.1/185.0 for 1-acetoxy-6α-hydroxyeriolanolide, m/z 249.0/231.1 for 1β-hydroxyalantolactone and ivangustin and m/z 285.0/193.0 for diazepam, respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),,231.1,6693,DB00829,Diazepam
,22819204,m/z,"The quantification was performed using the transitions of m/z 309.1/185.0 for 1-acetoxy-6α-hydroxyeriolanolide, m/z 249.0/231.1 for 1β-hydroxyalantolactone and ivangustin and m/z 285.0/193.0 for diazepam, respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),,285.0,6694,DB00829,Diazepam
,22819204,m/z,"The quantification was performed using the transitions of m/z 309.1/185.0 for 1-acetoxy-6α-hydroxyeriolanolide, m/z 249.0/231.1 for 1β-hydroxyalantolactone and ivangustin and m/z 285.0/193.0 for diazepam, respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),,193.0,6695,DB00829,Diazepam
,22819204,limit of detection (LOD),"The limit of detection (LOD) was 1 ng/mL for 1-acetoxy-6α-hydroxyeriolanolide, 1.6 ng/mL for 1β-hydroxyalantolactone and ivangustin (S/N=3).",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),[ng] / [ml],1,6696,DB00829,Diazepam
,22819204,limit of detection (LOD),"The limit of detection (LOD) was 1 ng/mL for 1-acetoxy-6α-hydroxyeriolanolide, 1.6 ng/mL for 1β-hydroxyalantolactone and ivangustin (S/N=3).",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),[ng] / [ml],1.6,6697,DB00829,Diazepam
,22819204,S/N,"The limit of detection (LOD) was 1 ng/mL for 1-acetoxy-6α-hydroxyeriolanolide, 1.6 ng/mL for 1β-hydroxyalantolactone and ivangustin (S/N=3).",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),,3,6698,DB00829,Diazepam
,22819204,t(½),"The method was successfully applied to pharmacokinetic studies of the three sesquiterpene lactones after oral administration of 300 mg/kg Herba Inula extract to rats, the t(½) of 1-acetoxy-6α-hydroxyeriolanolide, 1β-hydroxyalantolactone and ivangustin was 9.65±1.43, 14.88±0.82 and 13.93±2.74 (h).",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),h,9.65,6699,DB00829,Diazepam
,22819204,t(½),"The method was successfully applied to pharmacokinetic studies of the three sesquiterpene lactones after oral administration of 300 mg/kg Herba Inula extract to rats, the t(½) of 1-acetoxy-6α-hydroxyeriolanolide, 1β-hydroxyalantolactone and ivangustin was 9.65±1.43, 14.88±0.82 and 13.93±2.74 (h).",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),h,14.88,6700,DB00829,Diazepam
,22819204,t(½),"The method was successfully applied to pharmacokinetic studies of the three sesquiterpene lactones after oral administration of 300 mg/kg Herba Inula extract to rats, the t(½) of 1-acetoxy-6α-hydroxyeriolanolide, 1β-hydroxyalantolactone and ivangustin was 9.65±1.43, 14.88±0.82 and 13.93±2.74 (h).",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),h,13.93,6701,DB00829,Diazepam
,22819204,AUC((0-t)),"The AUC((0-t)) of 1-acetoxy-6α-hydroxyeriolanolide, 1β-hydroxyalantolactone and ivangustin was 1102.46±247.04, 808.92±117.53 and 990.35±275.49 (ng h/mL), respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),[h·ng] / [ml],1102.46,6702,DB00829,Diazepam
,22819204,AUC((0-t)),"The AUC((0-t)) of 1-acetoxy-6α-hydroxyeriolanolide, 1β-hydroxyalantolactone and ivangustin was 1102.46±247.04, 808.92±117.53 and 990.35±275.49 (ng h/mL), respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),[h·ng] / [ml],808.92,6703,DB00829,Diazepam
,22819204,AUC((0-t)),"The AUC((0-t)) of 1-acetoxy-6α-hydroxyeriolanolide, 1β-hydroxyalantolactone and ivangustin was 1102.46±247.04, 808.92±117.53 and 990.35±275.49 (ng h/mL), respectively.",Simultaneous determination of three sesquiterpene lactones from Herba Inula extract in rat plasma by LC/MS/MS and its application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22819204/),[h·ng] / [ml],990.35,6704,DB00829,Diazepam
,7075421,lag time,"After a lag time averaging 12 min elapsed between tablet ingestion and the start of absorption, first-order absorption proceeded with a mean half-life of 19 min (range: 0--96 min), with peak plasma concentrations reached 0.9 hr after dosage (range: 0.25--2.5 hr).","Diazepam absorption: effects of age, sex, and Billroth gastrectomy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075421/),min,12,7104,DB00829,Diazepam
,7075421,half-life,"After a lag time averaging 12 min elapsed between tablet ingestion and the start of absorption, first-order absorption proceeded with a mean half-life of 19 min (range: 0--96 min), with peak plasma concentrations reached 0.9 hr after dosage (range: 0.25--2.5 hr).","Diazepam absorption: effects of age, sex, and Billroth gastrectomy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075421/),min,19,7105,DB00829,Diazepam
,7075421,peak plasma concentrations,"After a lag time averaging 12 min elapsed between tablet ingestion and the start of absorption, first-order absorption proceeded with a mean half-life of 19 min (range: 0--96 min), with peak plasma concentrations reached 0.9 hr after dosage (range: 0.25--2.5 hr).","Diazepam absorption: effects of age, sex, and Billroth gastrectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075421/),h,0.9,7106,DB00829,Diazepam
,7075421,Peak plasma concentrations,"Peak plasma concentrations averaged 157 ng/ml, and tended to be higher in women than in men because of lower body weights in women.","Diazepam absorption: effects of age, sex, and Billroth gastrectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075421/),[ng] / [ml],157,7107,DB00829,Diazepam
,7075421,bioavailability,"Based on areas under the oral versus intravenous plasma concentration curve, bioavailability of diazepam averaged 97%.","Diazepam absorption: effects of age, sex, and Billroth gastrectomy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075421/),%,97,7108,DB00829,Diazepam
,7870919,pseudo steady state levels,Breath alcohol reached pseudo steady state levels of 0.38 g/l (range: 0.24-0.57) after alcohol alone and 0.37 g/l (range: 0.27-0.52) in combination with diazepam.,Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7870919/),[g] / [l],0.38,7352,DB00829,Diazepam
,7870919,pseudo steady state levels,Breath alcohol reached pseudo steady state levels of 0.38 g/l (range: 0.24-0.57) after alcohol alone and 0.37 g/l (range: 0.27-0.52) in combination with diazepam.,Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7870919/),[g] / [l],0.37,7353,DB00829,Diazepam
,10328567,bioavailability,Peak concentration was achieved after 18+/-11 min and the bioavailability was 50.4+/-23.3%.,Intranasal administration of diazepam aiming at the treatment of acute seizures: clinical trials in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10328567/),%,50.4,8523,DB00829,Diazepam
,6127197,time to peak,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,2.99,10627,DB00829,Diazepam
,6127197,elimination half-life,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,14.7,10628,DB00829,Diazepam
,32338380,time to mean,"Diazepam pharmacokinetic profiles were similar under both conditions, with approximately 2-hour median time to mean (SD) maximum plasma concentrations of 164 (88) and 189 (110) ng/mL for ictal/peri-ictal and interictal conditions, respectively; drug exposure during the first 6 hours postdosing was 532 (313) and 615 (368) h•ng/mL, respectively.","Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32338380/),[ng] / [ml],164,12493,DB00829,Diazepam
,32338380,time to mean,"Diazepam pharmacokinetic profiles were similar under both conditions, with approximately 2-hour median time to mean (SD) maximum plasma concentrations of 164 (88) and 189 (110) ng/mL for ictal/peri-ictal and interictal conditions, respectively; drug exposure during the first 6 hours postdosing was 532 (313) and 615 (368) h•ng/mL, respectively.","Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32338380/),[ng] / [ml],189,12494,DB00829,Diazepam
,32338380,exposure,"Diazepam pharmacokinetic profiles were similar under both conditions, with approximately 2-hour median time to mean (SD) maximum plasma concentrations of 164 (88) and 189 (110) ng/mL for ictal/peri-ictal and interictal conditions, respectively; drug exposure during the first 6 hours postdosing was 532 (313) and 615 (368) h•ng/mL, respectively.","Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32338380/),[h·ng] / [ml],532,12495,DB00829,Diazepam
,32338380,exposure,"Diazepam pharmacokinetic profiles were similar under both conditions, with approximately 2-hour median time to mean (SD) maximum plasma concentrations of 164 (88) and 189 (110) ng/mL for ictal/peri-ictal and interictal conditions, respectively; drug exposure during the first 6 hours postdosing was 532 (313) and 615 (368) h•ng/mL, respectively.","Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32338380/),[h·ng] / [ml],615,12496,DB00829,Diazepam
,11920923,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 991 and 839 ng x ml(-1) for seizure terminated and not terminated, respectively.",Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],991,13442,DB00829,Diazepam
,11920923,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 991 and 839 ng x ml(-1) for seizure terminated and not terminated, respectively.",Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],839,13443,DB00829,Diazepam
,11920923,plasma Cmax,The plasma Cmax in seizure-terminated animals in this study is similar to the minimum range of plasma diazepam (200-800 ng x ml(-1)) reported to suppress seizure activity in humans.,Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],200-800,13444,DB00829,Diazepam
,11920923,Cmax,It has been reported in an earlier study that the minimum effective i.m. dose (0.1 mg x kg(-1)) required to prevent soman-induced convulsions in Rhesus monkeys produces a mean Cmax of 50 ng x ml(-1) for diazepam.,Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920923/),[ng] / [ml],50,13445,DB00829,Diazepam
below,24114833,polydispersity index,The characterization revealed the small spherical droplets in the range 195 -220 nm with polydispersity index below 0.15 and zeta potential between -30 and - 60 mV.,Experimental design in formulation of diazepam nanoemulsions: physicochemical and pharmacokinetic performances. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114833/),,0.15,13581,DB00829,Diazepam
,24114833,zeta potential,The characterization revealed the small spherical droplets in the range 195 -220 nm with polydispersity index below 0.15 and zeta potential between -30 and - 60 mV.,Experimental design in formulation of diazepam nanoemulsions: physicochemical and pharmacokinetic performances. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114833/),m,60,13582,DB00829,Diazepam
,11522481,C(max),"Besides very moderate prolongation of drug release, the submicron emulsion as a vehicle did not alter pharmacokinetics of diazepam when compared with the solution: the mean C(max) was 48.9+/-24.0 and 49.5+/-17.0 ng/ml, and area under the curve was 134.0+/-42.3 and 186.8+/-59.8 ng h/ml, for solution and emulsion, respectively.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),[ng] / [ml],48.9,14048,DB00829,Diazepam
,11522481,C(max),"Besides very moderate prolongation of drug release, the submicron emulsion as a vehicle did not alter pharmacokinetics of diazepam when compared with the solution: the mean C(max) was 48.9+/-24.0 and 49.5+/-17.0 ng/ml, and area under the curve was 134.0+/-42.3 and 186.8+/-59.8 ng h/ml, for solution and emulsion, respectively.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),[ng] / [ml],49.5,14049,DB00829,Diazepam
,11522481,area under the curve,"Besides very moderate prolongation of drug release, the submicron emulsion as a vehicle did not alter pharmacokinetics of diazepam when compared with the solution: the mean C(max) was 48.9+/-24.0 and 49.5+/-17.0 ng/ml, and area under the curve was 134.0+/-42.3 and 186.8+/-59.8 ng h/ml, for solution and emulsion, respectively.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),[h·ng] / [ml],134.0,14050,DB00829,Diazepam
,11522481,area under the curve,"Besides very moderate prolongation of drug release, the submicron emulsion as a vehicle did not alter pharmacokinetics of diazepam when compared with the solution: the mean C(max) was 48.9+/-24.0 and 49.5+/-17.0 ng/ml, and area under the curve was 134.0+/-42.3 and 186.8+/-59.8 ng h/ml, for solution and emulsion, respectively.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),[h·ng] / [ml],186.8,14051,DB00829,Diazepam
,11522481,relative bioavailability,"The low relative bioavailability, 47% compared to the solution, was observed after administration of SLN.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),%,47,14052,DB00829,Diazepam
,3930095,limit of detection,The limit of detection in serum is about 10 micrograms/L for each drug.,"Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),[μg] / [l],10,15853,DB00829,Diazepam
,3930095,Analytical recovery,"Analytical recovery of each drug added to the serum varied from 91 to 102% for oxazepam and temazepam, from 82 to 99% for nordiazepam and diazepam.","Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),%,91 to 102,15854,DB00829,Diazepam
,3930095,Analytical recovery,"Analytical recovery of each drug added to the serum varied from 91 to 102% for oxazepam and temazepam, from 82 to 99% for nordiazepam and diazepam.","Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),%,82 to 99,15855,DB00829,Diazepam
,2328309,t1/2,"The control t1/2, CL and Vd of HI-offere 27 min, 8.6 ml min-1 kg-1 and 0.34 l kg-1, respectively.","Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),min,27,16343,DB00829,Diazepam
,2328309,CL,"The control t1/2, CL and Vd of HI-offere 27 min, 8.6 ml min-1 kg-1 and 0.34 l kg-1, respectively.","Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),[ml] / [kg·min],8.6,16344,DB00829,Diazepam
,2328309,Vd,"The control t1/2, CL and Vd of HI-offere 27 min, 8.6 ml min-1 kg-1 and 0.34 l kg-1, respectively.","Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),[l] / [kg],0.34,16345,DB00829,Diazepam
,2328309,t1/2,Methoxyflurane anesthesia resulted in a significant increase in the HI-6 t1/2 to 61 min concomitant with a decrease in the CL to 4.1 ml min-1 kg-1 with no change in the Vd.,"Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),min,61,16346,DB00829,Diazepam
,2328309,CL,Methoxyflurane anesthesia resulted in a significant increase in the HI-6 t1/2 to 61 min concomitant with a decrease in the CL to 4.1 ml min-1 kg-1 with no change in the Vd.,"Pharmacokinetics of the acetylcholinesterase oxime reactivator, HI-6, in rhesus monkeys (Macaca mulatta): effect of atropine, diazepam, and methoxyflurane anesthesia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328309/),[ml] / [kg·min],4.1,16347,DB00829,Diazepam
,9105544,plasma radioactivity,"In normal skin mice and rabbits, the plasma radioactivity peaked at 8 h (40.8 ng eq./ml) and at 12 h (34.0 ng eq./ml) after application, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),[eq·ng] / [ml],40.8,17098,DB00829,Diazepam
,9105544,plasma radioactivity,"In normal skin mice and rabbits, the plasma radioactivity peaked at 8 h (40.8 ng eq./ml) and at 12 h (34.0 ng eq./ml) after application, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),[eq·ng] / [ml],34.0,17099,DB00829,Diazepam
,9105544,Percutaneous absorption,"Percutaneous absorption of 14C-Am-80 was less than 2% of the dose for dogs, 34% for mice and 23% for rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,34,17100,DB00829,Diazepam
,9105544,Percutaneous absorption,"Percutaneous absorption of 14C-Am-80 was less than 2% of the dose for dogs, 34% for mice and 23% for rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,23,17101,DB00829,Diazepam
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,2.4,17102,DB00829,Diazepam
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,7.2,17103,DB00829,Diazepam
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,4.1,17104,DB00829,Diazepam
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,3.5,17105,DB00829,Diazepam
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,94.7,17106,DB00829,Diazepam
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,27.0,17107,DB00829,Diazepam
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,73.2,17108,DB00829,Diazepam
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,43.5,17109,DB00829,Diazepam
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,3.5,17110,DB00829,Diazepam
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,94.7,17111,DB00829,Diazepam
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,27.0,17112,DB00829,Diazepam
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,73.2,17113,DB00829,Diazepam
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,43.5,17114,DB00829,Diazepam
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,45.6,17115,DB00829,Diazepam
more,9105544,plasma protein binding,In vivo plasma protein binding of 14C-Am-80 and/or its radioactive metabolites was also found to be more than 98% in rats and dogs after subcutaneous administration of 14C-Am-80.,"Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,98,17116,DB00829,Diazepam
smaller,29427702,brain to blood,"PKRinh showed a supra dose-proportional blood exposure that was not observed in the brain, and a brain to blood AUC ratio of unbound drug smaller than 1 at all tested doses.",High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427702/),,1,17268,DB00829,Diazepam
smaller,29427702,AUC ratio of unbound drug,"PKRinh showed a supra dose-proportional blood exposure that was not observed in the brain, and a brain to blood AUC ratio of unbound drug smaller than 1 at all tested doses.",High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427702/),,1,17269,DB00829,Diazepam
≅,29427702,km,Fitting the data to a Michaelis-Menten equation revealed that PKRinh transport through the BBB is composed of a passive unsaturable flux and an active saturable protein-mediated efflux with a km of ≅ 3 μM.,High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427702/),μM,3,17270,DB00829,Diazepam
,29427702,brain uptake clearance,"Finally, PKRinh had high brain uptake clearance (14 μl/g/s) despite it is a good P-gp substrate (P-gp Efflux ratio ≅ 3.6), and reached similar values than the cerebral blood flow reference, diazepam, in P-gp saturation conditions.",High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427702/),[μl] / [g·s],14,17271,DB00829,Diazepam
≅,29427702,Efflux ratio,"Finally, PKRinh had high brain uptake clearance (14 μl/g/s) despite it is a good P-gp substrate (P-gp Efflux ratio ≅ 3.6), and reached similar values than the cerebral blood flow reference, diazepam, in P-gp saturation conditions.",High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427702/),,3.6,17272,DB00829,Diazepam
,6119726,Absorption half-life (t1/2 a),Absorption half-life (t1/2 a) averaged 24 min.,Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119726/),min,24,18761,DB00829,Diazepam
,6119726,elimination half-life (t1/2 beta),"After a rapid phase of distribution, DMDZ elimination was slow, with a mean elimination half-life (t1/2 beta) of 82 h (range 27-219 h).",Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119726/),h,82,18762,DB00829,Diazepam
,6119726,free fraction (FF),"The mean free fraction (FF) was 3.1% (range 2.0-4.3%), and increased significantly with declining plasma albumin concentrations (r=-0.57, P less than 0.001).",Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119726/),%,3.1,18763,DB00829,Diazepam
,17286787,time to peak,"For nitrazepam and diazepam, the time to peak was delayed about 1 h in fed condition (P > 0.05).","Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17286787/),h,1,19560,DB00829,Diazepam
,17286787,Reaction time,Reaction time of quazepam with light food was prolonged at 4 and 6 h after dosing and its area under the effect-time curve from 0 to 10 h was increased (P < 0.05).,"Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17286787/),h,4,19561,DB00829,Diazepam
,17286787,Reaction time,Reaction time of quazepam with light food was prolonged at 4 and 6 h after dosing and its area under the effect-time curve from 0 to 10 h was increased (P < 0.05).,"Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17286787/),h,6,19562,DB00829,Diazepam
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,176,19818,DB00829,Diazepam
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,516,19819,DB00829,Diazepam
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,27.1,19820,DB00829,Diazepam
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,42.5,19821,DB00829,Diazepam
,2394062,total duration of neuromuscular blockade,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,51.8,19822,DB00829,Diazepam
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,9.6,19823,DB00829,Diazepam
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,64.1,19824,DB00829,Diazepam
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,16.7,19825,DB00829,Diazepam
,32215046,flow rate,"The chromatographic separation was performed on a Waters XBridge™ C18 column (2.1 mm × 100 mm, 3.5 μm) using a gradient elution with the mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.3 mL/min.",HPLC-MS/MS Analysis of Aconiti Lateralis Radix Praeparata and Its Combination with Red Ginseng Effect on Rat CYP450 Activities Using the Cocktail Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32215046/),[ml] / [min],0.3,20924,DB00829,Diazepam
,22150444,ED(50),"Thirty minutes after the induction of SE, the calculated rat ED(50) for SPD against convulsive SE in this model was 84 mg/kg.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],84,21547,DB00829,Diazepam
,22150444,ED(50),"SPD ED(50) values in guinea pigs were 67 and 92 mg/kg when administered at SE onset or 40 min after SE onset, respectively.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],67,21548,DB00829,Diazepam
,22150444,ED(50),"SPD ED(50) values in guinea pigs were 67 and 92 mg/kg when administered at SE onset or 40 min after SE onset, respectively.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],92,21549,DB00829,Diazepam
,22150444,plasma levels,"Assuming linear pharmacokinetics (PK), the PK-PD (pharmacodynamic) results (rats) suggests that effective SPD plasma levels ranged between 8 and 40 mg/L (20 min after the onset of soman-induced seizures) and 12-50 mg/L (40 min after the onset of soman-induced seizures).",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [l],8 and 40,21550,DB00829,Diazepam
,22150444,plasma levels,"Assuming linear pharmacokinetics (PK), the PK-PD (pharmacodynamic) results (rats) suggests that effective SPD plasma levels ranged between 8 and 40 mg/L (20 min after the onset of soman-induced seizures) and 12-50 mg/L (40 min after the onset of soman-induced seizures).",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [l],12-50,21551,DB00829,Diazepam
,8269597,clearance,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),[ml] / [kg·min],3.32,21672,DB00829,Diazepam
,8269597,area under the concentration-time curve (AUC,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),[h·ng] / [ml],"5,412",21673,DB00829,Diazepam
,8269597,elimination half-life,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),h,3.03,21674,DB00829,Diazepam
,8269597,elimination half-life,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),[ml] / [kg·min],2.80,21675,DB00829,Diazepam
,8269597,elimination half-life,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),[h·ng] / [ml],"6,475",21676,DB00829,Diazepam
,8269597,elimination half-life,"Patients who received phenytoin demonstrated significantly higher clearance (mean +/- SD, 3.32 +/- 0.99 ml min-1 kg-1), a lower area under the concentration-time curve (AUC, 5,412 +/- 1,534 ng h ml-1; corrected for dose/kilogram) and a shorter elimination half-life (3.03 +/- 0.57 h) for the last dose of d8-BU (dose 16) as compared with the first dose (2.80 +/- 0.78 ml min-1 kg-1, 6,475 +/- 2,223 ng h ml-1 and 3.94 +/- 1.10 h, respectively).",Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269597/),h,3.94,21677,DB00829,Diazepam
,17345074,run time,NONMEM population parameter estimates were in close agreement with those produced by the Bayesian analysis although there was a substantial shortening of run time for both the animal WBPBPK model (4.5 vs. 21 h) and human WBPBPK models (2 vs. 167 h).,Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17345074/),h,4.5,22206,DB00829,Diazepam
,17345074,run time,NONMEM population parameter estimates were in close agreement with those produced by the Bayesian analysis although there was a substantial shortening of run time for both the animal WBPBPK model (4.5 vs. 21 h) and human WBPBPK models (2 vs. 167 h).,Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17345074/),h,21,22207,DB00829,Diazepam
,17345074,run time,NONMEM population parameter estimates were in close agreement with those produced by the Bayesian analysis although there was a substantial shortening of run time for both the animal WBPBPK model (4.5 vs. 21 h) and human WBPBPK models (2 vs. 167 h).,Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17345074/),h,2,22208,DB00829,Diazepam
,17345074,run time,NONMEM population parameter estimates were in close agreement with those produced by the Bayesian analysis although there was a substantial shortening of run time for both the animal WBPBPK model (4.5 vs. 21 h) and human WBPBPK models (2 vs. 167 h).,Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17345074/),h,167,22209,DB00829,Diazepam
,11243202,minimal detectable concentration,The minimal detectable concentration in plasma was 1 ng.,[Determination of nifedipine in human plasma by gas chromatography and its pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243202/),ng,1,22793,DB00829,Diazepam
less,3108012,distribution phase,"Pharmacokinetic parameters were derived assuming a two compartment model, distribution phase less than 6 h, and 100% oral systemic availability.",Differences in diazepam pharmacokinetics in Chinese and white Caucasians--relation to body lipid stores. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108012/),h,6,23101,DB00829,Diazepam
,29181594,flow rate,"Chromatographic separation of lesinurad and diazepam (internal standard, IS) was performed on a Rapid Resolution HT C18 column (3.0 × 100 mm, 1.8 µm) using methanol-water (70:30, v/v) as the mobile phase at a flow rate of 0.3 mL/min.",Determination of lesinurad in rat plasma by a UHPLC-MS/MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29181594/),[ml] / [min],0.3,24123,DB00829,Diazepam
,7555001,Cmax,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[μg] / [ml],2.165,24149,DB00829,Diazepam
,7555001,Cmax,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[μg] / [ml],2.239,24150,DB00829,Diazepam
,7555001,Tmax,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),h,2,24151,DB00829,Diazepam
,7555001,Tmax,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),h,2.13,24152,DB00829,Diazepam
,7555001,T1/2,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),h,7.004,24153,DB00829,Diazepam
,7555001,T1/2,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),h,7.82,24154,DB00829,Diazepam
,7555001,Cls/f,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[ml] / [h·kg],153.63,24155,DB00829,Diazepam
,7555001,Cls/f,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[ml] / [h·kg],134.87,24156,DB00829,Diazepam
,7555001,AUC0-alpha,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[h·μg] / [ml],22.131,24157,DB00829,Diazepam
,7555001,AUC0-alpha,"Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, Cls/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p > 0.05) effect of diazepam on quinidine disposition kinetics.",Absence of a pharmacokinetic interaction between quinidine and diazepam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555001/),[h·μg] / [ml],24.321,24158,DB00829,Diazepam
,1980307,total chromatography time,The total chromatography time for a single sample is approximately 10 min.,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),min,10,25141,DB00829,Diazepam
,1980307,sensitivity,A sensitivity of 1 ng/mL for halazepam and nordiazepam is attained when 1 mL of plasma is extracted.,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),[ng] / [ml],1,25142,DB00829,Diazepam
,1980307,Ana,Analytical recovery of halazepam and nordiazepam added to the plasma ranged from 89 to 96%.,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),%,89 to 96,25143,DB00829,Diazepam
,1980307,oral plasma clearance,Mean oral plasma clearance of halazepam was 24 L/h.,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),[l] / [h],24,25144,DB00829,Diazepam
,1980307,apparent elimination half-life,The mean apparent elimination half-life of nordiazepam (45.22 h) is considerably longer than that of halazepam (21.15 h).,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),h,45.22,25145,DB00829,Diazepam
,1980307,apparent elimination half-life,The mean apparent elimination half-life of nordiazepam (45.22 h) is considerably longer than that of halazepam (21.15 h).,Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1980307/),h,21.15,25146,DB00829,Diazepam
,31916704,time to peak concentration,NRL-1 administration resulted in rapid diazepam absorption (median time to peak concentration 1.4-1.5 hours).,Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL-1 to Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31916704/),h,1.4-1.5,26238,DB00829,Diazepam
,31916704,Cmax,"Plasma concentration-time profiles showed similar patterns of exposure that appeared to be dose dependent, with Cmax of 85.6, 133.6, and 235.3 ng/mL for the 5-, 10-, and 20-mg doses, respectively, although the lower 90%CI for Cmax and AUC0-∞ exceeded dose proportionality criteria.",Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL-1 to Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31916704/),[ng] / [ml],85.6,26239,DB00829,Diazepam
,31916704,Cmax,"Plasma concentration-time profiles showed similar patterns of exposure that appeared to be dose dependent, with Cmax of 85.6, 133.6, and 235.3 ng/mL for the 5-, 10-, and 20-mg doses, respectively, although the lower 90%CI for Cmax and AUC0-∞ exceeded dose proportionality criteria.",Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL-1 to Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31916704/),[ng] / [ml],133.6,26240,DB00829,Diazepam
,31916704,Cmax,"Plasma concentration-time profiles showed similar patterns of exposure that appeared to be dose dependent, with Cmax of 85.6, 133.6, and 235.3 ng/mL for the 5-, 10-, and 20-mg doses, respectively, although the lower 90%CI for Cmax and AUC0-∞ exceeded dose proportionality criteria.",Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL-1 to Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31916704/),[ng] / [ml],235.3,26241,DB00829,Diazepam
,2619028,peak plasma concentrations,Group 2: Rectal midazolam 0.35 mg/kg has a remarkably short onset of action with peak plasma concentrations (71 ng/ml) in the range of sedative levels in adults occurring in 7.5 min.,[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),[ng] / [ml],71,28058,DB00829,Diazepam
,2619028,peak levels,"Group 3 patients had peak levels of midazolam of 246 ng/ml after 12.5 min, falling to an average concentration of 120 ng/ml after 2 h.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),[ng] / [ml],246,28059,DB00829,Diazepam
,2619028,peak levels,"Group 3 patients had peak levels of midazolam of 246 ng/ml after 12.5 min, falling to an average concentration of 120 ng/ml after 2 h.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),ng,120,28060,DB00829,Diazepam
,2619028,bioavailability,"The bioavailability of rectal midazolam, comparing the area under the median curves, is 4.7% in group 2 and 16.1% in group 3.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),%,4.7,28061,DB00829,Diazepam
,2619028,bioavailability,"The bioavailability of rectal midazolam, comparing the area under the median curves, is 4.7% in group 2 and 16.1% in group 3.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),%,16.1,28062,DB00829,Diazepam
,3102240,half-life,"Plasma levels declined with a biphasic pattern, and the elimination phase had a half-life of 82.9 +/- 14.1 hours.",Pharmacokinetics of chlordesmethyldiazepam after single-dose oral administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102240/),h,82.9,32414,DB00829,Diazepam
,27473996,peak remifentanil concentration,Mean peak remifentanil concentration was 7.14ηgmL(-1) at 50min after start of infusion.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],7.14,33193,DB00829,Diazepam
,27473996,volume of distribution,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[mlkg],268,33194,DB00829,Diazepam
,27473996,half-life,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),min,12.8,33195,DB00829,Diazepam
,27473996,Limit of quantification,Limit of quantification was 0.2ηgmL(-1).,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],0.2,33196,DB00829,Diazepam
,26943262,flow rate,"Chromatographic separation was achieved on a Phenomenex Kinetex C18 column (100×2.1mm, 2.6μm) with gradient elution using mobile phase consisting of acetonitrile -0.1% formic acid in water at a flow rate of 0.3mL/min.",Simultaneous determination of seven alkaloids in rat plasma by UFLC-MS/MS and its application to a pharmacokinetic study after oral administration of Cerebralcare Granule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26943262/),[ml] / [min],0.3,33302,DB00829,Diazepam
,15776275,peak plasma concentration,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),[ng] / [ml],17.5,34055,DB00829,Diazepam
,15776275,peak plasma concentration,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),[ng] / [ml],13.9,34056,DB00829,Diazepam
,15776275,total area under the plasma concentration-time curve,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),[h·ng] / [ml],194.8,34057,DB00829,Diazepam
,15776275,total area under the plasma concentration-time curve,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),[h·ng] / [ml],105.9,34058,DB00829,Diazepam
,15776275,elimination half-life,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),h,11.1,34059,DB00829,Diazepam
,15776275,elimination half-life,"Carbamazepine treatment significantly decreased the peak plasma concentration (17.5+/-4.1 ng/ml versus 13.9+/-4.1 ng/ml; P<0.05), total area under the plasma concentration-time curve (194.8+/-88.9 ng h/ml versus 105.9+/-33.0 ng h/ml; P<0.001), and elimination half-life (11.1+/-4.6 h versus 6.8+/-2.8 h; P<0.01) of etizolam.",Induction of the metabolism of etizolam by carbamazepine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15776275/),h,6.8,34060,DB00829,Diazepam
>,24947446,CL,"2. The clearance (CL) values of high CL compounds (CL > 50 mL/min/kg, namely propranolol, diazepam, phenytoin, ethinylestradiol, lorcaserin and fenfluramine) decreased significantly (1.5- to 6-fold) in DIO and AM rats as compared to lean rats, while there was no clear trend for change in CL for the low-to-moderate CL compounds (CL < 50 mL/min/kg, namely atenolol, chlorzoxazone, vancomycin and sibutramine).","Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947446/),[ml] / [kg·min],50,34154,DB00829,Diazepam
<,24947446,CL,"2. The clearance (CL) values of high CL compounds (CL > 50 mL/min/kg, namely propranolol, diazepam, phenytoin, ethinylestradiol, lorcaserin and fenfluramine) decreased significantly (1.5- to 6-fold) in DIO and AM rats as compared to lean rats, while there was no clear trend for change in CL for the low-to-moderate CL compounds (CL < 50 mL/min/kg, namely atenolol, chlorzoxazone, vancomycin and sibutramine).","Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947446/),[ml] / [kg·min],50,34155,DB00829,Diazepam
,2150984,Ratio,"Ratio values were highest in the group with the highest lymph lipid content (the oil-fed group, 2.20 +/- 0.08) and fell significantly in the other groups (fed group 1.46 +/- 0.09, unfed group 1.15 +/- 0.05).","Influence of the composition of rat central lymph on the pharmacokinetics (the steady state during infusion, bioavailability, absorption) of diazepam, studied in the blood and lymph. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150984/),,2.20,35544,DB00829,Diazepam
,2150984,Ratio,"Ratio values were highest in the group with the highest lymph lipid content (the oil-fed group, 2.20 +/- 0.08) and fell significantly in the other groups (fed group 1.46 +/- 0.09, unfed group 1.15 +/- 0.05).","Influence of the composition of rat central lymph on the pharmacokinetics (the steady state during infusion, bioavailability, absorption) of diazepam, studied in the blood and lymph. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150984/),,1.46,35545,DB00829,Diazepam
,2150984,Ratio,"Ratio values were highest in the group with the highest lymph lipid content (the oil-fed group, 2.20 +/- 0.08) and fell significantly in the other groups (fed group 1.46 +/- 0.09, unfed group 1.15 +/- 0.05).","Influence of the composition of rat central lymph on the pharmacokinetics (the steady state during infusion, bioavailability, absorption) of diazepam, studied in the blood and lymph. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150984/),,1.15,35546,DB00829,Diazepam
,19456308,C(max),"The C(max) and T(max) values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),[ng] / [ml],179.2,38753,DB00829,Diazepam
,19456308,C(max),"The C(max) and T(max) values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),[ng] / [ml],62.8,38754,DB00829,Diazepam
,19456308,T(max),"The C(max) and T(max) values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),min,28.8,38755,DB00829,Diazepam
,19456308,T(max),"The C(max) and T(max) values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),min,21.6,38756,DB00829,Diazepam
,19456308,to,"Immediately following i.n. administration, subjects reported tolerability scores of 6.75 and 6.0, and identical pain scores, 3.2, for DZP and MDZ, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),,6,38757,DB00829,Diazepam
,11736860,bioavailabilities,"The bioavailabilities of 4 and 7 mg i.n. formulations, were found to be similar, 45% [32, 58] and 42% [22, 62], respectively.",Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736860/),%,45,39133,DB00829,Diazepam
,11736860,bioavailabilities,"The bioavailabilities of 4 and 7 mg i.n. formulations, were found to be similar, 45% [32, 58] and 42% [22, 62], respectively.",Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736860/),%,42,39134,DB00829,Diazepam
,22309773,Recoveries,Recoveries (73.9-96.1%) and matrix effects (76.4-97.2%) were satisfactory in all the biological matrices examined.,"Application of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to the pharmacokinetics, tissue distribution and excretion studies of felotaxel (SHR110008) in tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22309773/),%,73.9-96.1,39820,DB00829,Diazepam
,21107819,flow rate,"A 200-μl plasma sample was extracted by methyl tert-butyl ether and the separation was performed on Kromasil C(18) column (150 × 4.6 mm, 5 μm) with the mobile phase of acetonitrile (containing 0.1% of formic acid)-water (73:27, v/v) at a flow rate of 0.8 ml/min in a run time of 10 min.",A sensitive liquid chromatography-mass spectrometry method for simultaneous determination of alisol A and alisol A 24-acetate from Alisma orientale (Sam.) Juz. in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107819/),[ml] / [min],0.8,42377,DB00829,Diazepam
,21107819,run time,"A 200-μl plasma sample was extracted by methyl tert-butyl ether and the separation was performed on Kromasil C(18) column (150 × 4.6 mm, 5 μm) with the mobile phase of acetonitrile (containing 0.1% of formic acid)-water (73:27, v/v) at a flow rate of 0.8 ml/min in a run time of 10 min.",A sensitive liquid chromatography-mass spectrometry method for simultaneous determination of alisol A and alisol A 24-acetate from Alisma orientale (Sam.) Juz. in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107819/),min,10,42378,DB00829,Diazepam
above,21107819,extraction recoveries,The mean extraction recoveries were above 74.7% for alisol A and above 72.4% for alisol A 24-acetate from biological matrixes.,A sensitive liquid chromatography-mass spectrometry method for simultaneous determination of alisol A and alisol A 24-acetate from Alisma orientale (Sam.) Juz. in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107819/),%,74.7,42379,DB00829,Diazepam
above,21107819,extraction recoveries,The mean extraction recoveries were above 74.7% for alisol A and above 72.4% for alisol A 24-acetate from biological matrixes.,A sensitive liquid chromatography-mass spectrometry method for simultaneous determination of alisol A and alisol A 24-acetate from Alisma orientale (Sam.) Juz. in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107819/),%,72.4,42380,DB00829,Diazepam
,2065698,elimination half-life (t1/2),The mean elimination half-life (t1/2) averaged 3.4 h.,Single and multiple dose pharmacokinetics of etizolam in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2065698/),h,3.4,42936,DB00829,Diazepam
,2065698,t1/2,"At steady state plasma concentrations of the main metabolite, alpha-hydroxyetizolam, were higher and disappeared more slowly (mean t1/2 8.2 h) than those of the parent compound.",Single and multiple dose pharmacokinetics of etizolam in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2065698/),h,8.2,42937,DB00829,Diazepam
,18069077,m/z,"The quantification of target compounds was obtained by using multiple reaction monitoring (MRM) transitions; m/z 302.5, 173.2 and 285.4, 193.2 were measured in positive mode for tegaserod and internal standard (diazepam), respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),,302.5,43073,DB00829,Diazepam
,18069077,m/z,"The quantification of target compounds was obtained by using multiple reaction monitoring (MRM) transitions; m/z 302.5, 173.2 and 285.4, 193.2 were measured in positive mode for tegaserod and internal standard (diazepam), respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),,173.2,43074,DB00829,Diazepam
,18069077,m/z,"The quantification of target compounds was obtained by using multiple reaction monitoring (MRM) transitions; m/z 302.5, 173.2 and 285.4, 193.2 were measured in positive mode for tegaserod and internal standard (diazepam), respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),,285.4,43075,DB00829,Diazepam
,18069077,m/z,"The quantification of target compounds was obtained by using multiple reaction monitoring (MRM) transitions; m/z 302.5, 173.2 and 285.4, 193.2 were measured in positive mode for tegaserod and internal standard (diazepam), respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),,193.2,43076,DB00829,Diazepam
more,18069077,absolute recovery,The mean absolute recovery of tegaserod was more than 85.56%.,Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),%,85.56,43077,DB00829,Diazepam
,18069077,area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[h·ng] / [ml],2.89,43078,DB00829,Diazepam
,18069077,area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[h·ng] / [ml],5.32,43079,DB00829,Diazepam
,18069077,area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[h·ng] / [ml],9.38,43080,DB00829,Diazepam
,18069077,peak plasma concentration (Cmax),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[ng] / [ml],1.25,43081,DB00829,Diazepam
,18069077,peak plasma concentration (Cmax),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[ng] / [ml],2.21,43082,DB00829,Diazepam
,18069077,peak plasma concentration (Cmax),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[ng] / [ml],4.34,43083,DB00829,Diazepam
,18069077,apparent volume of distribution (Vd/F),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),l,6630.5,43084,DB00829,Diazepam
,18069077,apparent volume of distribution (Vd/F),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),l,7615.2,43085,DB00829,Diazepam
,18069077,apparent volume of distribution (Vd/F),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),l,7163.7,43086,DB00829,Diazepam
,18069077,clearance rate (CL/F),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[l] / [h],1851.4,43087,DB00829,Diazepam
,18069077,clearance rate (CL/F),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[l] / [h],1596.2,43088,DB00829,Diazepam
,18069077,clearance rate (CL/F),"After administration of a single dose of tegaserod maleate 4 mg, 6 mg and 12 mg, respectively, the area under the plasma concentration versus time curve from time 0 h to 12 h (AUC0-12) were (2.89+/-0.88), (5.32+/-1.21) and (9.38+/-3.42) ng h/ml, respectively; peak plasma concentration (Cmax) were (1.25+/-0.53), (2.21+/-0.52) and (4.34+/-1.66) ng/ml, respectively; apparent volume of distribution (Vd/F) were (6630.5+/-2057.8), (7615.2+/-2242.8) and (7163.7+/-2057.2) l, respectively; clearance rate (CL/F) were (1851.4+/-496.9), (1596.2+/-378.5) and (1894.2+/-459.3) l/h, respectively; time to Cmax (Tmax) were (1.00+/-0.21), (1.05+/-0.28) and (1.04+/-0.16) h, respectively; and elimination half-life (t1/2) were (3.11+/-0.78), (3.93+/-0.92) and (3.47+/-0.53) h, respectively; MRT were (3.74+/-0.85), (4.04+/-0.56) and (3.28+/-0.66) h, respectively.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[l] / [h],1894.2,43089,DB00829,Diazepam
,18069077,Cssmax,"The essential pharmacokinetic parameters after oral multiple doses (6mg, b.i.d) were as follows: Cssmax, (2.72+/-0.61) ng/ml; Tmax, (1.10+/-0.25) h; Cssmin, (0.085+/-0.01) ng/ml; Cav, (0.54+/-0.12) ng/ml; DF, (4.84+/-0.86); AUCss, (6.53+/-1.5) ngh/ml.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[ng] / [ml],2.72,43090,DB00829,Diazepam
,18069077,Tmax,"The essential pharmacokinetic parameters after oral multiple doses (6mg, b.i.d) were as follows: Cssmax, (2.72+/-0.61) ng/ml; Tmax, (1.10+/-0.25) h; Cssmin, (0.085+/-0.01) ng/ml; Cav, (0.54+/-0.12) ng/ml; DF, (4.84+/-0.86); AUCss, (6.53+/-1.5) ngh/ml.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),h,1.10,43091,DB00829,Diazepam
,18069077,Cssmin,"The essential pharmacokinetic parameters after oral multiple doses (6mg, b.i.d) were as follows: Cssmax, (2.72+/-0.61) ng/ml; Tmax, (1.10+/-0.25) h; Cssmin, (0.085+/-0.01) ng/ml; Cav, (0.54+/-0.12) ng/ml; DF, (4.84+/-0.86); AUCss, (6.53+/-1.5) ngh/ml.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[ng] / [ml],0.085,43092,DB00829,Diazepam
,18069077,Cav,"The essential pharmacokinetic parameters after oral multiple doses (6mg, b.i.d) were as follows: Cssmax, (2.72+/-0.61) ng/ml; Tmax, (1.10+/-0.25) h; Cssmin, (0.085+/-0.01) ng/ml; Cav, (0.54+/-0.12) ng/ml; DF, (4.84+/-0.86); AUCss, (6.53+/-1.5) ngh/ml.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[ng] / [ml],0.54,43093,DB00829,Diazepam
,18069077,DF,"The essential pharmacokinetic parameters after oral multiple doses (6mg, b.i.d) were as follows: Cssmax, (2.72+/-0.61) ng/ml; Tmax, (1.10+/-0.25) h; Cssmin, (0.085+/-0.01) ng/ml; Cav, (0.54+/-0.12) ng/ml; DF, (4.84+/-0.86); AUCss, (6.53+/-1.5) ngh/ml.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),,4.84,43094,DB00829,Diazepam
,18069077,AUCss,"The essential pharmacokinetic parameters after oral multiple doses (6mg, b.i.d) were as follows: Cssmax, (2.72+/-0.61) ng/ml; Tmax, (1.10+/-0.25) h; Cssmin, (0.085+/-0.01) ng/ml; Cav, (0.54+/-0.12) ng/ml; DF, (4.84+/-0.86); AUCss, (6.53+/-1.5) ngh/ml.",Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18069077/),[ngh] / [ml],6.53,43095,DB00829,Diazepam
,8864328,clearance,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),[1] / [h·kg],0.021,44920,DB00829,Diazepam
,8864328,elimination half-life,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),h,36.8,44921,DB00829,Diazepam
,8864328,elimination half-life,"There was no effect on diazepam clearance (0.021 1 h-1 kg-1 for test and reference) and elimination half-life (36.8 for test, 40.4 h for reference).",Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864328/),h,40.4,44922,DB00829,Diazepam
,3378804,maximum measured levels,The maximum measured levels of boric acid and cinchocaine chloride approximately 6 h after ingestion were 26 micrograms/ml and 71 ng/ml respectively.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[μg] / [ml],26,45549,DB00829,Diazepam
,3378804,maximum measured levels,The maximum measured levels of boric acid and cinchocaine chloride approximately 6 h after ingestion were 26 micrograms/ml and 71 ng/ml respectively.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ng] / [ml],71,45550,DB00829,Diazepam
,3378804,plasma half-life,The plasma half-life of boric acid was 7.0 h and decreased to 3.6 and 4.4 h during the two haemodialyses.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),h,7.0,45551,DB00829,Diazepam
,3378804,plasma half-life,The plasma half-life of boric acid was 7.0 h and decreased to 3.6 and 4.4 h during the two haemodialyses.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),h,3.6,45552,DB00829,Diazepam
,3378804,plasma half-life,The plasma half-life of boric acid was 7.0 h and decreased to 3.6 and 4.4 h during the two haemodialyses.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),h,4.4,45553,DB00829,Diazepam
,3378804,total body clearance,The total body clearance of boric acid increased correspondingly from 21 ml/min to 41 and 34 ml/min.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ml] / [min],21,45554,DB00829,Diazepam
,3378804,total body clearance,The total body clearance of boric acid increased correspondingly from 21 ml/min to 41 and 34 ml/min.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ml] / [min],41,45555,DB00829,Diazepam
,3378804,total body clearance,The total body clearance of boric acid increased correspondingly from 21 ml/min to 41 and 34 ml/min.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ml] / [min],34,45556,DB00829,Diazepam
,3378804,clearance,The in vitro clearance of boric acid of the dialyser was later determined to be 18 ml/min.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ml] / [min],18,45557,DB00829,Diazepam
,10630270,elimination half-life,Plasma hydroxychloroquine level was 29.40 mumol/L (9.87 mg/L) 2 hours after ingestion and the elimination half-life of hydroxychloroquine was 22 hours.,Hydroxychloroquine overdose: toxicokinetics and management. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630270/),h,22,46844,DB00829,Diazepam
,1103916,Peak concentrations,"Peak concentrations in serum were 209+/-49, 152+/-60 and 143+/-62 ng/ml ((means+/-SD) at 90, 60 and 60 min after oral, shoulder and thigh administration respectively.",Absorption and sedative effects of diazepam after oral administration and intramuscular administration into the vastus lateralis muscle and the deltoid muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1103916/),[ng] / [ml],209,47210,DB00829,Diazepam
,1103916,Peak concentrations,"Peak concentrations in serum were 209+/-49, 152+/-60 and 143+/-62 ng/ml ((means+/-SD) at 90, 60 and 60 min after oral, shoulder and thigh administration respectively.",Absorption and sedative effects of diazepam after oral administration and intramuscular administration into the vastus lateralis muscle and the deltoid muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1103916/),[ng] / [ml],152,47211,DB00829,Diazepam
,1103916,Peak concentrations,"Peak concentrations in serum were 209+/-49, 152+/-60 and 143+/-62 ng/ml ((means+/-SD) at 90, 60 and 60 min after oral, shoulder and thigh administration respectively.",Absorption and sedative effects of diazepam after oral administration and intramuscular administration into the vastus lateralis muscle and the deltoid muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1103916/),[ng] / [ml],143,47212,DB00829,Diazepam
,7656504,plasma elimination half-life (t1/2),Mean plasma elimination half-life (t1/2) is between 1.3 and 2.1 hours in healthy volunteers.,Clinical pharmacokinetics of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656504/),h,1.3 and 2.1,47682,DB00829,Diazepam
,17592586,limit of detections,"The limit of detections of the method from whole blood were 1.7, 1.4 and 2.8 ng mL(-1) for the analysis of diazepam, nordiazepam and oxazepam respectively, and the linear range was from 4 ng mL(-1) to 2 microg mL(-1).",Evaluation of bio-compatible poly(ethylene glycol)-based solid-phase microextraction fiber for in vivo pharmacokinetic studies of diazepam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592586/),[ng] / [ml],1.7,47833,DB00829,Diazepam
,17592586,limit of detections,"The limit of detections of the method from whole blood were 1.7, 1.4 and 2.8 ng mL(-1) for the analysis of diazepam, nordiazepam and oxazepam respectively, and the linear range was from 4 ng mL(-1) to 2 microg mL(-1).",Evaluation of bio-compatible poly(ethylene glycol)-based solid-phase microextraction fiber for in vivo pharmacokinetic studies of diazepam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592586/),[ng] / [ml],1.4,47834,DB00829,Diazepam
,17592586,limit of detections,"The limit of detections of the method from whole blood were 1.7, 1.4 and 2.8 ng mL(-1) for the analysis of diazepam, nordiazepam and oxazepam respectively, and the linear range was from 4 ng mL(-1) to 2 microg mL(-1).",Evaluation of bio-compatible poly(ethylene glycol)-based solid-phase microextraction fiber for in vivo pharmacokinetic studies of diazepam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592586/),[ng] / [ml],2.8,47835,DB00829,Diazepam
,1936060,plasma elimination half-life,A plasma elimination half-life of 23 +/- 2.3 h was calculated.,Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936060/),h,23,47993,DB00829,Diazepam
,1936060,peak chlormezanone plasma level,"The mean peak chlormezanone plasma level was 1.86 +/- 0.2 micrograms/ml, 1 h after ingestion.",Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936060/),[μg] / [ml],1.86,47994,DB00829,Diazepam
,1936060,plasma levels,"After 5 days of repeated daily doses of 3 x 200 mg (group 2; 12 patients) or 3 x 400 mg (group 3; 10 patients) of chlormezanone, mean predose chlormezanone plasma levels were 12.0 +/- 2.0 micrograms/ml (group 2) and 22.7 +/- 4.0 micrograms/ml (group 3), respectively.",Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936060/),μ,12.0,47995,DB00829,Diazepam
,1936060,plasma levels,"After 5 days of repeated daily doses of 3 x 200 mg (group 2; 12 patients) or 3 x 400 mg (group 3; 10 patients) of chlormezanone, mean predose chlormezanone plasma levels were 12.0 +/- 2.0 micrograms/ml (group 2) and 22.7 +/- 4.0 micrograms/ml (group 3), respectively.",Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936060/),[μg] / [ml],22.7,47996,DB00829,Diazepam
,17676319,elimination half-life (t(1/2)),This was associated with the prolongation of the mean elimination half-life (t(1/2)) from 31 h to 61 h (p < 0.01) after voriconazole.,Voriconazole and fluconazole increase the exposure to oral diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17676319/),h,31,48210,DB00829,Diazepam
,17676319,elimination half-life (t(1/2)),This was associated with the prolongation of the mean elimination half-life (t(1/2)) from 31 h to 61 h (p < 0.01) after voriconazole.,Voriconazole and fluconazole increase the exposure to oral diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17676319/),h,61,48211,DB00829,Diazepam
,17676319,t(1/2),"In the fluconazole phase, the AUC 0-infinity of diazepam was increased 2.5-fold (p < 0.01; 90% CI 1.94 to 3.40), and the t(1/2) was prolonged from 31 h to 73 h (p < 0.001).",Voriconazole and fluconazole increase the exposure to oral diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17676319/),h,31,48212,DB00829,Diazepam
,17676319,t(1/2),"In the fluconazole phase, the AUC 0-infinity of diazepam was increased 2.5-fold (p < 0.01; 90% CI 1.94 to 3.40), and the t(1/2) was prolonged from 31 h to 73 h (p < 0.001).",Voriconazole and fluconazole increase the exposure to oral diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17676319/),h,73,48213,DB00829,Diazepam
,32219697,time of maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,1.04,48787,DB00829,Diazepam
,32219697,time of maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,133.14,48788,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],87.37,48789,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,129.07,48790,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,133.14,48791,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],3.80,48792,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,100.29,48793,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.62,48794,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,44.43,48795,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,66.86,48796,DB00829,Diazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.10,48797,DB00829,Diazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,129.07,48798,DB00829,Diazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,382.86,48799,DB00829,Diazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,44.43,48800,DB00829,Diazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],2.08,48801,DB00829,Diazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,130.53,48802,DB00829,Diazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,66.86,48803,DB00829,Diazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.10,48804,DB00829,Diazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,240.66,48805,DB00829,Diazepam
,34020149,maximum plasma midazolam concentration,"Mean maximum plasma midazolam concentration was 78.0 ng/mL, and mean time to peak concentration was 20.5 min, demonstrating that achieving maximum plasma midazolam concentration is not required for seizure cessation.","A Phase 3 open-label study of the efficacy, safety and pharmacokinetics of buccally administered midazolam hydrochloride for the treatment of status epilepticus in pediatric Japanese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34020149/),[ng] / [ml],78.0,48844,DB00829,Diazepam
,34020149,time to peak concentration,"Mean maximum plasma midazolam concentration was 78.0 ng/mL, and mean time to peak concentration was 20.5 min, demonstrating that achieving maximum plasma midazolam concentration is not required for seizure cessation.","A Phase 3 open-label study of the efficacy, safety and pharmacokinetics of buccally administered midazolam hydrochloride for the treatment of status epilepticus in pediatric Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34020149/),min,20.5,48845,DB00829,Diazepam
exceeding,23981345,half-life,"DORAs, with a half-life exceeding 8 h in humans, are expected to fulfill this requirement as exposures drop to sub-threshold receptor occupancy levels prior to the wake period, potentially avoiding next-day residual effects at therapeutic doses.",The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23981345/),h,8,48929,DB00829,Diazepam
,8592663,steady state plasma concentrations,Zero order infusions together with matched bolus doses of omeprazole were used to achieve a range of steady state plasma concentrations (10-50mg/L) and to study the diazepam-omeprazole interaction in vivo.,Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),[mg] / [l],10-50,49348,DB00829,Diazepam
,8592663,KIs,"The 3-hydroxlation pathway was more prone to inhibition (KIs 108 +/- 30 and 28 +/- 11 microM in microsomes and hepatocytes, respectively) than the demethylation pathway (KIs of 226 +/- 76 and 59 +/- 27 microM in microsomes and hepatocytes, respectively).",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,108,49349,DB00829,Diazepam
,8592663,KIs,"The 3-hydroxlation pathway was more prone to inhibition (KIs 108 +/- 30 and 28 +/- 11 microM in microsomes and hepatocytes, respectively) than the demethylation pathway (KIs of 226 +/- 76 and 59 +/- 27 microM in microsomes and hepatocytes, respectively).",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,28,49350,DB00829,Diazepam
,8592663,KIs,"The 3-hydroxlation pathway was more prone to inhibition (KIs 108 +/- 30 and 28 +/- 11 microM in microsomes and hepatocytes, respectively) than the demethylation pathway (KIs of 226 +/- 76 and 59 +/- 27 microM in microsomes and hepatocytes, respectively).",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,226,49351,DB00829,Diazepam
,8592663,KIs,"The 3-hydroxlation pathway was more prone to inhibition (KIs 108 +/- 30 and 28 +/- 11 microM in microsomes and hepatocytes, respectively) than the demethylation pathway (KIs of 226 +/- 76 and 59 +/- 27 microM in microsomes and hepatocytes, respectively).",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,59,49352,DB00829,Diazepam
larger,8592663,Km/KI ratios,"In both in vitro systems, the mechanism of inhibition was competitive with Km/KI ratios larger than 1 for the 3HDZ pathway and smaller than 1 for the NDZ pathway.",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),,1,49353,DB00829,Diazepam
smaller,8592663,Km/KI ratios,"In both in vitro systems, the mechanism of inhibition was competitive with Km/KI ratios larger than 1 for the 3HDZ pathway and smaller than 1 for the NDZ pathway.",Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),,1,49354,DB00829,Diazepam
,8592663,KI,There was an omeprazole concentration dependent decrease in diazepam clearance in vivo which could be modelled using a simple inhibition equation with a KI of 57 microM (19.8mg/L).,Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),μM,57,49355,DB00829,Diazepam
,8592663,KI,There was an omeprazole concentration dependent decrease in diazepam clearance in vivo which could be modelled using a simple inhibition equation with a KI of 57 microM (19.8mg/L).,Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592663/),[mg] / [l],19.8,49356,DB00829,Diazepam
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,350.1,49923,DB00829,Diazepam
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,281.1,49924,DB00829,Diazepam
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,366.1,49925,DB00829,Diazepam
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,224.1,49926,DB00829,Diazepam
,30594035,m,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,285.0,49927,DB00829,Diazepam
,25221916,flow rate,"Separation of bifendate and diazepam (internal standard, IS) was performed on an HSS C18 SB column (3×100mm, 1.8μm) with a mobile phase consisting of CO2 (≥99.99%) - methanol (95:5, v/v) at a flow rate of 2mL/min and the compensation solvent was methanol with 2% formic acid at a flow rate of 0.2mL/min.",Preclinical pharmacokinetic evaluation of a new formulation of a bifendate solid dispersion using a supercritical fluid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25221916/),[ml] / [min],2,50193,DB00829,Diazepam
,25221916,flow rate,"Separation of bifendate and diazepam (internal standard, IS) was performed on an HSS C18 SB column (3×100mm, 1.8μm) with a mobile phase consisting of CO2 (≥99.99%) - methanol (95:5, v/v) at a flow rate of 2mL/min and the compensation solvent was methanol with 2% formic acid at a flow rate of 0.2mL/min.",Preclinical pharmacokinetic evaluation of a new formulation of a bifendate solid dispersion using a supercritical fluid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25221916/),[ml] / [min],0.2,50194,DB00829,Diazepam
,25221916,m/z,"Quantification of the ion transitions was at m/z 419.2→387.0 and 284.5→193.2 for bifendate and IS, respectively.",Preclinical pharmacokinetic evaluation of a new formulation of a bifendate solid dispersion using a supercritical fluid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25221916/),,419.2,50195,DB00829,Diazepam
,25221916,m/z,"Quantification of the ion transitions was at m/z 419.2→387.0 and 284.5→193.2 for bifendate and IS, respectively.",Preclinical pharmacokinetic evaluation of a new formulation of a bifendate solid dispersion using a supercritical fluid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25221916/),,387.0,50196,DB00829,Diazepam
,25221916,m/z,"Quantification of the ion transitions was at m/z 419.2→387.0 and 284.5→193.2 for bifendate and IS, respectively.",Preclinical pharmacokinetic evaluation of a new formulation of a bifendate solid dispersion using a supercritical fluid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25221916/),,284.5,50197,DB00829,Diazepam
,25221916,m/z,"Quantification of the ion transitions was at m/z 419.2→387.0 and 284.5→193.2 for bifendate and IS, respectively.",Preclinical pharmacokinetic evaluation of a new formulation of a bifendate solid dispersion using a supercritical fluid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25221916/),,193.2,50198,DB00829,Diazepam
,1811505,half-life,"The short half-life of codeine in serum was 2-4 hours, the final half-life was 9-11 hours.",[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,2-4,50213,DB00829,Diazepam
,1811505,final half-life,"The short half-life of codeine in serum was 2-4 hours, the final half-life was 9-11 hours.",[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,9-11,50214,DB00829,Diazepam
,1811505,half-life,In urine we found a short half-life of 1-6 hours as well as a long half-life of 7-12 hours.,[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,1-6,50215,DB00829,Diazepam
,1811505,half-life,In urine we found a short half-life of 1-6 hours as well as a long half-life of 7-12 hours.,[Pilot study of the metabolism of codeine to morphine and a possible modification by benzodiazepines]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811505/),h,7-12,50216,DB00829,Diazepam
,24176745,flow rate,"DPT and IS were extracted with ethyl acetate, and the chromatographic separation was accomplished by using a Waters Symmetry C18 analytical column (2.1mm×150mm, 5μm) with a mobile phase consisting of acetonitrile and deionized water (70:30, v:v) containing 0.1% formic acid at a flow rate of 0.2mL/min.",Validated LC-MS/MS assay for quantitative determination of deoxypodophyllotoxin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24176745/),[ml] / [min],0.2,52492,DB00829,Diazepam
,24176745,m/z,"The monitored transitions were set at m/z 399.05-231.00 and m/z 285.00-154.00 for DPT and IS, respectively.",Validated LC-MS/MS assay for quantitative determination of deoxypodophyllotoxin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24176745/),,399.05-231.00,52493,DB00829,Diazepam
,24176745,m/z,"The monitored transitions were set at m/z 399.05-231.00 and m/z 285.00-154.00 for DPT and IS, respectively.",Validated LC-MS/MS assay for quantitative determination of deoxypodophyllotoxin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24176745/),,285.00-154.00,52494,DB00829,Diazepam
less,7076345,T50 (,Diazepam dissolved rapidly at pH 1.2; the T50 (the time of 50% dissolution) values were less than 5 min.,The bioavailability of diazepam from uncoated tablets in humans--Part I: correlation with the dissolution rates of the tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7076345/),min,5,53157,DB00829,Diazepam
,7076345,T50,"But at pH 4.6, T50 estimated by rotating basket method lasted 3-120 min.",The bioavailability of diazepam from uncoated tablets in humans--Part I: correlation with the dissolution rates of the tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7076345/),min,3-120,53158,DB00829,Diazepam
,7438711,terminal plasma half-life,2. The terminal plasma half-life of diazepam ranged from 15.0 to 125 h and was positively correlated with age (r = 0.797).,The effect of age on the pharmacokinetics of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438711/),h,15.0 to 125,53230,DB00829,Diazepam
,7438711,free fraction,3. The free fraction of diazepam ranged from 0.0137 to 0.0386 and was significantly correlated with age (r = +0.863).,The effect of age on the pharmacokinetics of diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438711/),,0.0137 to 0.0386,53231,DB00829,Diazepam
,7438711,clearance,"Free diazepam clearance, which ranged from 432 to 1870 ml/min, was also correlated with age (r = -0.717).",The effect of age on the pharmacokinetics of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438711/),[ml] / [min],432 to 1870,53232,DB00829,Diazepam
,21219339,bioavailability,"The bioavailability of diazepam after i.n. drop and atomized nasal administration was 42% and 41%, respectively.",Diazepam pharmacokinetics after nasal drop and atomized nasal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219339/),%,42,54279,DB00829,Diazepam
,21219339,bioavailability,"The bioavailability of diazepam after i.n. drop and atomized nasal administration was 42% and 41%, respectively.",Diazepam pharmacokinetics after nasal drop and atomized nasal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219339/),%,41,54280,DB00829,Diazepam
,6146571,half-life,"The plasma curve was described by an open one-compartment model, and half-life was 11.5 +/- 1.3 h.","Pharmacokinetics and metabolism of premazepam, a new potential anxiolytic, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146571/),h,11.5,54859,DB00829,Diazepam
,6146571,Half-life,Half-life of the unchanged compound was 7.9 +/- 1.2 h.,"Pharmacokinetics and metabolism of premazepam, a new potential anxiolytic, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146571/),h,7.9,54860,DB00829,Diazepam
,2810699,distribution half-life (T alpha 1/2),"The distribution half-life (T alpha 1/2) of midazolam, 1.24 minutes, was shorter than that of diazepam, 3.85 minutes.",[Usefulness of midazolam in a modified NLA--study on plasma concentrations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810699/),min,1.24,55579,DB00829,Diazepam
,2810699,distribution half-life (T alpha 1/2),"The distribution half-life (T alpha 1/2) of midazolam, 1.24 minutes, was shorter than that of diazepam, 3.85 minutes.",[Usefulness of midazolam in a modified NLA--study on plasma concentrations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810699/),min,3.85,55580,DB00829,Diazepam
,2810699,elimination half-life (T beta 1/2),"The elimination half-life (T beta 1/2) of midazolam, 5.44 hours, was similar to that of diazepam, 5.02 hours.",[Usefulness of midazolam in a modified NLA--study on plasma concentrations]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810699/),h,5.44,55581,DB00829,Diazepam
,2810699,elimination half-life (T beta 1/2),"The elimination half-life (T beta 1/2) of midazolam, 5.44 hours, was similar to that of diazepam, 5.02 hours.",[Usefulness of midazolam in a modified NLA--study on plasma concentrations]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810699/),h,5.02,55582,DB00829,Diazepam
,27232153,flow rate,"The plasma sample was deproteinized with methanol after addition of diazepam (internal standard, IS) and separated on a 38°C Hedera ODS-2 analytical column with a mobile phase of methanol and 5mM ammonium acetate buffer solution containing 0.1% formic acid at an isocratic flow rate of 400μL/min.",A rapid and sensitive LC-MS/MS method for determination of lercanidipine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27232153/),[μl] / [min],400,56780,DB00829,Diazepam
,17586125,m/z,"Quantification was performed using selected reaction monitoring (SRM) of the transitions m/z 240.88-->197.91 and m/z 285.01-->193.02 for ATT and for the IS, respectively.",Determination of anethole trithione in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17586125/),,240.88,56991,DB00829,Diazepam
,17586125,m/z,"Quantification was performed using selected reaction monitoring (SRM) of the transitions m/z 240.88-->197.91 and m/z 285.01-->193.02 for ATT and for the IS, respectively.",Determination of anethole trithione in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17586125/),,197.91,56992,DB00829,Diazepam
,17586125,m/z,"Quantification was performed using selected reaction monitoring (SRM) of the transitions m/z 240.88-->197.91 and m/z 285.01-->193.02 for ATT and for the IS, respectively.",Determination of anethole trithione in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17586125/),,285.01,56993,DB00829,Diazepam
,17586125,m/z,"Quantification was performed using selected reaction monitoring (SRM) of the transitions m/z 240.88-->197.91 and m/z 285.01-->193.02 for ATT and for the IS, respectively.",Determination of anethole trithione in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17586125/),,193.02,56994,DB00829,Diazepam
,17586125,analysis time,The analysis time for each run was 5.0 min.,Determination of anethole trithione in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17586125/),min,5.0,56995,DB00829,Diazepam
more,17586125,recoveries,The recoveries were more than 80%.,Determination of anethole trithione in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17586125/),%,80,56996,DB00829,Diazepam
,20954210,flow rate,"DL-Praeruptorin A and diazepam (internal standard) extracted from rat plasma samples with chloroform and analyzed on an XTerra™ RP₁₈ column (150 mm x 4.6 mm i.d., 5 µm) were chromatographically separated within 5.5 min using methanol-water (75:25, v/v; flow rate 1 mL/min) as the mobile phase.",Liquid chromatography tandem mass spectrometry pharmacokinetic study of DL-praeruptorin A in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954210/),[ml] / [min],1,57789,DB00829,Diazepam
,2702793,volumes of distribution,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[l] / [kg],1.2,58973,DB00829,Diazepam
,2702793,volumes of distribution,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[l] / [kg],2.3,58974,DB00829,Diazepam
,2702793,half-life,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),h,33,58975,DB00829,Diazepam
,2702793,half-life,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),h,2.8,58976,DB00829,Diazepam
,2702793,metabolic clearance,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[ml] / [kg·min],0.5,58977,DB00829,Diazepam
,2702793,metabolic clearance,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[ml] / [kg·min],11.0,58978,DB00829,Diazepam
,2702793,apparent EC50,The relationship of EEG change to plasma drug concentration indicated an apparent EC50 value of 269 ng/ml for diazepam as opposed to 35 ng/ml for midazolam.,"Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[ng] / [ml],269,58979,DB00829,Diazepam
,2702793,apparent EC50,The relationship of EEG change to plasma drug concentration indicated an apparent EC50 value of 269 ng/ml for diazepam as opposed to 35 ng/ml for midazolam.,"Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[ng] / [ml],35,58980,DB00829,Diazepam
,2702793,Emax,"However, Emax values were similar for both drugs (+19.4% and +21.3%, respectively).","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),%,19.4,58981,DB00829,Diazepam
,2702793,Emax,"However, Emax values were similar for both drugs (+19.4% and +21.3%, respectively).","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),%,21.3,58982,DB00829,Diazepam
,15533682,retention times,"Praziquantel was separated from the internal standard (diazepam) on a Luna C18 column (250 mm x 4.6mm, 5 microm particle size), with retention times of 4.8 and 6.2 min, respectively.",A high-performance liquid chromatographic method for determination of praziquantel in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15533682/),min,4.8,60099,DB00829,Diazepam
,15533682,retention times,"Praziquantel was separated from the internal standard (diazepam) on a Luna C18 column (250 mm x 4.6mm, 5 microm particle size), with retention times of 4.8 and 6.2 min, respectively.",A high-performance liquid chromatographic method for determination of praziquantel in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15533682/),min,6.2,60100,DB00829,Diazepam
,15533682,flow rate,"The mobile phase consisted of acetonitrile and distilled water (70:30, v/v), running through the column at a flow rate of 1.0 ml/min.",A high-performance liquid chromatographic method for determination of praziquantel in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15533682/),[ml] / [min],1.0,60101,DB00829,Diazepam
,15533682,Limit of quantification (LOQ),Limit of quantification (LOQ) was accepted as 5 ng using 1 ml samples.,A high-performance liquid chromatographic method for determination of praziquantel in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15533682/),ng,5,60102,DB00829,Diazepam
greater,15533682,recovery,The mean recovery for praziquantel and the internal standard were greater than 90% for both praziquantel and internal standard.,A high-performance liquid chromatographic method for determination of praziquantel in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15533682/),%,90,60103,DB00829,Diazepam
,31010782,peak diazepam concentration (Cmax),The mean peak diazepam concentration (Cmax) of 31.0 ng/mL was detected at a mean time (Tmax) of 3.1 hours after suppository placement.,Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010782/),[ng] / [ml],31.0,60194,DB00829,Diazepam
,31010782,time (Tmax),The mean peak diazepam concentration (Cmax) of 31.0 ng/mL was detected at a mean time (Tmax) of 3.1 hours after suppository placement.,Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010782/),h,3.1,60195,DB00829,Diazepam
,31010782,bioavailability,"The bioavailability was found to be 70.5%, and the mean terminal elimination half-life was 82 hours.",Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010782/),%,70.5,60196,DB00829,Diazepam
,31010782,terminal elimination half-life,"The bioavailability was found to be 70.5%, and the mean terminal elimination half-life was 82 hours.",Vaginal Diazepam for Nonrelaxing Pelvic Floor Dysfunction: The Pharmacokinetic Profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010782/),h,82,60197,DB00829,Diazepam
,32768890,flow rate,The mobile phase was consisted of acetonitrile (solution A) and 0.1 % formic acid in water (solution B) in a linear gradient elution procedure with a flow rate of 0.40 mL/min.,Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32768890/),[ml] / [min],0.40,62985,DB00829,Diazepam
,32768890,m/,"Selected multiple reaction monitoring (MRM) mode was employed to detect the parent-to-daughter ion transitions as follows: m/z 497.4 → 302.2 for selexipag, m/z 420.1 → 378.2 for ACT-333679, and m/z 285.0 → 154.0 for diazepam (IS), respectively.",Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32768890/),,497.4,62986,DB00829,Diazepam
,32768890,m/,"Selected multiple reaction monitoring (MRM) mode was employed to detect the parent-to-daughter ion transitions as follows: m/z 497.4 → 302.2 for selexipag, m/z 420.1 → 378.2 for ACT-333679, and m/z 285.0 → 154.0 for diazepam (IS), respectively.",Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32768890/),,302.2,62987,DB00829,Diazepam
,32768890,m/,"Selected multiple reaction monitoring (MRM) mode was employed to detect the parent-to-daughter ion transitions as follows: m/z 497.4 → 302.2 for selexipag, m/z 420.1 → 378.2 for ACT-333679, and m/z 285.0 → 154.0 for diazepam (IS), respectively.",Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32768890/),,420.1,62988,DB00829,Diazepam
,32768890,m/z,"Selected multiple reaction monitoring (MRM) mode was employed to detect the parent-to-daughter ion transitions as follows: m/z 497.4 → 302.2 for selexipag, m/z 420.1 → 378.2 for ACT-333679, and m/z 285.0 → 154.0 for diazepam (IS), respectively.",Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32768890/),,285.0,62989,DB00829,Diazepam
,32768890,m/z,"Selected multiple reaction monitoring (MRM) mode was employed to detect the parent-to-daughter ion transitions as follows: m/z 497.4 → 302.2 for selexipag, m/z 420.1 → 378.2 for ACT-333679, and m/z 285.0 → 154.0 for diazepam (IS), respectively.",Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32768890/),,154.0,62990,DB00829,Diazepam
,6849499,Elimination half-life,"Elimination half-life was longer in elderly than in young men (101 v 32 h, P less than 0.025), partly due to the increased Vd as well as to a significant reduction in total metabolic clearance (0.24 v 0.46 ml/min/kg, P less than 0.05).",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),h,101,66066,DB00829,Diazepam
,6849499,Elimination half-life,"Elimination half-life was longer in elderly than in young men (101 v 32 h, P less than 0.025), partly due to the increased Vd as well as to a significant reduction in total metabolic clearance (0.24 v 0.46 ml/min/kg, P less than 0.05).",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),h,32,66067,DB00829,Diazepam
,6849499,total metabolic clearance,"Elimination half-life was longer in elderly than in young men (101 v 32 h, P less than 0.025), partly due to the increased Vd as well as to a significant reduction in total metabolic clearance (0.24 v 0.46 ml/min/kg, P less than 0.05).",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),[ml] / [kg·min],0.24,66068,DB00829,Diazepam
,6849499,total metabolic clearance,"Elimination half-life was longer in elderly than in young men (101 v 32 h, P less than 0.025), partly due to the increased Vd as well as to a significant reduction in total metabolic clearance (0.24 v 0.46 ml/min/kg, P less than 0.05).",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),[ml] / [kg·min],0.46,66069,DB00829,Diazepam
,6849499,half-life,"However, the prolonged half-life in elderly as opposed to young women (99 v 44 h; P less than .01) was due mainly to increased Vd because clearance was not significantly changed (0.29 v 0.35 ml/min/kg).",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),h,99,66070,DB00829,Diazepam
,6849499,half-life,"However, the prolonged half-life in elderly as opposed to young women (99 v 44 h; P less than .01) was due mainly to increased Vd because clearance was not significantly changed (0.29 v 0.35 ml/min/kg).",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),h,44,66071,DB00829,Diazepam
,6849499,clearance,"However, the prolonged half-life in elderly as opposed to young women (99 v 44 h; P less than .01) was due mainly to increased Vd because clearance was not significantly changed (0.29 v 0.35 ml/min/kg).",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),[ml] / [kg·min],0.29,66072,DB00829,Diazepam
,6849499,clearance,"However, the prolonged half-life in elderly as opposed to young women (99 v 44 h; P less than .01) was due mainly to increased Vd because clearance was not significantly changed (0.29 v 0.35 ml/min/kg).",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),[ml] / [kg·min],0.35,66073,DB00829,Diazepam
,6849499,Absolute bioavailability,"Absolute bioavailability averaged 94%, indicating essentially complete absorption.",Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849499/),%,94,66074,DB00829,Diazepam
,15924720,peak blood level,"(1) Animal study: IBU and DZP were both rapidly absorbed from rectum with a peak blood level of (11.7 +/- 1.2) min and (9.4 +/- 2.7) min in rabbits, respectively.",[Animal and clinical studies on rectal administration of a mixed solution of ibuprofen and diazepam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15924720/),min,11.7,68851,DB00829,Diazepam
,15924720,peak blood level,"(1) Animal study: IBU and DZP were both rapidly absorbed from rectum with a peak blood level of (11.7 +/- 1.2) min and (9.4 +/- 2.7) min in rabbits, respectively.",[Animal and clinical studies on rectal administration of a mixed solution of ibuprofen and diazepam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15924720/),min,9.4,68852,DB00829,Diazepam
,15924720,peak values,"The peak values were (57.8 +/- 7.9) mg/L and (450.1 +/- 158.7) microg/L, respectively.",[Animal and clinical studies on rectal administration of a mixed solution of ibuprofen and diazepam]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15924720/),[mg] / [l],57.8,68853,DB00829,Diazepam
,15924720,peak values,"The peak values were (57.8 +/- 7.9) mg/L and (450.1 +/- 158.7) microg/L, respectively.",[Animal and clinical studies on rectal administration of a mixed solution of ibuprofen and diazepam]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15924720/),[μg] / [l],450.1,68854,DB00829,Diazepam
,25913929,flow rate,The chromatographic separation of analytes was successfully achieved on an XTerra® MS C18 column using a gradient elution of methanol and water containing 0.1% formic acid at a flow rate of 0.5 mL/min.,Simultaneous Quantification of Diazepam and Dexamethasone in Plasma by High-Performance Liquid Chromatography with Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Comparison between Normoxic and Hypoxic Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913929/),[ml] / [min],0.5,69187,DB00829,Diazepam
,43552,elimination half-life,Values of elimination half-life ranged from 8.3--31.2 h (mean 17.0 h) and did not vary significantly with dose.,"Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/43552/),h,17.0,69442,DB00829,Diazepam
,43552,observed accumulation ratio,"The mean observed accumulation ratio was 1.84, which was slightly larger than the predicted ratio of 1.53.","Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43552/),,1.84,69443,DB00829,Diazepam
,8723850,time to peak plasma concentration (Cmax),The mean (+/-sd) time to peak plasma concentration (Cmax) was shorter for im midazolam (17.5 +/- 6.5 min) relative to diazepam (33.8 +/- 7.5 min).,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),min,17.5,70819,DB00829,Diazepam
,8723850,time to peak plasma concentration (Cmax),The mean (+/-sd) time to peak plasma concentration (Cmax) was shorter for im midazolam (17.5 +/- 6.5 min) relative to diazepam (33.8 +/- 7.5 min).,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),min,33.8,70820,DB00829,Diazepam
,8723850,time to peak absorption rate,The mean (+sd) time to peak absorption rate was also shorter for midazolam (9 +/- 2 vs 13.8 +/- 7.5 min).,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),min,9,70821,DB00829,Diazepam
,8723850,time to peak absorption rate,The mean (+sd) time to peak absorption rate was also shorter for midazolam (9 +/- 2 vs 13.8 +/- 7.5 min).,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),min,13.8,70822,DB00829,Diazepam
,8723850,peak rate of absorption,The peak rate of absorption was identical (0.18 mg.,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),mg,0.18,70823,DB00829,Diazepam
,8723850,bioavailability,min-1) and bioavailability was 1.0 for both drugs.,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),,1.0,70824,DB00829,Diazepam
,6790396,elimination half life,"The time course of the active metabolite descyclopropylmethylprazepam (= norprazepam), representing 80-90% of all prazepam metabolites in plasma, can be described by an open one compartment model with a mean elimination half life of 70 h and a plasma clearance of 1.0-1.4 l/h.",[Pharmacokinetics of oral prazepam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6790396/),h,70,73119,DB00829,Diazepam
,6790396,plasma clearance,"The time course of the active metabolite descyclopropylmethylprazepam (= norprazepam), representing 80-90% of all prazepam metabolites in plasma, can be described by an open one compartment model with a mean elimination half life of 70 h and a plasma clearance of 1.0-1.4 l/h.",[Pharmacokinetics of oral prazepam]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6790396/),[l] / [h],1.0-1.4,73120,DB00829,Diazepam
,6790396,peak levels,"3-5 h after single doses of 20 mg prazepam, the corresponding peak levels of norprazepam are 120-160 ng/ml.",[Pharmacokinetics of oral prazepam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6790396/),[ng] / [ml],120-160,73121,DB00829,Diazepam
,6790396,steady state levels,Following repeated doses of daily 20 mg prazepam steady state levels of norprazepam are 600-800 ng/ml.,[Pharmacokinetics of oral prazepam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6790396/),[ng] / [ml],600-800,73122,DB00829,Diazepam
,321178,half-life (T 1/2(beta),"In the initial study, 11 patients with liver disease (cirrhosis and fibrosis) had a longer half-life (T 1/2(beta) of 99.2 +/- 23.2 hr after a single intravenous bolus of 0.1 mg/kg of D than to age-matched normal subjects (46.6 +/- 14.2).",Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),h,99.2,73559,DB00829,Diazepam
,321178,half-life (T 1/2(beta),"In the initial study, 11 patients with liver disease (cirrhosis and fibrosis) had a longer half-life (T 1/2(beta) of 99.2 +/- 23.2 hr after a single intravenous bolus of 0.1 mg/kg of D than to age-matched normal subjects (46.6 +/- 14.2).",Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),h,46.6,73560,DB00829,Diazepam
,321178,T 1/2(beta),After subchronic treatment with 10 mg of D for 7 days T 1/2(beta) was prolonged only slightly (p = 0.043) in these patients (107.6 +/- 25.2 hr).,Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),h,107.6,73561,DB00829,Diazepam
,321178,T 1/2(beta),"The cross-over study in the four normal subjects demonstrated that DD was eliminated much more slowly than D. Whereas for D, T 1/2(beta) and Cl were 32.6 +/- 11.3 hr and 32.3 +/- 11.0 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min.",Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),h,32.6,73562,DB00829,Diazepam
,321178,T 1/2(beta),"The cross-over study in the four normal subjects demonstrated that DD was eliminated much more slowly than D. Whereas for D, T 1/2(beta) and Cl were 32.6 +/- 11.3 hr and 32.3 +/- 11.0 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min.",Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),h,50.9,73563,DB00829,Diazepam
,321178,Cl,"The cross-over study in the four normal subjects demonstrated that DD was eliminated much more slowly than D. Whereas for D, T 1/2(beta) and Cl were 32.6 +/- 11.3 hr and 32.3 +/- 11.0 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min.",Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),[ml] / [min],32.3,73564,DB00829,Diazepam
,321178,Cl,"The cross-over study in the four normal subjects demonstrated that DD was eliminated much more slowly than D. Whereas for D, T 1/2(beta) and Cl were 32.6 +/- 11.3 hr and 32.3 +/- 11.0 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min.",Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),[ml] / [min],11.3,73565,DB00829,Diazepam
,321178,Cl,"The cross-over study in the four normal subjects demonstrated that DD was eliminated much more slowly than D. Whereas for D, T 1/2(beta) and Cl were 32.6 +/- 11.3 hr and 32.3 +/- 11.0 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min, respectively, the corresponding values for DD were 50.9 +/- 6.2 hr and 11.3 +/- 3.1 ml/min.",Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),h,50.9,73566,DB00829,Diazepam
,321178,T 1/2(beta),In these patients T 1/2(beta) for DD was prolonged (p = 0.015) to 108.2 +/- 40.3 hr.,Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),h,108.2,73567,DB00829,Diazepam
,321178,Cl,"This prolongation was caused by a decrease in Cl of 4.6 +/- 1.1 ml/min, (p = 0.003) whereas Vd(Cl) did not change significantly.",Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/321178/),[ml] / [min],4.6,73568,DB00829,Diazepam
,25794556,extraction ratio,Intermittent haemodialysis was performed for 4 h and resulted in a theophylline extraction ratio of 0.57 with elimination half-life of 2.3 h.,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.57,74512,DB00829,Diazepam
,25794556,elimination half-life,Intermittent haemodialysis was performed for 4 h and resulted in a theophylline extraction ratio of 0.57 with elimination half-life of 2.3 h.,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,2.3,74513,DB00829,Diazepam
,25794556,extraction ratio,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.46,74514,DB00829,Diazepam
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,5.3,74515,DB00829,Diazepam
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.61,74516,DB00829,Diazepam
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,10.6,74517,DB00829,Diazepam
,25794556,elimination half-life,"After cessation of SLED, elimination half-life was 26 h.",Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,26,74518,DB00829,Diazepam
,26505163,tmax,Δ9-THC was well absorbed with a mean tmax of 123 min.,"Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26505163/),min,123,75694,DB00829,Diazepam
,1782980,unbound fraction,The unbound fraction of the drug in renal patients was higher (5.5%) than in controls (2.9%).,Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782980/),%,5.5,76387,DB00829,Diazepam
,1782980,unbound fraction,The unbound fraction of the drug in renal patients was higher (5.5%) than in controls (2.9%).,Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782980/),%,2.9,76388,DB00829,Diazepam
,1782980,apparent volume of distribution,Correction for differences in protein binding revealed a reduced apparent volume of distribution (47 vs. 140 l.kg-1) and a reduced clearance (5.0 vs. 10.5 ml.min-1.kg-1) in the patients.,Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782980/),[l] / [kg],47,76389,DB00829,Diazepam
,1782980,apparent volume of distribution,Correction for differences in protein binding revealed a reduced apparent volume of distribution (47 vs. 140 l.kg-1) and a reduced clearance (5.0 vs. 10.5 ml.min-1.kg-1) in the patients.,Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782980/),[l] / [kg],140,76390,DB00829,Diazepam
,1782980,clearance,Correction for differences in protein binding revealed a reduced apparent volume of distribution (47 vs. 140 l.kg-1) and a reduced clearance (5.0 vs. 10.5 ml.min-1.kg-1) in the patients.,Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782980/),[ml] / [kg·min],5.0,76391,DB00829,Diazepam
,1782980,clearance,Correction for differences in protein binding revealed a reduced apparent volume of distribution (47 vs. 140 l.kg-1) and a reduced clearance (5.0 vs. 10.5 ml.min-1.kg-1) in the patients.,Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782980/),[ml] / [kg·min],10.5,76392,DB00829,Diazepam
,1782980,systemic availability,The systemic availability of oral chlordesmethyldiazepam was good (82%) despite a relatively slow absorption rate.,Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782980/),%,82,76393,DB00829,Diazepam
,2746493,distribution volume,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),[l] / [kg],1.89,77010,DB00829,Diazepam
,2746493,distribution volume,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),[l] / [kg],1.81,77011,DB00829,Diazepam
,2746493,elimination half-life,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),h,11.5,77012,DB00829,Diazepam
,2746493,elimination half-life,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),h,12.2,77013,DB00829,Diazepam
,2746493,clearance,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),[ml] / [kg·min],2.08,77014,DB00829,Diazepam
,2746493,clearance,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),[ml] / [kg·min],1.88,77015,DB00829,Diazepam
shorter,22929751,elimination half-life,"In theory, accumulation does not occur with once-daily dosage of benzodiazepines that have an elimination half-life markedly shorter than 24 h, such as oxazepam, temazepam, and lorazepam.",[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929751/),h,24,77548,DB00829,Diazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],4.8,77646,DB00829,Diazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],7.2,77647,DB00829,Diazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],17.9,77648,DB00829,Diazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,9.3,77649,DB00829,Diazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,23,77650,DB00829,Diazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,63,77651,DB00829,Diazepam
,334648,plasma protein binding,The strong plasma protein binding of 95 to 98 percent determines the low hepatic clearance of diazepam.,[Important factors determining human distribution and elimination of diazepam]. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/334648/),%,95 to 98,77891,DB00829,Diazepam
,16867586,Recovery,Recovery was 95% +/- 12.77 (S.D.) determined by radioactive tracer experiments.,"Studies on the pharmacokinetics and metabolism of N(4)-carbamoyl-1,3,4,5-dihydro-diazepam (Uxepam(R)) in rats, dogs and man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867586/),%,95,78262,DB00829,Diazepam
,16867586,limit of detection,The limit of detection for uxepam was 10 ng ml(-1).,"Studies on the pharmacokinetics and metabolism of N(4)-carbamoyl-1,3,4,5-dihydro-diazepam (Uxepam(R)) in rats, dogs and man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867586/),[ng] / [ml],10,78263,DB00829,Diazepam
,15232663,total area under the plasma concentration-time curve (AUC,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),[h·ng·rectangle] / [ml],213,79185,DB00829,Diazepam
,15232663,total area under the plasma concentration-time curve (AUC,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),[h·ng·rectangle] / [ml],326,79186,DB00829,Diazepam
,15232663,elimination half-life,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),h,12.0,79187,DB00829,Diazepam
,15232663,elimination half-life,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),h,17.3,79188,DB00829,Diazepam
,6515128,t 1/2,"After transfusion with Fluosol DA 20%, the t 1/2 of sulfamethazine was increased from 3.15 +/- 0.56 to 7.65 +/- 2.41 hr (p less than 0.05) and the Vd was increased from 60.7 +/- 17.5 to 152 +/- 16 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),h,3.15,80475,DB00829,Diazepam
,6515128,t 1/2,"After transfusion with Fluosol DA 20%, the t 1/2 of sulfamethazine was increased from 3.15 +/- 0.56 to 7.65 +/- 2.41 hr (p less than 0.05) and the Vd was increased from 60.7 +/- 17.5 to 152 +/- 16 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),h,7.65,80476,DB00829,Diazepam
,6515128,Vd,"After transfusion with Fluosol DA 20%, the t 1/2 of sulfamethazine was increased from 3.15 +/- 0.56 to 7.65 +/- 2.41 hr (p less than 0.05) and the Vd was increased from 60.7 +/- 17.5 to 152 +/- 16 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),ml,60.7,80477,DB00829,Diazepam
,6515128,Vd,"After transfusion with Fluosol DA 20%, the t 1/2 of sulfamethazine was increased from 3.15 +/- 0.56 to 7.65 +/- 2.41 hr (p less than 0.05) and the Vd was increased from 60.7 +/- 17.5 to 152 +/- 16 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),ml,152,80478,DB00829,Diazepam
,6515128,AUC,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),[h·μg] / [ml],129,80479,DB00829,Diazepam
,6515128,AUC,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),[h·μg] / [ml],80.5,80480,DB00829,Diazepam
,6515128,Cl,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),[ml] / [h],12.2,80481,DB00829,Diazepam
,6515128,Cl,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),[ml] / [h],20.2,80482,DB00829,Diazepam
,6515128,Vd,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),ml,60.1,80483,DB00829,Diazepam
,6515128,Vd,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),ml,132,80484,DB00829,Diazepam
,2859206,bioavailability,"The bioavailability of DPC and DZM after i.m. administration, determined from computer calculated AUCs, was 1.04 and 0.85, respectively.",Intramuscular bioavailability of chlorazepate as compared to diazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859206/),,1.04,80788,DB00829,Diazepam
,2859206,bioavailability,"The bioavailability of DPC and DZM after i.m. administration, determined from computer calculated AUCs, was 1.04 and 0.85, respectively.",Intramuscular bioavailability of chlorazepate as compared to diazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859206/),,0.85,80789,DB00829,Diazepam
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00829,Diazepam
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00829,Diazepam
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00829,Diazepam
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00829,Diazepam
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00829,Diazepam
,481615,T 1/2 (beta),Following the single intravenous bolus of 5 mg/kg diazepam was eliminated more slowly in old rats (T 1/2 (beta) = 3.1 H) than in middle aged rats (1.4H).,Effect of age on levels of diazepam in plasma and brain of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/481615/),h,3.1,81645,DB00829,Diazepam
,481615,T 1/2 (beta),Following the single intravenous bolus of 5 mg/kg diazepam was eliminated more slowly in old rats (T 1/2 (beta) = 3.1 H) than in middle aged rats (1.4H).,Effect of age on levels of diazepam in plasma and brain of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/481615/),h,1.4,81646,DB00829,Diazepam
,481615,apparent volume of distribution Vd beta,This was due to an increase in the apparent volume of distribution Vd beta from 11.0 l/kg (control rats) to 29.5 l/kg.,Effect of age on levels of diazepam in plasma and brain of rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/481615/),[l] / [kg],11.0,81647,DB00829,Diazepam
,481615,apparent volume of distribution Vd beta,This was due to an increase in the apparent volume of distribution Vd beta from 11.0 l/kg (control rats) to 29.5 l/kg.,Effect of age on levels of diazepam in plasma and brain of rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/481615/),[l] / [kg],29.5,81648,DB00829,Diazepam
,9811432,peak plasma concentrations,"Mean peak plasma concentrations after i.v. administration were 5963 and 5565 ng/mL, before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],5963,81953,DB00829,Diazepam
,9811432,peak plasma concentrations,"Mean peak plasma concentrations after i.v. administration were 5963 and 5565 ng/mL, before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],5565,81954,DB00829,Diazepam
,9811432,peak concentrations,"After p.r. administration, mean peak concentrations were 629 ng/mL and 274 ng/mL and were reached within 30 min before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],629,81955,DB00829,Diazepam
,9811432,peak concentrations,"After p.r. administration, mean peak concentrations were 629 ng/mL and 274 ng/mL and were reached within 30 min before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],274,81956,DB00829,Diazepam
,9811432,time to attainment of target concentration,The target concentration for potential seizure control (i.e. 150 ng/mL) was attained in five dogs in the post phenobarbital p.r. group with a median time to attainment of target concentration of 8 min.,Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),min,8,81957,DB00829,Diazepam
,7130314,minimum detection range,The minimum detection range of each compound was approximately 2.5 ng per 100-microliter sample.,Determination of diazepam and its pharmacologically active metabolites in blood by bond Elut column extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7130314/),-1·ng,2.5,82713,DB00829,Diazepam
,34115414,plasma clearance,"The mean plasma clearance of DIA was 5.9 ml/min/kg, and the plasma elimination half-life in the terminal phase was 19.9 h.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),[ml] / [kg·min],5.9,83712,DB00829,Diazepam
,34115414,plasma elimination half-life in the terminal phase,"The mean plasma clearance of DIA was 5.9 ml/min/kg, and the plasma elimination half-life in the terminal phase was 19.9 h.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),h,19.9,83713,DB00829,Diazepam
,34115414,detection time,"The detection time according to the European Horserace Scientific Liaison Committee (EHSLC), that is the time for which observed DIA plasma concentrations of all investigated horses were below the IPC was 10 days.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),d,10,83714,DB00829,Diazepam
,17604610,lymphatic,"While DDT is known to have significant lymphatic bioavailability, diazepam has negligible intestinal lymphatic transport (0.014+/-0.004% of a given dose).",Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17604610/),%,0.014,83813,DB00829,Diazepam
,17604610,transport,"While DDT is known to have significant lymphatic bioavailability, diazepam has negligible intestinal lymphatic transport (0.014+/-0.004% of a given dose).",Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17604610/),%,0.014,83814,DB00829,Diazepam
,20542396,flow rate,"Chromatographic separation was carried out on an Agilent XDB-C(8) column with an isocratic mobile phase consisting of acetonitrile and water (70:30, V/V) at a flow rate of 0.5 mL/min.",Development of a LC-MS/MS method for the determination of antrodin B and antrodin C from Antrodia camphorata extract in rat plasma for pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542396/),[ml] / [min],0.5,84826,DB00829,Diazepam
,20542396,linear dynamic range,The assay exhibited a linear dynamic range of 47.6-4760 ng/mL for antrodin B and 56.6-5660 ng/mL for antrodin C.,Development of a LC-MS/MS method for the determination of antrodin B and antrodin C from Antrodia camphorata extract in rat plasma for pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542396/),[ng] / [ml],47.6-4760,84827,DB00829,Diazepam
,20542396,linear dynamic range,The assay exhibited a linear dynamic range of 47.6-4760 ng/mL for antrodin B and 56.6-5660 ng/mL for antrodin C.,Development of a LC-MS/MS method for the determination of antrodin B and antrodin C from Antrodia camphorata extract in rat plasma for pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542396/),[ng] / [ml],56.6-5660,84828,DB00829,Diazepam
,6780369,elimination half-life,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),h,51.7,85671,DB00829,Diazepam
,6780369,elimination half-life,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),h,72.6,85672,DB00829,Diazepam
,6780369,total plasma clearance,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),[ml] / [min],12.0,85673,DB00829,Diazepam
,6780369,total plasma clearance,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),[ml] / [min],8.6,85674,DB00829,Diazepam
,6778522,peak plasma levels,"The drug appears to be well absorbed, reaching peak plasma levels of 20--30 ng ml-1 1--2 h after administration; 72 h after administration, plasma concentrations are still measurable (5 ng ml-1).",Plasma levels of chlorodesmethyldiazepam in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6778522/),[ng] / [ml],20--30,85910,DB00829,Diazepam
,6132698,volume of distribution (Vd),"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.33,85924,DB00829,Diazepam
,6132698,volume of distribution (Vd),"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.45,85925,DB00829,Diazepam
,6132698,elimination t1/2,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,13.1,85926,DB00829,Diazepam
,6132698,elimination t1/2,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,12.2,85927,DB00829,Diazepam
,6132698,total clearance,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.25,85928,DB00829,Diazepam
,6132698,total clearance,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.50,85929,DB00829,Diazepam
,6132698,free fraction in,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,10.3,85930,DB00829,Diazepam
,6132698,Vd,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.05,85931,DB00829,Diazepam
,6132698,Vd,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.19,85932,DB00829,Diazepam
,6132698,t1/2,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,7.6,85933,DB00829,Diazepam
,6132698,t1/2,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,7.2,85934,DB00829,Diazepam
,6132698,total clearance,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.60,85935,DB00829,Diazepam
,6132698,total clearance,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],2.03,85936,DB00829,Diazepam
,6132698,free fraction,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,4.6,85937,DB00829,Diazepam
,6132698,free fraction,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,4.9,85938,DB00829,Diazepam
,25154625,Tmax,Diazepam median Tmax was 45 min.,Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25154625/),min,45,86529,DB00829,Diazepam
,6151170,serum half-life,It achieves peak serum concentrations within one hour and has a serum half-life of 2 to 5 hours.,"Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151170/),h,2 to 5,86750,DB00829,Diazepam
,7589052,elimination half-life,"After i.v. administration the kinetics of total chlordesmethyldiazepam in patients with liver disease differed from those in controls: elimination half-life was almost twice that in controls (395 and 204 h), as a consequence of a marked reduction in total clearance (0.13 and 0.25 ng.ml-1.h-1), whereas the apparent volume of distribution was similar in patients and controls (4.7 and 3.9 l/kg-1).",Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),h,395,86997,DB00829,Diazepam
,7589052,elimination half-life,"After i.v. administration the kinetics of total chlordesmethyldiazepam in patients with liver disease differed from those in controls: elimination half-life was almost twice that in controls (395 and 204 h), as a consequence of a marked reduction in total clearance (0.13 and 0.25 ng.ml-1.h-1), whereas the apparent volume of distribution was similar in patients and controls (4.7 and 3.9 l/kg-1).",Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),h,204,86998,DB00829,Diazepam
,7589052,total clearance,"After i.v. administration the kinetics of total chlordesmethyldiazepam in patients with liver disease differed from those in controls: elimination half-life was almost twice that in controls (395 and 204 h), as a consequence of a marked reduction in total clearance (0.13 and 0.25 ng.ml-1.h-1), whereas the apparent volume of distribution was similar in patients and controls (4.7 and 3.9 l/kg-1).",Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),[ng] / [h·ml],0.13,86999,DB00829,Diazepam
,7589052,total clearance,"After i.v. administration the kinetics of total chlordesmethyldiazepam in patients with liver disease differed from those in controls: elimination half-life was almost twice that in controls (395 and 204 h), as a consequence of a marked reduction in total clearance (0.13 and 0.25 ng.ml-1.h-1), whereas the apparent volume of distribution was similar in patients and controls (4.7 and 3.9 l/kg-1).",Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),[ng] / [h·ml],0.25,87000,DB00829,Diazepam
,7589052,apparent volume of distribution,"After i.v. administration the kinetics of total chlordesmethyldiazepam in patients with liver disease differed from those in controls: elimination half-life was almost twice that in controls (395 and 204 h), as a consequence of a marked reduction in total clearance (0.13 and 0.25 ng.ml-1.h-1), whereas the apparent volume of distribution was similar in patients and controls (4.7 and 3.9 l/kg-1).",Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),[l] / [kg],4.7,87001,DB00829,Diazepam
,7589052,apparent volume of distribution,"After i.v. administration the kinetics of total chlordesmethyldiazepam in patients with liver disease differed from those in controls: elimination half-life was almost twice that in controls (395 and 204 h), as a consequence of a marked reduction in total clearance (0.13 and 0.25 ng.ml-1.h-1), whereas the apparent volume of distribution was similar in patients and controls (4.7 and 3.9 l/kg-1).",Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),[l] / [kg],3.9,87002,DB00829,Diazepam
,7589052,free fraction,The free fraction of the drug in patients was higher (5.5%) than in controls (2.9%).,Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),%,5.5,87003,DB00829,Diazepam
,7589052,free fraction,The free fraction of the drug in patients was higher (5.5%) than in controls (2.9%).,Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),%,2.9,87004,DB00829,Diazepam
,7589052,clearance,Correction for differences in protein binding revealed clearance in the patients was one-fifth (1.8 and 10.5 ng ml-1.kg-1) and volume of distribution one-half (65.0 and 118.4 l.kg-1) that in controls.,Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),[ng] / [kg·ml],1.8,87005,DB00829,Diazepam
,7589052,clearance,Correction for differences in protein binding revealed clearance in the patients was one-fifth (1.8 and 10.5 ng ml-1.kg-1) and volume of distribution one-half (65.0 and 118.4 l.kg-1) that in controls.,Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),[ng] / [kg·ml],10.5,87006,DB00829,Diazepam
,7589052,volume of distribution one-half,Correction for differences in protein binding revealed clearance in the patients was one-fifth (1.8 and 10.5 ng ml-1.kg-1) and volume of distribution one-half (65.0 and 118.4 l.kg-1) that in controls.,Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),[l] / [kg],65.0,87007,DB00829,Diazepam
,7589052,volume of distribution one-half,Correction for differences in protein binding revealed clearance in the patients was one-fifth (1.8 and 10.5 ng ml-1.kg-1) and volume of distribution one-half (65.0 and 118.4 l.kg-1) that in controls.,Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),[l] / [kg],118.4,87008,DB00829,Diazepam
,7589052,systemic availability,The systemic availability of oral chlordesmethyldiazepam was high (110%) in spite of a relatively slow absorption rate.,Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589052/),%,110,87009,DB00829,Diazepam
,33041783,IC50,"The IC50 values of imperatorin to nordazepam and temazepam were 1.54 μM and 1.80 μM, respectively.",Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041783/),μM,1.54,87586,DB00829,Diazepam
,33041783,IC50,"The IC50 values of imperatorin to nordazepam and temazepam were 1.54 μM and 1.80 μM, respectively.",Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041783/),μM,1.80,87587,DB00829,Diazepam
,33041783,inhibitory constant,"The inhibitory constant values for temazepam and nordazepam were 1.24 μM and 1.29 μM, respectively.",Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041783/),μM,1.24,87588,DB00829,Diazepam
,33041783,inhibitory constant,"The inhibitory constant values for temazepam and nordazepam were 1.24 μM and 1.29 μM, respectively.",Inhibitory Effect of Imperatorin on the Pharmacokinetics of Diazepam In Vitro and In Vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041783/),μM,1.29,87589,DB00829,Diazepam
,8113798,maximal binding,"Its rapid cerebral kinetics is consistent with a hypnotic profile (maximal binding after 23 min, elimination half-life of 202 min).",In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),min,23,88000,DB00829,Diazepam
,8113798,elimination half-life,"Its rapid cerebral kinetics is consistent with a hypnotic profile (maximal binding after 23 min, elimination half-life of 202 min).",In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),min,202,88001,DB00829,Diazepam
,8113798,ID50,Triazolam is very potent in displacing [11C]flumazenil (ID50 = 28 +/- 6 micrograms/kg).,In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8113798/),[μg] / [kg],28,88002,DB00829,Diazepam
,26325216,plasma Cmax,"Following administration of 10mgkg(-1) (i.m.), MB327 DMS reached plasma Cmax of 22μM at 12min with an elimination t1/2 of 22min.",Pharmacokinetic profile and quantitation of protection against soman poisoning by the antinicotinic compound MB327 in the guinea-pig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325216/),μM,22,88616,DB00829,Diazepam
,26325216,elimination t1/2,"Following administration of 10mgkg(-1) (i.m.), MB327 DMS reached plasma Cmax of 22μM at 12min with an elimination t1/2 of 22min.",Pharmacokinetic profile and quantitation of protection against soman poisoning by the antinicotinic compound MB327 in the guinea-pig. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325216/),min,22,88617,DB00829,Diazepam
,7312934,elimination half-life,"Diazepam elimination half-life among males (mean: 66 h) increased significantly with age (r = 0.53, p less than 0.005).",Diazepam kinetics in relation to age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312934/),h,66,88627,DB00829,Diazepam
,7312934,Volume of distribution,"Volume of distribution (mean: 1.39 liters/kg) also increased significantly with age (r = 0.67, p less than 0.001).",Diazepam kinetics in relation to age and sex. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312934/),[l] / [kg],1.39,88628,DB00829,Diazepam
,7312934,Clearance,"Clearance of total diazepam in males (mean: 0.42 ml/min/kg) tended to decline with age (r = 0.32), but the association was of borderline significance (p = 0.1).",Diazepam kinetics in relation to age and sex. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312934/),[ml] / [kg·min],0.42,88629,DB00829,Diazepam
,7312934,free fraction,"Diazepam was extensively bound to plasma protein, with a mean free fraction among male subjects of 1.34%.",Diazepam kinetics in relation to age and sex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312934/),%,1.34,88630,DB00829,Diazepam
,7312934,volumes of distribution,"Compared to young males, young females had larger volumes of distribution (1.87 vs. 1.34 liters/kg) and higher total clearance (0.63 vs. 0.49 ml/min/kg).",Diazepam kinetics in relation to age and sex. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312934/),[l] / [kg],1.87,88631,DB00829,Diazepam
,7312934,volumes of distribution,"Compared to young males, young females had larger volumes of distribution (1.87 vs. 1.34 liters/kg) and higher total clearance (0.63 vs. 0.49 ml/min/kg).",Diazepam kinetics in relation to age and sex. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312934/),[l] / [kg],1.34,88632,DB00829,Diazepam
,7312934,total clearance,"Compared to young males, young females had larger volumes of distribution (1.87 vs. 1.34 liters/kg) and higher total clearance (0.63 vs. 0.49 ml/min/kg).",Diazepam kinetics in relation to age and sex. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312934/),[ml] / [kg·min],0.63,88633,DB00829,Diazepam
,7312934,total clearance,"Compared to young males, young females had larger volumes of distribution (1.87 vs. 1.34 liters/kg) and higher total clearance (0.63 vs. 0.49 ml/min/kg).",Diazepam kinetics in relation to age and sex. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312934/),[ml] / [kg·min],0.49,88634,DB00829,Diazepam
,17085083,flow-rate,"The mobile phase for separation consisted of 10mM ammonium acetate and methanol (50:50, v/v) and was delivered at a flow-rate of 0.2ml/min.",A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085083/),[ml] / [min],0.2,89781,DB00829,Diazepam
less,17085083,total time for,The total time for chromatographic separation was less than 16min.,A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085083/),min,16,89782,DB00829,Diazepam
,17085083,recoveries,Mean recoveries were 93.6% for MDZ and 86.6% for 1-OHMDZ.,A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085083/),%,93.6,89783,DB00829,Diazepam
,17085083,recoveries,Mean recoveries were 93.6% for MDZ and 86.6% for 1-OHMDZ.,A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085083/),%,86.6,89784,DB00829,Diazepam
,6415130,accumulation half-life,"Determination of diazepam and desmethyldiazepam plasma concentrations during the dosing period and for a withdrawal period indicated that accumulation half-life for both diazepam (7.8 days in obese vs. 3.1 days in normal subjects, P less than 0.05) and desmethyldiazepam (30.3 vs.",Prolonged accumulation of diazepam in obesity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),d,7.8,90011,DB00829,Diazepam
,6415130,accumulation half-life,"Determination of diazepam and desmethyldiazepam plasma concentrations during the dosing period and for a withdrawal period indicated that accumulation half-life for both diazepam (7.8 days in obese vs. 3.1 days in normal subjects, P less than 0.05) and desmethyldiazepam (30.3 vs.",Prolonged accumulation of diazepam in obesity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),d,3.1,90012,DB00829,Diazepam
,6415130,accumulation half-life,"Determination of diazepam and desmethyldiazepam plasma concentrations during the dosing period and for a withdrawal period indicated that accumulation half-life for both diazepam (7.8 days in obese vs. 3.1 days in normal subjects, P less than 0.05) and desmethyldiazepam (30.3 vs.",Prolonged accumulation of diazepam in obesity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),,30.3,90013,DB00829,Diazepam
,6415130,steady-state plasma concentrations,"However, mean steady-state plasma concentrations of diazepam (68 vs. 67 ng/ml) and desmethyldiazepam (156 vs. 91 ng/ml) did not significantly differ between groups.",Prolonged accumulation of diazepam in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ng] / [ml],68,90014,DB00829,Diazepam
,6415130,steady-state plasma concentrations,"However, mean steady-state plasma concentrations of diazepam (68 vs. 67 ng/ml) and desmethyldiazepam (156 vs. 91 ng/ml) did not significantly differ between groups.",Prolonged accumulation of diazepam in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ng] / [ml],67,90015,DB00829,Diazepam
,6415130,steady-state plasma concentrations,"However, mean steady-state plasma concentrations of diazepam (68 vs. 67 ng/ml) and desmethyldiazepam (156 vs. 91 ng/ml) did not significantly differ between groups.",Prolonged accumulation of diazepam in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ng] / [ml],156,90016,DB00829,Diazepam
,6415130,steady-state plasma concentrations,"However, mean steady-state plasma concentrations of diazepam (68 vs. 67 ng/ml) and desmethyldiazepam (156 vs. 91 ng/ml) did not significantly differ between groups.",Prolonged accumulation of diazepam in obesity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ng] / [ml],91,90017,DB00829,Diazepam
,6415130,elimination half-life,"Diazepam elimination half-life was greatly prolonged in the obese subjects (82 vs. 32 hours, P less than 0.005), with no change in total metabolic clearance (32 vs. 26 ml/min).",Prolonged accumulation of diazepam in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),h,82,90018,DB00829,Diazepam
,6415130,elimination half-life,"Diazepam elimination half-life was greatly prolonged in the obese subjects (82 vs. 32 hours, P less than 0.005), with no change in total metabolic clearance (32 vs. 26 ml/min).",Prolonged accumulation of diazepam in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),h,32,90019,DB00829,Diazepam
,6415130,total metabolic clearance,"Diazepam elimination half-life was greatly prolonged in the obese subjects (82 vs. 32 hours, P less than 0.005), with no change in total metabolic clearance (32 vs. 26 ml/min).",Prolonged accumulation of diazepam in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ml] / [min],32,90020,DB00829,Diazepam
,6415130,total metabolic clearance,"Diazepam elimination half-life was greatly prolonged in the obese subjects (82 vs. 32 hours, P less than 0.005), with no change in total metabolic clearance (32 vs. 26 ml/min).",Prolonged accumulation of diazepam in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ml] / [min],26,90021,DB00829,Diazepam
,6415130,volume of distribution,"Instead, a large increase in volume of distribution (228 vs. 70 liters, P less than 0.01) was the reason for prolongation of the elimination half-life.",Prolonged accumulation of diazepam in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),l,228,90022,DB00829,Diazepam
,6415130,volume of distribution,"Instead, a large increase in volume of distribution (228 vs. 70 liters, P less than 0.01) was the reason for prolongation of the elimination half-life.",Prolonged accumulation of diazepam in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),l,70,90023,DB00829,Diazepam
,6415130,elimination half-life,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),h,130,90024,DB00829,Diazepam
,6415130,elimination half-life,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),h,56,90025,DB00829,Diazepam
,6415130,total metabolic clearance,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ml] / [min],13.7,90026,DB00829,Diazepam
,6415130,total metabolic clearance,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),[ml] / [min],19.2,90027,DB00829,Diazepam
,6415130,volume of distribution,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),l,151,90028,DB00829,Diazepam
,6415130,volume of distribution,"Similarly for desmethyldiazepam, elimination half-life was prolonged in obese subjects (130 vs. 56 hours, P less than 0.01), without a change in total metabolic clearance (13.7 vs. 19.2 ml/min), due to increased volume of distribution (151 vs. 73 liters, P less than 0.01).",Prolonged accumulation of diazepam in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6415130/),l,73,90029,DB00829,Diazepam
,21594876,flow rate,"A gradient elution was performed on a Hedera ODS-2 column (150×2.1 mm i.d., 5 µm), using a mobile phase consisting of 0.1% formic acid solution and methanol at a flow rate of 0.5 mL/min.",Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594876/),[ml] / [min],0.5,90268,DB00829,Diazepam
,21594876,m,"The single quadrupole mass spectrometer was operated in selected-ion monitoring mode via positive electrospray ionization interface detecting m/z 239.1 and 285.1 for ipriflavone and diazepam (the internal standard), respectively.",Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594876/),,239.1,90269,DB00829,Diazepam
,21594876,m,"The single quadrupole mass spectrometer was operated in selected-ion monitoring mode via positive electrospray ionization interface detecting m/z 239.1 and 285.1 for ipriflavone and diazepam (the internal standard), respectively.",Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594876/),,285.1,90270,DB00829,Diazepam
,21594876,C(max,"After oral administration of a single 200 mg ipriflavone tablet, the C(max,) AUC(0-72 h) , t(1/2) and T(max) were 6.3±6.3 ng/mL, 80.0±69.1 µg h/L, 23.0±8.6 h and 3.4±2.1 h, respectively.",Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594876/),[ng] / [ml],6.3,90271,DB00829,Diazepam
,21594876,t(1/2),"After oral administration of a single 200 mg ipriflavone tablet, the C(max,) AUC(0-72 h) , t(1/2) and T(max) were 6.3±6.3 ng/mL, 80.0±69.1 µg h/L, 23.0±8.6 h and 3.4±2.1 h, respectively.",Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594876/),h,23.0,90272,DB00829,Diazepam
,21594876,T(max),"After oral administration of a single 200 mg ipriflavone tablet, the C(max,) AUC(0-72 h) , t(1/2) and T(max) were 6.3±6.3 ng/mL, 80.0±69.1 µg h/L, 23.0±8.6 h and 3.4±2.1 h, respectively.",Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594876/),h,3.4,90273,DB00829,Diazepam
,17685392,flow rate,"The chromatographic separation was achieved on a reversed-phase C(18) column by gradient elution using acetonitrile and 0.025% (v/v) phosphoric acid solution as mobile phase, at a flow rate of 1.0 mL/min.",Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17685392/),[ml] / [min],1.0,90755,DB00829,Diazepam
,17685392,limit of,"The limit of detection and the limit of quantification for danshensu, salvianolic acid B and tanshinone IIA in plasma were 0.065, 0.043, 0.022, 0.131, 0.085 and 0.044 microg/mL, respectively.",Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17685392/),[μg] / [ml],0.065,90756,DB00829,Diazepam
,17685392,limit of,"The limit of detection and the limit of quantification for danshensu, salvianolic acid B and tanshinone IIA in plasma were 0.065, 0.043, 0.022, 0.131, 0.085 and 0.044 microg/mL, respectively.",Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17685392/),[μg] / [ml],0.043,90757,DB00829,Diazepam
,17685392,limit of,"The limit of detection and the limit of quantification for danshensu, salvianolic acid B and tanshinone IIA in plasma were 0.065, 0.043, 0.022, 0.131, 0.085 and 0.044 microg/mL, respectively.",Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17685392/),[μg] / [ml],0.022,90758,DB00829,Diazepam
,17685392,limit of,"The limit of detection and the limit of quantification for danshensu, salvianolic acid B and tanshinone IIA in plasma were 0.065, 0.043, 0.022, 0.131, 0.085 and 0.044 microg/mL, respectively.",Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17685392/),[μg] / [ml],0.131,90759,DB00829,Diazepam
,17685392,limit of,"The limit of detection and the limit of quantification for danshensu, salvianolic acid B and tanshinone IIA in plasma were 0.065, 0.043, 0.022, 0.131, 0.085 and 0.044 microg/mL, respectively.",Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17685392/),[μg] / [ml],0.085,90760,DB00829,Diazepam
,17685392,limit of,"The limit of detection and the limit of quantification for danshensu, salvianolic acid B and tanshinone IIA in plasma were 0.065, 0.043, 0.022, 0.131, 0.085 and 0.044 microg/mL, respectively.",Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17685392/),[μg] / [ml],0.044,90761,DB00829,Diazepam
,8193419,tmax,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,10-15,91599,DB00829,Diazepam
,8193419,tmax,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,15-20,91600,DB00829,Diazepam
,8193419,time to reach maximum concentration,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,10-15,91601,DB00829,Diazepam
,8193419,time to reach maximum concentration,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,15-20,91602,DB00829,Diazepam
,15282089,Nominal retention times,"Nominal retention times of R(+)-DRF 2725, S(-)-DRF 2725 and I.S. were 15.8, 17.7 and 22.4 min, respectively.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),min,15.8,92924,DB00829,Diazepam
,15282089,Nominal retention times,"Nominal retention times of R(+)-DRF 2725, S(-)-DRF 2725 and I.S. were 15.8, 17.7 and 22.4 min, respectively.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),min,17.7,92925,DB00829,Diazepam
,15282089,Nominal retention times,"Nominal retention times of R(+)-DRF 2725, S(-)-DRF 2725 and I.S. were 15.8, 17.7 and 22.4 min, respectively.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),min,22.4,92926,DB00829,Diazepam
,15282089,Absolute recovery,"Absolute recovery, when compared to neat standards, was 70-85% for DRF 2725 enantiomers and 96% for I.S. from rat plasma.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),%,70-85,92927,DB00829,Diazepam
,15282089,Absolute recovery,"Absolute recovery, when compared to neat standards, was 70-85% for DRF 2725 enantiomers and 96% for I.S. from rat plasma.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),%,96,92928,DB00829,Diazepam
,3515929,systemic availability,The mean systemic availability is approximately 4 percent.,Metabolism and disposition of buspirone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),%,4,93421,DB00829,Diazepam
,3515929,Half-life,Half-life values observed in healthy volunteers ranged from two to 33 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,two to 33,93422,DB00829,Diazepam
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,2,93423,DB00829,Diazepam
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,11,93424,DB00829,Diazepam
,32813265,absolute bioavailability,The absolute bioavailability was ~ 50% with both intranasal free-diazepam and ATIS-diazepam.,Nose-to-Brain Delivery of Diazepam from an Intranasal Aqua-Triggered In-Situ (ATIS) Gelling Microemulsion: Monitoring Brain Uptake by Microdialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32813265/),%,50,93505,DB00829,Diazepam
<,10855607,elimination half-lives,"Drugs with elimination half-lives of <12, 12-23, and > or = 24 hours had adjusted rate ratios of 1.15 (0.94-1.40), 1.45 (1.33-1.59), and 1.73 (1.40-2.14), respectively.",Benzodiazepines and the risk of falls in nursing home residents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10855607/),h,12,94303,DB00829,Diazepam
<,10855607,elimination half-lives,"Drugs with elimination half-lives of <12, 12-23, and > or = 24 hours had adjusted rate ratios of 1.15 (0.94-1.40), 1.45 (1.33-1.59), and 1.73 (1.40-2.14), respectively.",Benzodiazepines and the risk of falls in nursing home residents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10855607/),h,12-23,94304,DB00829,Diazepam
,10855607,elimination half-lives,"Drugs with elimination half-lives of <12, 12-23, and > or = 24 hours had adjusted rate ratios of 1.15 (0.94-1.40), 1.45 (1.33-1.59), and 1.73 (1.40-2.14), respectively.",Benzodiazepines and the risk of falls in nursing home residents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10855607/),h,24,94305,DB00829,Diazepam
<,10855607,elimination half-lives,Users of hypnotics with elimination half-lives <12 hours had an increased rate of falls occurring during the night (adjusted rate ratio 2.82 [2.02-3.94]).,Benzodiazepines and the risk of falls in nursing home residents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10855607/),h,12,94306,DB00829,Diazepam
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.6,94730,DB00829,Diazepam
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.5,94731,DB00829,Diazepam
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94732,DB00829,Diazepam
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94733,DB00829,Diazepam
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94734,DB00829,Diazepam
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94735,DB00829,Diazepam
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,32.3,94736,DB00829,Diazepam
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,28.9,94737,DB00829,Diazepam
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94738,DB00829,Diazepam
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94739,DB00829,Diazepam
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94740,DB00829,Diazepam
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94741,DB00829,Diazepam
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.7,94742,DB00829,Diazepam
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.3,94743,DB00829,Diazepam
,6319067,Vd,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94744,DB00829,Diazepam
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94745,DB00829,Diazepam
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.65,94746,DB00829,Diazepam
,11082461,ED(50),The ED(50) values for ganaxolone after 3- and 7-day treatment with ganaxolone were not significantly different from that in naive rats (ED(50) = 3.5 mg/kg).,Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082461/),[mg] / [kg],3.5,96457,DB00829,Diazepam
,11082461,ED(50),"In contrast, in animals that were treated chronically with ganaxolone for 7 days, there was a significant reduction in the anticonvulsant potency of diazepam (ED(50) = 4.0 versus 1.9 mg/kg for naive controls).",Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082461/),[mg] / [kg],4.0,96458,DB00829,Diazepam
,11082461,ED(50),"In contrast, in animals that were treated chronically with ganaxolone for 7 days, there was a significant reduction in the anticonvulsant potency of diazepam (ED(50) = 4.0 versus 1.9 mg/kg for naive controls).",Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082461/),[mg] / [kg],1.9,96459,DB00829,Diazepam
,11082461,ED(50),"Chronic treatment with diazepam was not associated with a reduction in the potency of ganaxolone, but there was a reduction in the potency of diazepam (ED(50) = 3.7 mg/kg).",Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082461/),[mg] / [kg],3.7,96460,DB00829,Diazepam
,11082461,equilibrium plasma concentrations,The estimated equilibrium plasma concentrations of ganaxolone associated with threshold (750-950 ng/ml) and 50% seizure protection (1215-1295 ng/ml) were similar in naive and chronically treated rats.,Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082461/),[ng] / [ml],750-950,96461,DB00829,Diazepam
,11082461,equilibrium plasma concentrations,The estimated equilibrium plasma concentrations of ganaxolone associated with threshold (750-950 ng/ml) and 50% seizure protection (1215-1295 ng/ml) were similar in naive and chronically treated rats.,Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082461/),[ng] / [ml],1215-1295,96462,DB00829,Diazepam
,26355771,flow rate,"The nintedanib and its metabolite and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1 mm×50 mm, 1.7 μm) using gradient elution with a mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of 0.30 mL/min.",Simultaneous determination of nintedanib and its metabolite by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355771/),[ml] / [min],0.30,96708,DB00829,Diazepam
,26355771,Total time,Total time for each chromatograph was 3.0 min.,Simultaneous determination of nintedanib and its metabolite by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26355771/),min,3.0,96709,DB00829,Diazepam
,11689002,bound fraction of,"Binding assays of studied compounds to purified 1% (w/v) HSA at 0 degrees C, indicate that bound fraction of 2-7 ranges from 13 to 47%, exhibiting a higher affinity to HSA than AZT (12%), which would introduce some interesting improvements in their pharmacokinetic properties.",Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689002/),%,13 to 47,96817,DB00829,Diazepam
,11689002,DeltaS,"In addition, by means of displacement studies using HSA site specific drugs such as diazepam and salicylate, it was determined that AZT binds to site I of the HSA molecule, by a mainly entropy driven process (DeltaS = 10.834 cal/mol degrees K), being these observations extensive to 2-7.",Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689002/),[cal] / [degrees·k·mol],10.834,96818,DB00829,Diazepam
,7267697,Peak plasma diazepam levels,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[ng] / [ml],166,97200,DB00829,Diazepam
,7267697,Peak plasma diazepam levels,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[ng] / [ml],140,97201,DB00829,Diazepam
,7267697,Peak plasma diazepam levels,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[ng] / [ml],145,97202,DB00829,Diazepam
,7267697,time of peak concentration,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,0.71,97203,DB00829,Diazepam
,7267697,time of peak concentration,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,2.1,97204,DB00829,Diazepam
,7267697,time of peak concentration,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,1.5,97205,DB00829,Diazepam
,7267697,Total areas under the plasma concentration curve,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[μg] / [h·ml],2.7,97206,DB00829,Diazepam
,7267697,Total areas under the plasma concentration curve,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[μg] / [h·ml],2.8,97207,DB00829,Diazepam
,7267697,Total areas under the plasma concentration curve,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[μg] / [h·ml],2.9,97208,DB00829,Diazepam
,7267697,elimination half-life,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,29,97209,DB00829,Diazepam
,7267697,elimination half-life,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,36,97210,DB00829,Diazepam
,7267697,elimination half-life,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,35,97211,DB00829,Diazepam
,30837282,bioavailability,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),%,114,97385,DB00829,Diazepam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],71.5,97386,DB00829,Diazepam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],388,97387,DB00829,Diazepam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],355,97388,DB00829,Diazepam
,30837282,times to peak plasma concentration,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),min,5,97389,DB00829,Diazepam
,30837282,times to peak plasma concentration,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),min,8,97390,DB00829,Diazepam
,30837282,first-order absorption rate constants,Enzyme kinetics incorporated into a physiologically based pharmacokinetic model enabled estimation of the first-order absorption rate constants: 0.0689 ± 0.0080 minutes-1 for diazepam and 0.122 ± 0.022 minutes-1 for the intermediate.,Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),1/[min],0.0689,97391,DB00829,Diazepam
,30837282,first-order absorption rate constants,Enzyme kinetics incorporated into a physiologically based pharmacokinetic model enabled estimation of the first-order absorption rate constants: 0.0689 ± 0.0080 minutes-1 for diazepam and 0.122 ± 0.022 minutes-1 for the intermediate.,Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),1/[min],0.122,97392,DB00829,Diazepam
,26226766,T(max),"After the oral administration, the concentrations of Co and De in plasma increased with the increase in dose, with T(max) between 10.65-12.98 h, indicating a long time to reach peak plasma concentrations; C(max) of costunolide and dehydrocostuslactone ranged between 3.750-5.450,15.34-44.52 μg x L(-1), respectively.",[Pharmacokinetics study on costunolide and dehydrocostuslactone after administration of traditional Chinese medicine Weichang'an pills]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26226766/),h,10.65-12.98,98150,DB00829,Diazepam
,26226766,C(max),"After the oral administration, the concentrations of Co and De in plasma increased with the increase in dose, with T(max) between 10.65-12.98 h, indicating a long time to reach peak plasma concentrations; C(max) of costunolide and dehydrocostuslactone ranged between 3.750-5.450,15.34-44.52 μg x L(-1), respectively.",[Pharmacokinetics study on costunolide and dehydrocostuslactone after administration of traditional Chinese medicine Weichang'an pills]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26226766/),[μg] / [l],3.750-5.450,98151,DB00829,Diazepam
,26226766,C(max),"After the oral administration, the concentrations of Co and De in plasma increased with the increase in dose, with T(max) between 10.65-12.98 h, indicating a long time to reach peak plasma concentrations; C(max) of costunolide and dehydrocostuslactone ranged between 3.750-5.450,15.34-44.52 μg x L(-1), respectively.",[Pharmacokinetics study on costunolide and dehydrocostuslactone after administration of traditional Chinese medicine Weichang'an pills]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26226766/),[μg] / [l],15.34-44.52,98152,DB00829,Diazepam
,6368753,serum diazepam level,Pharmacokinetic studies revealed a wide range of serum diazepam concentrations 60 min after administration of the suppository (mean serum diazepam level 190 +/- 73 (SD ng/ml).,A clinical trial of single dose rectal and oral administration of diazepam for the prevention of serial seizures in adult epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6368753/),ng,190,98233,DB00829,Diazepam
,10496655,tissue retention half lives,"Diclofenac had estimated tissue retention half lives of 18.1 hr and 3.5 hr for the dextran and BSA containing perfusates, respectively.",A physiological pharmacokinetic model for solute disposition in tissues below a topical below a topical application site. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496655/),h,18.1,99194,DB00829,Diazepam
,10496655,tissue retention half lives,"Diclofenac had estimated tissue retention half lives of 18.1 hr and 3.5 hr for the dextran and BSA containing perfusates, respectively.",A physiological pharmacokinetic model for solute disposition in tissues below a topical below a topical application site. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496655/),h,3.5,99195,DB00829,Diazepam
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],16.1,99215,DB00829,Diazepam
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],13.7,99216,DB00829,Diazepam
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,25.5,99217,DB00829,Diazepam
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,33.3,99218,DB00829,Diazepam
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,97.5,99219,DB00829,Diazepam
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,95.1,99220,DB00829,Diazepam
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,347.6,99221,DB00829,Diazepam
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],5.34,99222,DB00829,Diazepam
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],6.30,99223,DB00829,Diazepam
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.91,99224,DB00829,Diazepam
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,633,99225,DB00829,Diazepam
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,78.7,99226,DB00829,Diazepam
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.05,99227,DB00829,Diazepam
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.27,99228,DB00829,Diazepam
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],11.2,99229,DB00829,Diazepam
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.92,99230,DB00829,Diazepam
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,9.7,99231,DB00829,Diazepam
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,32.5,99232,DB00829,Diazepam
,2085227,Maximal nordiazepam concentrations,"Maximal nordiazepam concentrations ranged from 446 to 1,542 ng/ml (814 +/- 334 ng/ml), at 59 to 180 minutes (97.9 +/- 42.0 minutes) after a single oral dose of clorazepate.",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ng] / [ml],"446 to 1,542",99260,DB00829,Diazepam
,2085227,Maximal nordiazepam concentrations,"Maximal nordiazepam concentrations ranged from 446 to 1,542 ng/ml (814 +/- 334 ng/ml), at 59 to 180 minutes (97.9 +/- 42.0 minutes) after a single oral dose of clorazepate.",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ng] / [ml],814,99261,DB00829,Diazepam
,2085227,Maximal nordiazepam concentrations,"Maximal nordiazepam concentrations ranged from 927 to 1,460 ng/ml (1,308 +/- 187.6 ng/ml), at 120 to 239 minutes (153 +/- 57.9 minutes) after multiple oral doses of clorazepate.",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ng] / [ml],"927 to 1,460",99262,DB00829,Diazepam
,2085227,Maximal nordiazepam concentrations,"Maximal nordiazepam concentrations ranged from 927 to 1,460 ng/ml (1,308 +/- 187.6 ng/ml), at 120 to 239 minutes (153 +/- 57.9 minutes) after multiple oral doses of clorazepate.",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ng] / [ml],"1,308",99263,DB00829,Diazepam
,2085227,mean residence time,"Using data determined by the predictive equations method, the mean residence time after multiple doses (712 +/- 214 minutes) was longer (P less than 0.05) than after a single dose (527 +/- 95.8 minutes).",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),min,712,99264,DB00829,Diazepam
,2085227,mean residence time,"Using data determined by the predictive equations method, the mean residence time after multiple doses (712 +/- 214 minutes) was longer (P less than 0.05) than after a single dose (527 +/- 95.8 minutes).",Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),min,527,99265,DB00829,Diazepam
,2085227,Oral volume of distribution,Oral volume of distribution after multiple doses of clorazepate (1.76 +/- 0.647 L/kg) was smaller (P less than 0.02) than after a single dose (3.18 +/- 1.52 L/kg).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[l] / [kg],1.76,99266,DB00829,Diazepam
,2085227,Oral volume of distribution,Oral volume of distribution after multiple doses of clorazepate (1.76 +/- 0.647 L/kg) was smaller (P less than 0.02) than after a single dose (3.18 +/- 1.52 L/kg).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[l] / [kg],3.18,99267,DB00829,Diazepam
,2085227,Oral clearance,Oral clearance after multiple doses of clorazepate (3.09 +/- 0.726 ml/min/kg) was less (P less than 0.001) than after a single dose (6.54 +/- 2.15 ml/min/kg).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ml] / [kg·min],3.09,99268,DB00829,Diazepam
,2085227,Oral clearance,Oral clearance after multiple doses of clorazepate (3.09 +/- 0.726 ml/min/kg) was less (P less than 0.001) than after a single dose (6.54 +/- 2.15 ml/min/kg).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),[ml] / [kg·min],6.54,99269,DB00829,Diazepam
,2085227,Absorption half-life,Absorption half-life after multiple doses (72 minutes) was longer (P less than 0.01) than after a single dose (33 minutes).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),min,72,99270,DB00829,Diazepam
,2085227,Absorption half-life,Absorption half-life after multiple doses (72 minutes) was longer (P less than 0.01) than after a single dose (33 minutes).,Disposition of clorazepate in dogs after single- and multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085227/),min,33,99271,DB00829,Diazepam
,27116356,flow rate,"The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1 mm × 50 mm, 1.7 μm) using gradient elution with a mobile phase of acetonitrile and 0.1 % formic acid in water at a flow rate of 0.4 mL/min.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),[ml] / [min],0.4,100915,DB00829,Diazepam
,27116356,m/,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,460.0,100916,DB00829,Diazepam
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,548.2,100917,DB00829,Diazepam
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,366.1,100918,DB00829,Diazepam
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,285.2,100919,DB00829,Diazepam
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,193.1,100920,DB00829,Diazepam
,27116356,Total time,Total time for each chromatograph was 3.5 min.,"Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),min,3.5,100921,DB00829,Diazepam
>,25582505,extraction efficiency,"The extraction efficiency was >90.5%, and the matrix effects ranged from 84.3 to 114.2%.","Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582505/),%,90.5,101195,DB00829,Diazepam
,7337498,elimination half-life t0.5(beta),"After i.v. administration of 2 mg/kg diazepam to dogs, concentrations of unmetabolized drug showed a triexponential decline with an average elimination half-life t0.5(beta) of 3.2 hr.",Pharmacokinetics of diazepam in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),h,3.2,103264,DB00829,Diazepam
,7337498,Elimination half-lives,Elimination half-lives of this metabolite averaged 3.6 hr.,Pharmacokinetics of diazepam in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),h,3.6,103265,DB00829,Diazepam
,7337498,maximal plasma concentrations,Oxazepam reached maximal plasma concentrations in the range of 100 ng/ml after about 2 hr which then declined with a half-life of 5.7 hr.,Pharmacokinetics of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),[ng] / [ml],100,103266,DB00829,Diazepam
,7337498,half-life,Oxazepam reached maximal plasma concentrations in the range of 100 ng/ml after about 2 hr which then declined with a half-life of 5.7 hr.,Pharmacokinetics of diazepam in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),h,5.7,103267,DB00829,Diazepam
,7337498,Oral bioavailability,Oral bioavailability was in the range of 74-100%.,Pharmacokinetics of diazepam in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),%,74-100,103268,DB00829,Diazepam
,7337498,steady state plasma concentrations,By continued oral administration of 1 or 2 mg/kg diazepam t.i.d. it was possible to maintain steady state plasma concentrations of 1000-2000 ng/ml desmethyldiazepam and maximal diazepam concentrations of 100-800 ng/ml.,Pharmacokinetics of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),[ng] / [ml],1000-2000,103269,DB00829,Diazepam
,7337498,maximal diazepam concentrations,By continued oral administration of 1 or 2 mg/kg diazepam t.i.d. it was possible to maintain steady state plasma concentrations of 1000-2000 ng/ml desmethyldiazepam and maximal diazepam concentrations of 100-800 ng/ml.,Pharmacokinetics of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),[ng] / [ml],100-800,103270,DB00829,Diazepam
,2114376,t1/2,"The mean elimination half-life of diazepam fell within the range observed in healthy persons after the ingestion of therapeutic doses (5), or it was only moderately prolonged (t1/2 49.7 h).",Diazepam loading in alcohol withdrawal: clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2114376/),h,49.7,103280,DB00829,Diazepam
,2253674,plasma clearance,The plasma clearance was 6.85 ml.min-1 and the elimination half-life was 6.52 h.,Pharmacokinetics of midazolam in critically ill neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253674/),[ml] / [min],6.85,103517,DB00829,Diazepam
,2253674,elimination half-life,The plasma clearance was 6.85 ml.min-1 and the elimination half-life was 6.52 h.,Pharmacokinetics of midazolam in critically ill neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253674/),h,6.52,103518,DB00829,Diazepam
,2225714,half-time of blood:brain,The half-time of blood:brain equilibration was significantly longer for midazolam than diazepam (4.8 minutes versus 1.6 minutes).,Electroencephalographic effects of benzodiazepines. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225714/),min,4.8,103698,DB00829,Diazepam
,2225714,half-time of blood:brain,The half-time of blood:brain equilibration was significantly longer for midazolam than diazepam (4.8 minutes versus 1.6 minutes).,Electroencephalographic effects of benzodiazepines. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225714/),min,1.6,103699,DB00829,Diazepam
,2225714,intrinsic steady-state potency,Midazolam was found to have an intrinsic steady-state potency that was approximately five times greater than that of diazepam (152 ng/ml versus 958 ng/ml).,Electroencephalographic effects of benzodiazepines. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225714/),[ng] / [ml],152,103700,DB00829,Diazepam
,2225714,intrinsic steady-state potency,Midazolam was found to have an intrinsic steady-state potency that was approximately five times greater than that of diazepam (152 ng/ml versus 958 ng/ml).,Electroencephalographic effects of benzodiazepines. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225714/),[ng] / [ml],958,103701,DB00829,Diazepam
,15739506,recoveries,The recoveries of diltiazem were 91%-104% for serum.,[HPLC determination of diltiazem in human serum and its pharmacokinetic parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739506/),%,91%-104,104797,DB00829,Diazepam
,15739506,peak level,"The results showed that the peak level in serum averaged 118.5 microg/L +/- 14.3 microg/L at 3.1 h +/- 0.4 h, and the areas under the drug concentration curves (AUC) was 793.1 microg x h/L +/- 83.1 microg x h/L.",[HPLC determination of diltiazem in human serum and its pharmacokinetic parameters]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739506/),[μg] / [l],118.5,104798,DB00829,Diazepam
,15739506,areas under the drug concentration curves (AUC),"The results showed that the peak level in serum averaged 118.5 microg/L +/- 14.3 microg/L at 3.1 h +/- 0.4 h, and the areas under the drug concentration curves (AUC) was 793.1 microg x h/L +/- 83.1 microg x h/L.",[HPLC determination of diltiazem in human serum and its pharmacokinetic parameters]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739506/),[h·μg] / [l],793.1,104799,DB00829,Diazepam
,797496,half-life,It has a relatively long half-life (in adults 2 to 3 days; in children shorter).,Clinical pharmacokinetics of anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/797496/),d,2 to 3,104851,DB00829,Diazepam
,2871051,elimination half-life,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,72,106430,DB00829,Diazepam
,2871051,elimination half-life,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,55,106431,DB00829,Diazepam
,2871051,total area under the curve (AUC),"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],11.8,106432,DB00829,Diazepam
,2871051,total area under the curve (AUC),"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.8,106433,DB00829,Diazepam
,2871051,total clearance,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.20,106434,DB00829,Diazepam
,2871051,total clearance,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.28,106435,DB00829,Diazepam
,2871051,AUC,"Seven-day AUC for desmethyldiazepam also increased (4.6 vs 3.8 hr-micrograms/mL, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],4.6,106436,DB00829,Diazepam
,2871051,AUC,"Seven-day AUC for desmethyldiazepam also increased (4.6 vs 3.8 hr-micrograms/mL, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.8,106437,DB00829,Diazepam
,2871051,elimination half-life,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,53,106438,DB00829,Diazepam
,2871051,elimination half-life,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,55,106439,DB00829,Diazepam
,2871051,total AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.5,106440,DB00829,Diazepam
,2871051,total AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.8,106441,DB00829,Diazepam
,2871051,total clearance,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.28,106442,DB00829,Diazepam
,2871051,AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.9,106443,DB00829,Diazepam
,2871051,AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.8,106444,DB00829,Diazepam
,16242290,flow rate,"Chromatography was performed on an Inertsil ODS column with a mobile phase consisting of methanol-distilled water (70/30, v/v) at a flow rate of 0.3 mL/min.",Determination of bifendate in human plasma by HPLC-MS and bioequivalence on bifendate pills in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16242290/),[ml] / [min],0.3,107281,DB00829,Diazepam
,2130609,flow rate,A mobile phase of methanol-KH2PO4 with a flow rate of 1 ml/min was used.,Pharmacokinetics of m-nisoldipine in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[ml] / [min],1,107378,DB00829,Diazepam
,2130609,T 1/2 alpha,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,4.3,107379,DB00829,Diazepam
,2130609,T 1/2 beta,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,63.6,107380,DB00829,Diazepam
,2130609,Vd,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[l] / [kg],0.805,107381,DB00829,Diazepam
,2130609,Cl,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[ml] / [kg·min],9,107382,DB00829,Diazepam
,2130609,T 1/2 alpha,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,5.0,107383,DB00829,Diazepam
,2130609,T 1/2 beta,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,78.3,107384,DB00829,Diazepam
,2130609,Vd,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[l] / [kg],1.191,107385,DB00829,Diazepam
,2130609,Cl,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[ml] / [kg·min],11,107386,DB00829,Diazepam
,2130609,T 1/2,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,84.8,107387,DB00829,Diazepam
,2130609,Tmax,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,31.2,107388,DB00829,Diazepam
,2130609,Cmax,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[μg] / [l],49.97,107389,DB00829,Diazepam
,2130609,Vd,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[l] / [kg],0.792,107390,DB00829,Diazepam
,2130609,Cl,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[ml] / [kg·min],25,107391,DB00829,Diazepam
,19300573,elimination half-life,"Peak plasma concentrations are attained 1.0-1.6 hours after a 3 mg dose, while the mean elimination half-life is 6 hours.",Eszopiclone: its use in the treatment of insomnia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300573/),h,6,108429,DB00829,Diazepam
,19300573,half-life,The half-life increases with age to about 9.0 hours in patients 65 years or older.,Eszopiclone: its use in the treatment of insomnia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300573/),h,9.0,108430,DB00829,Diazepam
,31616134,precursor-to-product ion,The precursor-to-product ion transitions were 394.2 → 363.2 for fruquintinib and m/z 285 → 154 for IS.,Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616134/),,394.2,108883,DB00829,Diazepam
,31616134,precursor-to-product ion,The precursor-to-product ion transitions were 394.2 → 363.2 for fruquintinib and m/z 285 → 154 for IS.,Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616134/),,363.2,108884,DB00829,Diazepam
,31616134,m/z,The precursor-to-product ion transitions were 394.2 → 363.2 for fruquintinib and m/z 285 → 154 for IS.,Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616134/),,285,108885,DB00829,Diazepam
,31616134,m/z,The precursor-to-product ion transitions were 394.2 → 363.2 for fruquintinib and m/z 285 → 154 for IS.,Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616134/),,154,108886,DB00829,Diazepam
,3841222,t beta 1/2,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,53.87,109020,DB00829,Diazepam
,3841222,AUC,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],101.05,109021,DB00829,Diazepam
,3841222,t beta 1/2,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,2.087,109022,DB00829,Diazepam
,3841222,AUC,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],1.37,109023,DB00829,Diazepam
,3841222,t beta 1/2,"FCE 20700 (5 micrograms/ml, sc) did not change, by itself, either SGPT or diazepam pharmacokinetic parameters, but significantly antagonized the changes induced by CC14 (SGPT: 45.3 +/- 5.3 mU/ml; t beta 1/2: 0.167 h; AUC: 2.426 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,0.167,109024,DB00829,Diazepam
,3841222,AUC,"FCE 20700 (5 micrograms/ml, sc) did not change, by itself, either SGPT or diazepam pharmacokinetic parameters, but significantly antagonized the changes induced by CC14 (SGPT: 45.3 +/- 5.3 mU/ml; t beta 1/2: 0.167 h; AUC: 2.426 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],2.426,109025,DB00829,Diazepam
,6811726,elimination half-life (t1/2),Obese subjects compared to controls had a prolonged desmethyldiazepam elimination half-life (t1/2) (154.1 hr versus 57.1 hr; p less than 0.005).,Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),h,154.1,109254,DB00829,Diazepam
,6811726,elimination half-life (t1/2),Obese subjects compared to controls had a prolonged desmethyldiazepam elimination half-life (t1/2) (154.1 hr versus 57.1 hr; p less than 0.005).,Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),h,57.1,109255,DB00829,Diazepam
,6811726,volume of distribution (Vd),"Assuming quantitative conversion of clorazepate to desmethyldiazepam and 100% systemic availability, volume of distribution (Vd) was greatly increased in the obese (158.8 liters versus 63.3 liters; p less than 0.001).",Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),l,158.8,109256,DB00829,Diazepam
,6811726,volume of distribution (Vd),"Assuming quantitative conversion of clorazepate to desmethyldiazepam and 100% systemic availability, volume of distribution (Vd) was greatly increased in the obese (158.8 liters versus 63.3 liters; p less than 0.001).",Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),l,63.3,109257,DB00829,Diazepam
,6811726,Vd,The value of Vd remained greater even after correction for body weight (1.52 liter/kg versus 0.94 liter/kg; p less than 0.005).,Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),[l] / [kg],1.52,109258,DB00829,Diazepam
,6811726,Vd,The value of Vd remained greater even after correction for body weight (1.52 liter/kg versus 0.94 liter/kg; p less than 0.005).,Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),[l] / [kg],0.94,109259,DB00829,Diazepam
,6811726,clearance,"However, clearance of desmethyldiazepam was not different between groups (13.2 ml/min in obese versus 13.4 ml/min in controls).",Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),[ml] / [min],13.2,109260,DB00829,Diazepam
,6811726,clearance,"However, clearance of desmethyldiazepam was not different between groups (13.2 ml/min in obese versus 13.4 ml/min in controls).",Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6811726/),[ml] / [min],13.4,109261,DB00829,Diazepam
,6813365,half-life,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),h,16.4,109996,DB00829,Diazepam
,6813365,half-life,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),h,11.0,109997,DB00829,Diazepam
,6813365,metabolic clearance,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),[ml] / [kg·min],0.48,109998,DB00829,Diazepam
,6813365,metabolic clearance,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),[ml] / [kg·min],0.72,109999,DB00829,Diazepam
,6813365,half-life,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,150,110000,DB00829,Diazepam
,6813365,half-life,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,153,110001,DB00829,Diazepam
,6813365,metabolic clearance,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,79,110002,DB00829,Diazepam
,6813365,metabolic clearance,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,69,110003,DB00829,Diazepam
,6813365,half-life,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,175,110004,DB00829,Diazepam
,6813365,half-life,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,164,110005,DB00829,Diazepam
,6813365,metabolic clearance,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,51,110006,DB00829,Diazepam
,6813365,metabolic clearance,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,65,110007,DB00829,Diazepam
,9578046,time to maximum concentration,"After a single intraperitoneal dose, DZP was rapidly absorbed with a time to maximum concentration of 10 min.",Comparison of single- and repeated-dose pharmacokinetics of diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578046/),min,10,110167,DB00829,Diazepam
,16261363,total area under the plasma concentration-time curve,"The PMs had significantly larger total area under the plasma concentration-time curve (287+/-74 vs 178+/-122 ng.h/ml, p<0.05) and longer elimination half-life (14.8+/-4.2 vs 10.5+/-3.9 h, p<0.05) of etizolam than the EMs.",Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261363/),[h·ng] / [ml],287,111585,DB00829,Diazepam
,16261363,total area under the plasma concentration-time curve,"The PMs had significantly larger total area under the plasma concentration-time curve (287+/-74 vs 178+/-122 ng.h/ml, p<0.05) and longer elimination half-life (14.8+/-4.2 vs 10.5+/-3.9 h, p<0.05) of etizolam than the EMs.",Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261363/),[h·ng] / [ml],178,111586,DB00829,Diazepam
,16261363,elimination half-life,"The PMs had significantly larger total area under the plasma concentration-time curve (287+/-74 vs 178+/-122 ng.h/ml, p<0.05) and longer elimination half-life (14.8+/-4.2 vs 10.5+/-3.9 h, p<0.05) of etizolam than the EMs.",Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261363/),h,14.8,111587,DB00829,Diazepam
,16261363,elimination half-life,"The PMs had significantly larger total area under the plasma concentration-time curve (287+/-74 vs 178+/-122 ng.h/ml, p<0.05) and longer elimination half-life (14.8+/-4.2 vs 10.5+/-3.9 h, p<0.05) of etizolam than the EMs.",Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261363/),h,10.5,111588,DB00829,Diazepam
,16261363,area under the score-time curve from 0 to 8 h,"The area under the score-time curve from 0 to 8 h of the Stanford Sleepiness Scale was significantly larger in the PMs than in EMs (28.9+/-5.2 vs 22.9+/-6.9 score.h, p<0.05).",Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261363/),h·score,28.9,111589,DB00829,Diazepam
,16261363,area under the score-time curve from 0 to 8 h,"The area under the score-time curve from 0 to 8 h of the Stanford Sleepiness Scale was significantly larger in the PMs than in EMs (28.9+/-5.2 vs 22.9+/-6.9 score.h, p<0.05).",Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261363/),h·score,22.9,111590,DB00829,Diazepam
,15953705,flow rate,Chromatographic separation was performed on an ODS column at flow rate of 0.2 ml/min.,Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[ml] / [min],0.2,111725,DB00829,Diazepam
,15953705,total chromatographic run time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,10.5,111726,DB00829,Diazepam
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,7.1,111727,DB00829,Diazepam
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,6.2,111728,DB00829,Diazepam
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,2.2,111729,DB00829,Diazepam
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],10,111730,DB00829,Diazepam
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],50,111731,DB00829,Diazepam
,9596205,initial maximum,"Diazepam rapidly appeared in plasma after rectal administration, exceeding 200 ng/mL within 15 min and reaching an initial maximum of 373 ng/ml at 45 min and a second maximum of 447 +/- 91.1 ng/ml at approximately 70 min.","A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596205/),[ng] / [ml],373,111853,DB00829,Diazepam
,9596205,second maximum,"Diazepam rapidly appeared in plasma after rectal administration, exceeding 200 ng/mL within 15 min and reaching an initial maximum of 373 ng/ml at 45 min and a second maximum of 447 +/- 91.1 ng/ml at approximately 70 min.","A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596205/),[ng] / [ml],447,111854,DB00829,Diazepam
,9596205,absolute bioavailability,The absolute bioavailability of DZP rectal gel was 90.4%.,"A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596205/),%,90.4,111855,DB00829,Diazepam
,8799523,steady target-blood concentration,"2. Bretazenil (0.5 mg), diazepam (10 mg) and matching placebos were given as single oral doses after intravenous infusion of alcohol to a steady target-blood concentration of 0.5 g l-1 or a control infusion of 5% w/v glucose at 1 week intervals.",Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799523/),[g] / [l],0.5,112400,DB00829,Diazepam
,6804244,Cl,Cl was significantly reduced (11.5 +/- 1.8 vs. 9.1 +/- 3.3 ml/min; p = 0.015) and elimination half-life tended to be prolonged (38.5 +/- 10.4 vs. 65.8 +/- 67.1 h; p = 0.15).,Clearance of diazepam can be impaired by its major metabolite desmethyldiazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804244/),[ml] / [min],11.5,114571,DB00829,Diazepam
,6804244,Cl,Cl was significantly reduced (11.5 +/- 1.8 vs. 9.1 +/- 3.3 ml/min; p = 0.015) and elimination half-life tended to be prolonged (38.5 +/- 10.4 vs. 65.8 +/- 67.1 h; p = 0.15).,Clearance of diazepam can be impaired by its major metabolite desmethyldiazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804244/),[ml] / [min],9.1,114572,DB00829,Diazepam
,6804244,elimination half-life,Cl was significantly reduced (11.5 +/- 1.8 vs. 9.1 +/- 3.3 ml/min; p = 0.015) and elimination half-life tended to be prolonged (38.5 +/- 10.4 vs. 65.8 +/- 67.1 h; p = 0.15).,Clearance of diazepam can be impaired by its major metabolite desmethyldiazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804244/),h,38.5,114573,DB00829,Diazepam
,6804244,elimination half-life,Cl was significantly reduced (11.5 +/- 1.8 vs. 9.1 +/- 3.3 ml/min; p = 0.015) and elimination half-life tended to be prolonged (38.5 +/- 10.4 vs. 65.8 +/- 67.1 h; p = 0.15).,Clearance of diazepam can be impaired by its major metabolite desmethyldiazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804244/),h,65.8,114574,DB00829,Diazepam
,10082193,ED50,The ED50 value of ethosuximide was significantly increased from 108 to 158 mg/kg.,N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082193/),[mg] / [kg],108,114767,DB00829,Diazepam
,10082193,ED50,The ED50 value of ethosuximide was significantly increased from 108 to 158 mg/kg.,N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082193/),[mg] / [kg],158,114768,DB00829,Diazepam
up to,6143468,time to the steady-state,"Due to the long half-life of phenobarbital its plasma concentrations change slowly, and time to the steady-state may be up to 30 days, if no loading dose is given.",Pharmacokinetics of antiepileptic drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),d,30,115019,DB00829,Diazepam
,6143468,half-lives,"Diazepam, clonazepam and nitrazepam are largely bound to plasma proteins and extensively metabolized with the half-lives of 20 to 60 hours.",Pharmacokinetics of antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),h,20 to 60,115020,DB00829,Diazepam
,24934774,Cmax,"The mean Cmax values for 20mg diazepam-NS and 20mg diazepam-RG were 378 ± 106 and 328 ± 152 ng/mL, achieved at 1.0 and 1.5h, respectively.",Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934774/),[ng] / [ml],378,115047,DB00829,Diazepam
,24934774,Cmax,"The mean Cmax values for 20mg diazepam-NS and 20mg diazepam-RG were 378 ± 106 and 328 ± 152 ng/mL, achieved at 1.0 and 1.5h, respectively.",Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934774/),[ng] / [ml],328,115048,DB00829,Diazepam
,28870,peak measured concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [ml],273,115120,DB00829,Diazepam
,28870,peak measured concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [ml],188,115121,DB00829,Diazepam
,28870,time of peak concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),h,1.8,115122,DB00829,Diazepam
,28870,time of peak concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),h,2.8,115123,DB00829,Diazepam
,28870,apparent absorption half-life,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),min,14.8,115124,DB00829,Diazepam
,28870,apparent absorption half-life,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),min,30.7,115125,DB00829,Diazepam
,28870,area under the 48-hr plasma concentration curve,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [h·ml],"6,028",115126,DB00829,Diazepam
,28870,area under the 48-hr plasma concentration curve,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [h·ml],"5,433",115127,DB00829,Diazepam
,1806626,elimination half-life,The elimination half-life is about 32 h; metabolism is by demethylation to an inactive metabolite.,Clinical implications of the pharmacology of sertraline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1806626/),h,32,117841,DB00829,Diazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),μg,9.7,117994,DB00829,Diazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),μg,243,117995,DB00829,Diazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),[ng] / [g],3.75,117996,DB00829,Diazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),[ng] / [g],455,117997,DB00829,Diazepam
,11792681,C(max),"Bergamottin predosing increased the plasma levels of diazepam as observed by C(max) (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC((0-TLDC))] (247.69 versus 2.79 ng x hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition.",The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792681/),[ng] / [ml],278.75,118625,DB00829,Diazepam
,11792681,C(max),"Bergamottin predosing increased the plasma levels of diazepam as observed by C(max) (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC((0-TLDC))] (247.69 versus 2.79 ng x hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition.",The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792681/),[ng] / [ml],5.49,118626,DB00829,Diazepam
,11792681,area under the curve [AUC((0-TLDC))],"Bergamottin predosing increased the plasma levels of diazepam as observed by C(max) (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC((0-TLDC))] (247.69 versus 2.79 ng x hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition.",The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792681/),[h·ng] / [ml],247.69,118627,DB00829,Diazepam
,11792681,area under the curve [AUC((0-TLDC))],"Bergamottin predosing increased the plasma levels of diazepam as observed by C(max) (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC((0-TLDC))] (247.69 versus 2.79 ng x hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition.",The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792681/),[h·ng] / [ml],2.79,118628,DB00829,Diazepam
,8553684,clearance,"No dose dependency was observed in either clearance or steady state volume of distribution, which were estimated to be 38 ml/min/SRW (where SRW is a standard rat weight of 250 g) and 1.3 L/SRW respectively.",Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8553684/),[ml] / [min·srw],38,118730,DB00829,Diazepam
,8553684,steady state volume of distribution,"No dose dependency was observed in either clearance or steady state volume of distribution, which were estimated to be 38 ml/min/SRW (where SRW is a standard rat weight of 250 g) and 1.3 L/SRW respectively.",Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8553684/),[l] / [sr],1.3,118731,DB00829,Diazepam
,8553684,unbound fraction,"Blood binding of DZ was concentration independent, the unbound fraction being 0.22.",Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8553684/),,0.22,118732,DB00829,Diazepam
,2922358,half-life,An intermediate half-life of 10-12 hours and a comparatively brief duration of activity relative to other anxiolytic benzodiazepines justified evaluation of a 0.5-mg test dose in an anxious patient with chronic obstructive lung disease.,"Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922358/),h,10-12,118927,DB00829,Diazepam
,10551971,elimination half-life,The calculated elimination half-life was 10.2 h and the molecule and/or its metabolites were found up to 90 h after ingestion.,Orphenadrine poisoning in a child: clinical and analytical data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551971/),h,10.2,119192,DB00829,Diazepam
,2295106,elimination,"After surgery the times to awakening and extubation, and alfentanil elimination half-life (t1/2B = 0.693/-k) were determined for each patient.",Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),,0.693,122218,DB00829,Diazepam
,2295106,times to awakening,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,3.2,122219,DB00829,Diazepam
,2295106,extubation,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,8.8,122220,DB00829,Diazepam
,2295106,elimination half-life,The elimination half-life for all patients was 5.1 +/- 1.0 hr (mean +/- SEM).,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,5.1,122221,DB00829,Diazepam
,30472551,Elimination half-life,Elimination half-life was 0.999 ± 0.241 h in seven patients.,"Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472551/),h,0.999,122998,DB00829,Diazepam
,30472551,Total body clearance,Total body clearance ranged from 423 to 1220 mL/h/kg in older children but was notably higher in a 10-month-old infant (2010 mL/h/kg).,"Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472551/),[ml] / [h·kg],423 to 1220,122999,DB00829,Diazepam
,30472551,Total body clearance,Total body clearance ranged from 423 to 1220 mL/h/kg in older children but was notably higher in a 10-month-old infant (2010 mL/h/kg).,"Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472551/),[ml] / [h·kg],2010,123000,DB00829,Diazepam
,30252204,flow rate,Acetonitrile and water (containing 0.1% formic acid) were chosen as the mobile phase at a flow rate of 0.4 mL/min.,Determination and pharmacokinetic study of AZD-3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30252204/),[ml] / [min],0.4,123324,DB00829,Diazepam
,30252204,m/z,The target fragment ions were m/z 460.38→141 for AZD-3759 and m/z 285.1→193.1 for internal standard diazepam.,Determination and pharmacokinetic study of AZD-3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30252204/),,460.38,123325,DB00829,Diazepam
,30252204,m/z,The target fragment ions were m/z 460.38→141 for AZD-3759 and m/z 285.1→193.1 for internal standard diazepam.,Determination and pharmacokinetic study of AZD-3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30252204/),,141,123326,DB00829,Diazepam
,30252204,m/z,The target fragment ions were m/z 460.38→141 for AZD-3759 and m/z 285.1→193.1 for internal standard diazepam.,Determination and pharmacokinetic study of AZD-3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30252204/),,285.1,123327,DB00829,Diazepam
,30252204,m/z,The target fragment ions were m/z 460.38→141 for AZD-3759 and m/z 285.1→193.1 for internal standard diazepam.,Determination and pharmacokinetic study of AZD-3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30252204/),,193.1,123328,DB00829,Diazepam
>,30252204,recovery rate,The recovery rate of AZD-3759 from plasma was > 76.4%.,Determination and pharmacokinetic study of AZD-3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30252204/),%,76.4,123329,DB00829,Diazepam
,23858609,time to stop seizures,"Intranasal midazolam was proved to be effective (complete remission;65%), rapidly (an average time to stop seizures; 5.7 min) and safe with no adverse effects including respiratory depression with this dosage (an average of 0.26 mg/kg).",[Study of an efficacy and a pharmacokinetics of intranasal midazolam for status epilepticus on childhood epilepsy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23858609/),min,5.7,123614,DB00829,Diazepam
,29682729,Vd,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),ml,608,124751,DB00829,Diazepam
,29682729,CL,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124752,DB00829,Diazepam
,29682729,CL,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124753,DB00829,Diazepam
,29682729,t1/2α (,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124754,DB00829,Diazepam
,29682729,t1/2α (,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124755,DB00829,Diazepam
,29682729,distribution half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124756,DB00829,Diazepam
,29682729,distribution half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124757,DB00829,Diazepam
,29682729,t1/2β (terminal half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,76.8,124758,DB00829,Diazepam
,29682729,minimal plasma diazepam concentration,The minimal plasma diazepam concentration associated with threshold elevations was estimated at approximately 70 ng/mL.,Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ng] / [ml],70,124759,DB00829,Diazepam
,30032018,flow rate,"After extraction with ethyl acetate, the chromatographic separation was implemented on a C18 column (Hypersil GOLD, 100 mm × 2.1 mm, 3.0 μm) using gradient elution with water (containing 0.1% formic acid) and methanol at the flow rate of 0.4 mL/min.",Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),[ml] / [min],0.4,125164,DB00829,Diazepam
,30032018,m/z,The analytes were measured under multiple reactions monitoring (MRM) mode with m/z 291.2 → 202.1 for carbinoxamine and m/z 285.0 → 193.2 for diazepam (IS) using electrospray ionization source (ESI) in the positive ion mode.,Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),,291.2,125165,DB00829,Diazepam
,30032018,m/z,The analytes were measured under multiple reactions monitoring (MRM) mode with m/z 291.2 → 202.1 for carbinoxamine and m/z 285.0 → 193.2 for diazepam (IS) using electrospray ionization source (ESI) in the positive ion mode.,Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),,202.1,125166,DB00829,Diazepam
,30032018,m/z,The analytes were measured under multiple reactions monitoring (MRM) mode with m/z 291.2 → 202.1 for carbinoxamine and m/z 285.0 → 193.2 for diazepam (IS) using electrospray ionization source (ESI) in the positive ion mode.,Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),,285.0,125167,DB00829,Diazepam
,30032018,m/z,The analytes were measured under multiple reactions monitoring (MRM) mode with m/z 291.2 → 202.1 for carbinoxamine and m/z 285.0 → 193.2 for diazepam (IS) using electrospray ionization source (ESI) in the positive ion mode.,Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),,193.2,125168,DB00829,Diazepam
,30032018,extraction recoveries,The mean extraction recoveries for carbinoxamine ranged from 74.00% to 86.4%.,Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),%,74.00,125169,DB00829,Diazepam
,30032018,extraction recoveries,The mean extraction recoveries for carbinoxamine ranged from 74.00% to 86.4%.,Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),%,86.4,125170,DB00829,Diazepam
,30032018,apparent volume of distribution of the central compartment (Vc,"Following intragastric administration (0.534 mL/kg), carbinoxamine possessed a large apparent volume of distribution of the central compartment (Vc = 1005.7 ± 945.9 L/kg), oral clearance (Cl = 112.446 ± 53.249 L/h/kg), and a relatively long absorption time (Tmax = 2.38 ± 1.00 h).",Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),[l] / [kg],1005.7,125171,DB00829,Diazepam
,30032018,oral clearance (Cl,"Following intragastric administration (0.534 mL/kg), carbinoxamine possessed a large apparent volume of distribution of the central compartment (Vc = 1005.7 ± 945.9 L/kg), oral clearance (Cl = 112.446 ± 53.249 L/h/kg), and a relatively long absorption time (Tmax = 2.38 ± 1.00 h).",Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),[l] / [h·kg],112.446,125172,DB00829,Diazepam
,30032018,absorption time (Tmax,"Following intragastric administration (0.534 mL/kg), carbinoxamine possessed a large apparent volume of distribution of the central compartment (Vc = 1005.7 ± 945.9 L/kg), oral clearance (Cl = 112.446 ± 53.249 L/h/kg), and a relatively long absorption time (Tmax = 2.38 ± 1.00 h).",Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032018/),h,2.38,125173,DB00829,Diazepam
,19054418,time,The median time from hospital admission to ivLEV was 36 min.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),min,36,126739,DB00829,Diazepam
,19054418,volume of distribution of central compartment,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [kg],0.45,126740,DB00829,Diazepam
,19054418,total body clearance,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [h·kg],0.0476,126741,DB00829,Diazepam
,19054418,"distribution rate constants, central to peripheral compartment (k(12))","Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.24,126742,DB00829,Diazepam
,19054418,peripheral to central (k(21)),"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.70,126743,DB00829,Diazepam
,19054418,maximal plasma concentration,Mean maximal plasma concentration was 85 (19) mg/L.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[mg] / [l],85,126744,DB00829,Diazepam
,24929057,Absolute recoveries,"Absolute recoveries of DLM, CIS and TRANS ranged from 86 to 95%.",Measurement of plasma protein and lipoprotein binding of pyrethroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24929057/),%,86 to 95,127507,DB00829,Diazepam
,8431572,total body clearance (TBC),"In the VASC group, ME total body clearance (TBC) was 6 +/- 2 mL/kg/min (mean +/- SD), which is less than in previous studies.",Comparison of the pharmacokinetics of methohexital during cardiac surgery with cardiopulmonary bypass and vascular surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431572/),[ml] / [kg·min],6,128144,DB00829,Diazepam
,32856316,half-life,Large and significant differences were found between young and elderly groups in mean half-life of diazepam (31 vs 86 hours; P < .005) and DMDZ (40 vs 80 hours; P < .02).,Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32856316/),h,31,128615,DB00829,Diazepam
,32856316,half-life,Large and significant differences were found between young and elderly groups in mean half-life of diazepam (31 vs 86 hours; P < .005) and DMDZ (40 vs 80 hours; P < .02).,Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32856316/),h,86,128616,DB00829,Diazepam
,32856316,half-life,Large and significant differences were found between young and elderly groups in mean half-life of diazepam (31 vs 86 hours; P < .005) and DMDZ (40 vs 80 hours; P < .02).,Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32856316/),h,40,128617,DB00829,Diazepam
,32856316,half-life,Large and significant differences were found between young and elderly groups in mean half-life of diazepam (31 vs 86 hours; P < .005) and DMDZ (40 vs 80 hours; P < .02).,Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32856316/),h,80,128618,DB00829,Diazepam
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00829,Diazepam
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00829,Diazepam
,1773780,peak plasma concentrations,"In an open dose-escalating study, LTG 240 mg produced peak plasma concentrations of around 3 micrograms/mg with no significant adverse events.",Clinical pharmacology of lamotrigine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773780/),[μg] / [mg],3,130119,DB00829,Diazepam
,1773780,half-life,"Subsequent pharmacokinetic studies revealed complete oral absorption, first-order kinetics with a mean half-life of approximately 1 day, and elimination mainly as a glucuronide in the urine.",Clinical pharmacology of lamotrigine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773780/),d,1,130120,DB00829,Diazepam
,33423953,terminal half-life,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),min,44.3,130142,DB00829,Diazepam
,33423953,volume of distribution,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[l] / [kg],0.43,130143,DB00829,Diazepam
,33423953,plasma clearance,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[ml] / [kg·min],7.77,130144,DB00829,Diazepam
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],1,132975,DB00829,Diazepam
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],15,132976,DB00829,Diazepam
,25224629,flow rate,"A simple mobile phase consisting of 0.01 mol/L NaH2PO4 solution and acetonitrile (38:62, V/V) was pumped at a flow rate of 1.0 mL/min through a reverse phase Diamonsil C18 column maintained at 30°C.","A simple, rapid, economical, and practical method for the determination of efavirenz in plasma of Chinese AIDS patients by reverse phase high-performance liquid chromatography with ultraviolet detector. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224629/),[ml] / [min],1.0,133866,DB00829,Diazepam
,25224629,plasma concentration,"The mean plasma concentration of efavirenz of the 406 patients was 2.21 ± 1.95 μg/mL, 77.3% of which were within the therapeutic window (1-4 μg/mL), 15.1% were below the window, and 7.6% were over it.","A simple, rapid, economical, and practical method for the determination of efavirenz in plasma of Chinese AIDS patients by reverse phase high-performance liquid chromatography with ultraviolet detector. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224629/),[μg] / [ml],2.21,133867,DB00829,Diazepam
,28343895,K027,"According to the results, both oximes had similar Cmax (K027: 106±19μg/mL and K203: 111±8μg/mL) in Tmax 19±5min, respectively, in 22±3min.",Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[μg] / [ml],106,134219,DB00829,Diazepam
,28343895,K203,"According to the results, both oximes had similar Cmax (K027: 106±19μg/mL and K203: 111±8μg/mL) in Tmax 19±5min, respectively, in 22±3min.",Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[μg] / [ml],111,134220,DB00829,Diazepam
,28343895,Tmax,"According to the results, both oximes had similar Cmax (K027: 106±19μg/mL and K203: 111±8μg/mL) in Tmax 19±5min, respectively, in 22±3min.",Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),min,19,134221,DB00829,Diazepam
,28343895,Tmax,"According to the results, both oximes had similar Cmax (K027: 106±19μg/mL and K203: 111±8μg/mL) in Tmax 19±5min, respectively, in 22±3min.",Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),min,22,134222,DB00829,Diazepam
,28343895,Bioavailability,Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minμg/mL) was halved compared to oxime K203 (16938±795minμg/mL).,Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[minμg] / [ml],8389,134223,DB00829,Diazepam
,28343895,Bioavailability,Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minμg/mL) was halved compared to oxime K203 (16938±795minμg/mL).,Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[minμg] / [ml],16938,134224,DB00829,Diazepam
,28343895,AUCtotal,Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minμg/mL) was halved compared to oxime K203 (16938±795minμg/mL).,Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[minμg] / [ml],8389,134225,DB00829,Diazepam
,28343895,AUCtotal,Bioavailability of oxime K027 calculated as AUCtotal (8389±1024minμg/mL) was halved compared to oxime K203 (16938±795minμg/mL).,Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28343895/),[minμg] / [ml],16938,134226,DB00829,Diazepam
,27507667,flow rate,"The separation was achieved by an ACQUITY UPC(2)™ BEH 2-EP column (100mm×3mm, 1.7μm) maintained at 35°C, using carbon dioxide (≥99.99%) and methanol (85:15, v/v) as the mobile phase at a flow rate of 1.0ml/min.",An improvement of separation and response applying post-column compensation and one-step acetone protein precipitation for the determination of coenzyme Q10 in rat plasma by SFC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507667/),[ml] / [min],1.0,138579,DB00829,Diazepam
,27507667,flow rate,"To improve the response and sensitivity, the compensation solvent of methanol with 2mM ammonium acetate at a flow rate of 0.2ml/min was used and the total analysis time was only 1.5min for each sample.",An improvement of separation and response applying post-column compensation and one-step acetone protein precipitation for the determination of coenzyme Q10 in rat plasma by SFC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507667/),[ml] / [min],0.2,138580,DB00829,Diazepam
,27507667,total analysis time,"To improve the response and sensitivity, the compensation solvent of methanol with 2mM ammonium acetate at a flow rate of 0.2ml/min was used and the total analysis time was only 1.5min for each sample.",An improvement of separation and response applying post-column compensation and one-step acetone protein precipitation for the determination of coenzyme Q10 in rat plasma by SFC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27507667/),min,1.5,138581,DB00829,Diazepam
,15902983,[Lofl),"On admission, the serum concentrations of the active metabolites of Lof ([Lofl) were 256 ng/mL, 425 ng/mL, and 177 ng/mL in cases 1, 2, and 3, respectively.",Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),ng,256,139112,DB00829,Diazepam
,15902983,[Lofl),"On admission, the serum concentrations of the active metabolites of Lof ([Lofl) were 256 ng/mL, 425 ng/mL, and 177 ng/mL in cases 1, 2, and 3, respectively.",Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),[ng] / [ml],425,139113,DB00829,Diazepam
,15902983,[Lofl),"On admission, the serum concentrations of the active metabolites of Lof ([Lofl) were 256 ng/mL, 425 ng/mL, and 177 ng/mL in cases 1, 2, and 3, respectively.",Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),[ng] / [ml],177,139114,DB00829,Diazepam
,15902983,receptor binding activities,"Serum benzodiazepine-receptor binding activities, expressed as diazepam equivalent concentrations ([Bz]), were 1800 ng/mL, 2200 ng/mL, and 1500 ng/mL.",Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),[ng] / [ml],1800,139115,DB00829,Diazepam
,15902983,receptor binding activities,"Serum benzodiazepine-receptor binding activities, expressed as diazepam equivalent concentrations ([Bz]), were 1800 ng/mL, 2200 ng/mL, and 1500 ng/mL.",Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),[ng] / [ml],2200,139116,DB00829,Diazepam
,15902983,receptor binding activities,"Serum benzodiazepine-receptor binding activities, expressed as diazepam equivalent concentrations ([Bz]), were 1800 ng/mL, 2200 ng/mL, and 1500 ng/mL.",Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),[ng] / [ml],1500,139117,DB00829,Diazepam
,15902983,T1/2(beta),The T1/2(beta) of [Lof] were 124 and 121 h in cases 1 and 2 and the T1/2(beta) of [Bz] were 75 and 87 h.,Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),h,124,139118,DB00829,Diazepam
,15902983,T1/2(beta),The T1/2(beta) of [Lof] were 124 and 121 h in cases 1 and 2 and the T1/2(beta) of [Bz] were 75 and 87 h.,Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),h,121,139119,DB00829,Diazepam
,15902983,T1/2(beta),The T1/2(beta) of [Lof] were 124 and 121 h in cases 1 and 2 and the T1/2(beta) of [Bz] were 75 and 87 h.,Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),h,75,139120,DB00829,Diazepam
,15902983,T1/2(beta),The T1/2(beta) of [Lof] were 124 and 121 h in cases 1 and 2 and the T1/2(beta) of [Bz] were 75 and 87 h.,Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902983/),h,87,139121,DB00829,Diazepam
,2512694,peak plasma concentration,"The distribution of peak plasma concentration (mean, 406 ng/ml) was not skewed and did not differ significantly from normal (Guassian).",A large-sample study of diazepam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2512694/),[ng] / [ml],406,139446,DB00829,Diazepam
,2512694,elimination half-life,"However, the distributions of elimination half-life (44.2 h), elimination rate constant (0.0219/h), clearance (26.6 ml/min), and volume of distribution (83 L) all were significantly skewed and deviated significantly fron normal.",A large-sample study of diazepam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2512694/),h,44.2,139447,DB00829,Diazepam
,2512694,elimination rate constant,"However, the distributions of elimination half-life (44.2 h), elimination rate constant (0.0219/h), clearance (26.6 ml/min), and volume of distribution (83 L) all were significantly skewed and deviated significantly fron normal.",A large-sample study of diazepam pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2512694/),1/[h],0.0219,139448,DB00829,Diazepam
,2512694,clearance,"However, the distributions of elimination half-life (44.2 h), elimination rate constant (0.0219/h), clearance (26.6 ml/min), and volume of distribution (83 L) all were significantly skewed and deviated significantly fron normal.",A large-sample study of diazepam pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2512694/),[ml] / [min],26.6,139449,DB00829,Diazepam
,2512694,volume of distribution,"However, the distributions of elimination half-life (44.2 h), elimination rate constant (0.0219/h), clearance (26.6 ml/min), and volume of distribution (83 L) all were significantly skewed and deviated significantly fron normal.",A large-sample study of diazepam pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2512694/),l,83,139450,DB00829,Diazepam
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB00829,Diazepam
,28762846,inhibition rates,"The results indicated that after incorporating into CMS, the therapeutic effects of NMS were obviously improved, and the inhibition rates of 1:3 NMS/CMS in all pharmacodynamics tests varied from 102.2% to 904.3%.",Biomimetic synthesis of proline-derivative templated mesoporous silica for increasing the brain distribution of diazepam and improving the pharmacodynamics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762846/),%,102.2,140527,DB00829,Diazepam
,28762846,inhibition rates,"The results indicated that after incorporating into CMS, the therapeutic effects of NMS were obviously improved, and the inhibition rates of 1:3 NMS/CMS in all pharmacodynamics tests varied from 102.2% to 904.3%.",Biomimetic synthesis of proline-derivative templated mesoporous silica for increasing the brain distribution of diazepam and improving the pharmacodynamics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762846/),%,904.3,140528,DB00829,Diazepam
,10850840,peak plasma concentration,"Mean (+/- SD) peak plasma concentration of BDZ following IV administration (1,316 +/- 216 microg/L) was greater than that following IN administration (448 +/- 41 microg/L).",Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),[μg] / [l],"1,316",141201,DB00829,Diazepam
,10850840,peak plasma concentration,"Mean (+/- SD) peak plasma concentration of BDZ following IV administration (1,316 +/- 216 microg/L) was greater than that following IN administration (448 +/- 41 microg/L).",Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),[μg] / [l],448,141202,DB00829,Diazepam
< or =,10850840,Time to peak concentration,Time to peak concentration was < or = 3 minutes following IV administration and 4.5 +/- 1.5 minutes following IN administration.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),min,3,141203,DB00829,Diazepam
,10850840,Time to peak concentration,Time to peak concentration was < or = 3 minutes following IV administration and 4.5 +/- 1.5 minutes following IN administration.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),min,4.5,141204,DB00829,Diazepam
,10850840,bioavailability,Mean bioavailability of BDZ following IN administration was 80 +/- 9%.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),%,80,141205,DB00829,Diazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,56-135,142641,DB00829,Diazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,35-116,142642,DB00829,Diazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,19-50,142643,DB00829,Diazepam
,2882760,Free fraction,"Free fraction in plasma varied from 0.13 for desmethyldiazepam to 0.30 for triazolam, and was unrelated to age.","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,0.13,142644,DB00829,Diazepam
,2882760,Free fraction,"Free fraction in plasma varied from 0.13 for desmethyldiazepam to 0.30 for triazolam, and was unrelated to age.","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,0.30,142645,DB00829,Diazepam
,7866520,extraction recovery,"The validation of the method shows that the extraction recovery is ca. 85%, the limit of detection is 2 ng/ml and the standard deviations of the intra-day precision test range from 5.8 to 7.4% with respect to the concentration.",Determination of nifedipine in human serum by gas chromatography-mass spectrometry: validation of the method and its use in bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866520/),%,85,143680,DB00829,Diazepam
,19681868,maximum concentration (C(max)),"The maximum concentration (C(max)) of diazepam after avizafone injection was higher than that obtained after injection of diazepam itself (231 vs. 148 ng.mL(-1)), while area under the curve (AUC) values were equal.",Bioavailability of diazepam after intramuscular injection of its water-soluble prodrug alone or with atropine-pralidoxime in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19681868/),[ng] / [ml],231,143771,DB00829,Diazepam
,19681868,maximum concentration (C(max)),"The maximum concentration (C(max)) of diazepam after avizafone injection was higher than that obtained after injection of diazepam itself (231 vs. 148 ng.mL(-1)), while area under the curve (AUC) values were equal.",Bioavailability of diazepam after intramuscular injection of its water-soluble prodrug alone or with atropine-pralidoxime in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19681868/),[ng] / [ml],148,143772,DB00829,Diazepam
,18760341,t(max),"After i.n. administration, DZ was rapidly absorbed into the systemic circulation, and readily and homogeneously distributed into the different regions of brain tissues with a t(max) of 5 and 10 min in rats and rabbits, respectively.",Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),min,5,144291,DB00829,Diazepam
,18760341,t(max),"After i.n. administration, DZ was rapidly absorbed into the systemic circulation, and readily and homogeneously distributed into the different regions of brain tissues with a t(max) of 5 and 10 min in rats and rabbits, respectively.",Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),min,10,144292,DB00829,Diazepam
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,68.4,144293,DB00829,Diazepam
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,67.7,144294,DB00829,Diazepam
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,32-47,144295,DB00829,Diazepam
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,51.6,144296,DB00829,Diazepam
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,45.9,144297,DB00829,Diazepam
,18760341,AUC(brain)/AUC(plasma) ratios,The AUC(brain)/AUC(plasma) ratios in rabbits after i.n. administration (3.77+/-0.17) were slightly lower than from i.v. administration (4.23+/-0.08).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),,3.77,144298,DB00829,Diazepam
,18760341,AUC(brain)/AUC(plasma) ratios,The AUC(brain)/AUC(plasma) ratios in rabbits after i.n. administration (3.77+/-0.17) were slightly lower than from i.v. administration (4.23+/-0.08).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),,4.23,144299,DB00829,Diazepam
,18760341,AUC(brain)/AUC(plasma) ratios,"However, in rats the AUC(brain)/AUC(plasma) ratios after i.v. (3.03+/-0.07) and i.n. (3.00+/-0.32) administration were nearly identical.",Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),,3.03,144300,DB00829,Diazepam
,18760341,AUC(brain)/AUC(plasma) ratios,"However, in rats the AUC(brain)/AUC(plasma) ratios after i.v. (3.03+/-0.07) and i.n. (3.00+/-0.32) administration were nearly identical.",Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),,3.00,144301,DB00829,Diazepam
,26770447,m,"An electrospray ionization source was applied and operated in positive ion mode; multiple reactions monitoring (MRM) mode was used for quantification using target fragment ions m/z 546.9→200.6 for ACT-132577, and m/z 285.1→193.1 for IS.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),,285.1,144306,DB00829,Diazepam
,26770447,recovery,"Mean recovery of ACT-132577 in rat plasma ranged from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranged from 101.4% to 115.2%.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),%,82.6,144307,DB00829,Diazepam
,26770447,recovery,"Mean recovery of ACT-132577 in rat plasma ranged from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranged from 101.4% to 115.2%.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),%,90.6,144308,DB00829,Diazepam
,26770447,matrix effect,"Mean recovery of ACT-132577 in rat plasma ranged from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranged from 101.4% to 115.2%.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),%,101.4,144309,DB00829,Diazepam
,26770447,matrix effect,"Mean recovery of ACT-132577 in rat plasma ranged from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranged from 101.4% to 115.2%.",Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770447/),%,115.2,144310,DB00829,Diazepam
,7639079,Vm,"The Vm and Km of phenytoin in a 60 kg adult out-patient, without combination with other drugs (phenobarbital, clonazepam or diazepam) were estimated to be 439 mg.d-1 and 6.21 micrograms.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),[mg] / [d],439,144566,DB00829,Diazepam
,7639079,Km,"The Vm and Km of phenytoin in a 60 kg adult out-patient, without combination with other drugs (phenobarbital, clonazepam or diazepam) were estimated to be 439 mg.d-1 and 6.21 micrograms.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),μg,6.21,144567,DB00829,Diazepam
,7639079,Vm,"The Vm of patients treated with phenytoin combined with phenobarbital, clonazepam or diazepam will increase 8.4 mg.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),mg,8.4,144568,DB00829,Diazepam
,2721106,free plasma clearance,"Disposition parameters were calculated for four of the patients; the mean free plasma clearance of diazepam was 42.5 ml/min/kg, similar to the mean value reported previously for nonpregnant women of comparable age.",The disposition and placental transfer of diazepam in cesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2721106/),[ml] / [kg·min],42.5,145065,DB00829,Diazepam
,20395105,flow rate,"A relatively simple mobile phase consisting of acetonitrile-ammonium formate buffer (pH 3; 10 mM) (45:55, v/v) was pumped at a low flow rate of 0.3 ml/min through a reverse phase Phenomenex Luna C18 (2) (5 microm, 150 mm x 2.0 mm i.d.) column maintained at 30 degrees C.",An efficient HPLC method for the quantitative determination of atazanavir in human plasma suitable for bioequivalence and pharmacokinetic studies in healthy human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395105/),[ml] / [min],0.3,145493,DB00829,Diazepam
,20395105,retention times,The major advantage of this method over previously reported procedures is that the narrow-bore HPLC column used resulted in relatively short retention times for the internal standard (6.8 min) and atazanavir (8.3 min) with excellent peak resolution and associated reduction in solvent usage.,An efficient HPLC method for the quantitative determination of atazanavir in human plasma suitable for bioequivalence and pharmacokinetic studies in healthy human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395105/),min,6.8,145494,DB00829,Diazepam
,20395105,retention times,The major advantage of this method over previously reported procedures is that the narrow-bore HPLC column used resulted in relatively short retention times for the internal standard (6.8 min) and atazanavir (8.3 min) with excellent peak resolution and associated reduction in solvent usage.,An efficient HPLC method for the quantitative determination of atazanavir in human plasma suitable for bioequivalence and pharmacokinetic studies in healthy human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395105/),min,8.3,145495,DB00829,Diazepam
,20395105,recovery,"Mean recovery based on high, medium and low quality control standards ranged between 94.4+/-1.07% and 100+/-2.22%.",An efficient HPLC method for the quantitative determination of atazanavir in human plasma suitable for bioequivalence and pharmacokinetic studies in healthy human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395105/),%,94.4,145496,DB00829,Diazepam
,20395105,recovery,"Mean recovery based on high, medium and low quality control standards ranged between 94.4+/-1.07% and 100+/-2.22%.",An efficient HPLC method for the quantitative determination of atazanavir in human plasma suitable for bioequivalence and pharmacokinetic studies in healthy human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20395105/),%,100,145497,DB00829,Diazepam
,23893840,m/,Ions monitored in the multiple-reaction monitoring mode were m/z 1091 → 650 for bivalirudin (at 2.70 min) and m/z 285 → 193 for diazepam (at 3.85 min).,Development and validation of a highly sensitive LC-MS/MS method for quantitation of bivalirudin in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893840/),,1091,145708,DB00829,Diazepam
,23893840,m/,Ions monitored in the multiple-reaction monitoring mode were m/z 1091 → 650 for bivalirudin (at 2.70 min) and m/z 285 → 193 for diazepam (at 3.85 min).,Development and validation of a highly sensitive LC-MS/MS method for quantitation of bivalirudin in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893840/),,650,145709,DB00829,Diazepam
,23893840,m/z,Ions monitored in the multiple-reaction monitoring mode were m/z 1091 → 650 for bivalirudin (at 2.70 min) and m/z 285 → 193 for diazepam (at 3.85 min).,Development and validation of a highly sensitive LC-MS/MS method for quantitation of bivalirudin in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893840/),,285,145710,DB00829,Diazepam
,23893840,m/z,Ions monitored in the multiple-reaction monitoring mode were m/z 1091 → 650 for bivalirudin (at 2.70 min) and m/z 285 → 193 for diazepam (at 3.85 min).,Development and validation of a highly sensitive LC-MS/MS method for quantitation of bivalirudin in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893840/),,193,145711,DB00829,Diazepam
,30773662,flow rate,"After extraction from 200 μL of plasma by protein precipitation, the analytes and internal standard (IS) diazepam were separated on a Hedera ODS-2 (5 μm, 150 × 2.1 mm) column with a mobile phase consisted of methanol-0.1% formic acid in 10 mm ammonium acetate solution (85:15, v/v) delivered at a flow rate of 0.5 mL/min.",LC-MS/MS method for simultaneous determination of ramelteon and its metabolite M-II in human plasma: Application to a clinical pharmacokinetic study in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30773662/),[ml] / [min],0.5,146902,DB00829,Diazepam
,30773662,maximum plasma concentration (Cmax ),"The maximum plasma concentration (Cmax ), the time to the Cmax and the elimination half-life for ramelteon were 4.50 ± 4.64ng/mL, 0.8 ± 0.4h and 1.0 ± 0.9 h, respectively, and for M-II were 136 ± 36 ng/mL, 1.1 ± 0.5 h, 2.1 ± 0.4 h, respectively.",LC-MS/MS method for simultaneous determination of ramelteon and its metabolite M-II in human plasma: Application to a clinical pharmacokinetic study in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30773662/),[ng] / [ml],4.50,146903,DB00829,Diazepam
,30773662,time to the Cmax,"The maximum plasma concentration (Cmax ), the time to the Cmax and the elimination half-life for ramelteon were 4.50 ± 4.64ng/mL, 0.8 ± 0.4h and 1.0 ± 0.9 h, respectively, and for M-II were 136 ± 36 ng/mL, 1.1 ± 0.5 h, 2.1 ± 0.4 h, respectively.",LC-MS/MS method for simultaneous determination of ramelteon and its metabolite M-II in human plasma: Application to a clinical pharmacokinetic study in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30773662/),h,0.8,146904,DB00829,Diazepam
,30773662,time to the Cmax,"The maximum plasma concentration (Cmax ), the time to the Cmax and the elimination half-life for ramelteon were 4.50 ± 4.64ng/mL, 0.8 ± 0.4h and 1.0 ± 0.9 h, respectively, and for M-II were 136 ± 36 ng/mL, 1.1 ± 0.5 h, 2.1 ± 0.4 h, respectively.",LC-MS/MS method for simultaneous determination of ramelteon and its metabolite M-II in human plasma: Application to a clinical pharmacokinetic study in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30773662/),[ng] / [ml],136,146905,DB00829,Diazepam
,30773662,time to the Cmax,"The maximum plasma concentration (Cmax ), the time to the Cmax and the elimination half-life for ramelteon were 4.50 ± 4.64ng/mL, 0.8 ± 0.4h and 1.0 ± 0.9 h, respectively, and for M-II were 136 ± 36 ng/mL, 1.1 ± 0.5 h, 2.1 ± 0.4 h, respectively.",LC-MS/MS method for simultaneous determination of ramelteon and its metabolite M-II in human plasma: Application to a clinical pharmacokinetic study in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30773662/),h,1.1,146906,DB00829,Diazepam
,30773662,elimination half-life,"The maximum plasma concentration (Cmax ), the time to the Cmax and the elimination half-life for ramelteon were 4.50 ± 4.64ng/mL, 0.8 ± 0.4h and 1.0 ± 0.9 h, respectively, and for M-II were 136 ± 36 ng/mL, 1.1 ± 0.5 h, 2.1 ± 0.4 h, respectively.",LC-MS/MS method for simultaneous determination of ramelteon and its metabolite M-II in human plasma: Application to a clinical pharmacokinetic study in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30773662/),h,1.0,146907,DB00829,Diazepam
,30773662,elimination half-life,"The maximum plasma concentration (Cmax ), the time to the Cmax and the elimination half-life for ramelteon were 4.50 ± 4.64ng/mL, 0.8 ± 0.4h and 1.0 ± 0.9 h, respectively, and for M-II were 136 ± 36 ng/mL, 1.1 ± 0.5 h, 2.1 ± 0.4 h, respectively.",LC-MS/MS method for simultaneous determination of ramelteon and its metabolite M-II in human plasma: Application to a clinical pharmacokinetic study in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30773662/),h,2.1,146908,DB00829,Diazepam
,22981338,C(max),"Mean DZP C(max) (±SD) was 181.8 ± 84.16, 151.3 ± 108.1 and 180.7 ± 82.1 ng/mL for Nas-A 10mg, Nas-B 10 and Nas-B 13.4 mg respectively; in comparison the C(max) for the rectal gel was 160.9 ± 109.4 ng/mL.",Bioavailability of intranasal vs. rectal diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22981338/),[ng] / [ml],181.8,147322,DB00829,Diazepam
,22981338,C(max),"Mean DZP C(max) (±SD) was 181.8 ± 84.16, 151.3 ± 108.1 and 180.7 ± 82.1 ng/mL for Nas-A 10mg, Nas-B 10 and Nas-B 13.4 mg respectively; in comparison the C(max) for the rectal gel was 160.9 ± 109.4 ng/mL.",Bioavailability of intranasal vs. rectal diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22981338/),[ng] / [ml],151.3,147323,DB00829,Diazepam
,22981338,C(max),"Mean DZP C(max) (±SD) was 181.8 ± 84.16, 151.3 ± 108.1 and 180.7 ± 82.1 ng/mL for Nas-A 10mg, Nas-B 10 and Nas-B 13.4 mg respectively; in comparison the C(max) for the rectal gel was 160.9 ± 109.4 ng/mL.",Bioavailability of intranasal vs. rectal diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22981338/),[ng] / [ml],180.7,147324,DB00829,Diazepam
,22981338,C(max),"Mean DZP C(max) (±SD) was 181.8 ± 84.16, 151.3 ± 108.1 and 180.7 ± 82.1 ng/mL for Nas-A 10mg, Nas-B 10 and Nas-B 13.4 mg respectively; in comparison the C(max) for the rectal gel was 160.9 ± 109.4 ng/mL.",Bioavailability of intranasal vs. rectal diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22981338/),[ng] / [ml],160.9,147325,DB00829,Diazepam
,22981338,T(max),Median T(max) was 0.75 h for all treatments.,Bioavailability of intranasal vs. rectal diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22981338/),h,0.75,147326,DB00829,Diazepam
,22981338,bioavailability,"Both intranasal formulations were well tolerated and exhibited relatively rapid, but variable, absorption with bioavailability of 70-90% relative to DZP rectal gel.",Bioavailability of intranasal vs. rectal diazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22981338/),%,70-90,147327,DB00829,Diazepam
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,589",147638,DB00829,Diazepam
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,065",147639,DB00829,Diazepam
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,243",147640,DB00829,Diazepam
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,254",147641,DB00829,Diazepam
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,206",147642,DB00829,Diazepam
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,589",147643,DB00829,Diazepam
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,065",147644,DB00829,Diazepam
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,243",147645,DB00829,Diazepam
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,168",147646,DB00829,Diazepam
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,254",147647,DB00829,Diazepam
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,206",147648,DB00829,Diazepam
,10815716,detection limit,The assay is linear from 10 to 500 ng ml(-1) with a detection limit of 5 ng ml(-1) and a mean recovery of 96.5%.,RP-LC method for the determination of cetirizine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10815716/),[ng] / [ml],5,148383,DB00829,Diazepam
,10815716,recovery,The assay is linear from 10 to 500 ng ml(-1) with a detection limit of 5 ng ml(-1) and a mean recovery of 96.5%.,RP-LC method for the determination of cetirizine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10815716/),%,96.5,148384,DB00829,Diazepam
above,1978486,bioavailability,After oral administration the drug is rapidly and almost completely absorbed with a bioavailability above 90%.,Clinical pharmacokinetics of remoxipride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),%,90,148873,DB00829,Diazepam
,1978486,systemic plasma clearance,"Thus remoxipride is a low clearance drug, with a systemic plasma clearance of about 120 ml/min, and without any first-pass metabolism.",Clinical pharmacokinetics of remoxipride. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),[ml] / [min],120,148874,DB00829,Diazepam
,1978486,apparent volume of distribution,"The apparent volume of distribution is 0.7 1/kg, about 80% being bound to plasma proteins (mainly alpha 1-acid glycoprotein).",Clinical pharmacokinetics of remoxipride. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),[1] / [kg],0.7,148875,DB00829,Diazepam
,1978486,plasma half-life,Remoxipride has a plasma half-life in the range of 4-7 h and is eliminated by both hepatic metabolism and renal excretion.,Clinical pharmacokinetics of remoxipride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),h,4-7,148876,DB00829,Diazepam
,7138754,elimination half-life,A significant increase in diazepam elimination half-life from (mean +/- s.e. mean) 66.9 +/- 21.4 to 89.6 +/- 22.5 h (P = 0.006) and area under the plasma concentration-time curve from 5.06 +/- 1.47 to 8.93 +/- 1.88 micrograms ml-1 h (P = 0.028) was observed indicating a probable cimetidine induced inhibition of diazepam hepatic metabolism.,Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138754/),h,66.9,149087,DB00829,Diazepam
,7138754,elimination half-life,A significant increase in diazepam elimination half-life from (mean +/- s.e. mean) 66.9 +/- 21.4 to 89.6 +/- 22.5 h (P = 0.006) and area under the plasma concentration-time curve from 5.06 +/- 1.47 to 8.93 +/- 1.88 micrograms ml-1 h (P = 0.028) was observed indicating a probable cimetidine induced inhibition of diazepam hepatic metabolism.,Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138754/),h,89.6,149088,DB00829,Diazepam
,7138754,area under the plasma concentration-time curve,A significant increase in diazepam elimination half-life from (mean +/- s.e. mean) 66.9 +/- 21.4 to 89.6 +/- 22.5 h (P = 0.006) and area under the plasma concentration-time curve from 5.06 +/- 1.47 to 8.93 +/- 1.88 micrograms ml-1 h (P = 0.028) was observed indicating a probable cimetidine induced inhibition of diazepam hepatic metabolism.,Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138754/),[h·μg] / [ml],5.06,149089,DB00829,Diazepam
,7138754,area under the plasma concentration-time curve,A significant increase in diazepam elimination half-life from (mean +/- s.e. mean) 66.9 +/- 21.4 to 89.6 +/- 22.5 h (P = 0.006) and area under the plasma concentration-time curve from 5.06 +/- 1.47 to 8.93 +/- 1.88 micrograms ml-1 h (P = 0.028) was observed indicating a probable cimetidine induced inhibition of diazepam hepatic metabolism.,Influence of cimetidine on oral diazepam elimination with measurement of subsequent cognitive change. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7138754/),[h·μg] / [ml],8.93,149090,DB00829,Diazepam
,3127102,bioavailability,"Following oral administration flumazenil is rapidly absorbed (peak concentrations are achieved after 20 to 90 minutes), but bioavailability is low (16%) due to significant presystemic elimination.",Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),%,16,149211,DB00829,Diazepam
,3127102,half-life,This can be characterised either by the short half-life (0.7 to 1.3 hours) or better by the high plasma or blood clearance of 520 to 1300 ml/min (31 to 78 L/h).,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),h,0.7 to 1.3,149212,DB00829,Diazepam
,3127102,plasma,This can be characterised either by the short half-life (0.7 to 1.3 hours) or better by the high plasma or blood clearance of 520 to 1300 ml/min (31 to 78 L/h).,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),[ml] / [min],520 to 1300,149213,DB00829,Diazepam
,3127102,blood clearance,This can be characterised either by the short half-life (0.7 to 1.3 hours) or better by the high plasma or blood clearance of 520 to 1300 ml/min (31 to 78 L/h).,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),[ml] / [min],520 to 1300,149214,DB00829,Diazepam
,3127102,blood clearance,This can be characterised either by the short half-life (0.7 to 1.3 hours) or better by the high plasma or blood clearance of 520 to 1300 ml/min (31 to 78 L/h).,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),[l] / [h],31 to 78,149215,DB00829,Diazepam
,3127102,plasma protein binding,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6 to 1.6 L/kg) or its partly flow-dependent hepatic elimination.,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),%,40,149216,DB00829,Diazepam
,3127102,apparent distribution volume,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6 to 1.6 L/kg) or its partly flow-dependent hepatic elimination.,Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127102/),[l] / [kg],0.6 to 1.6,149217,DB00829,Diazepam
,1184723,MCR,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),[l] / [d],383,149337,DB00829,Diazepam
,1184723,volume of distribution,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),l,61,149338,DB00829,Diazepam
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,424,149339,DB00829,Diazepam
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,977,149340,DB00829,Diazepam
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,149,149341,DB00829,Diazepam
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,69,149342,DB00829,Diazepam
,1505151,plasma half-life,"The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91.0 +/- 5.6 and 59.7 +/- 5.4 hours, p less than 0.005), and the poor metabolizers had the lower clearance of diazepam than the extensive metabolizers (9.4 +/- 0.5 and 17.0 +/- 1.4 ml/min, p less than 0.001).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),h,91.0,149357,DB00829,Diazepam
,1505151,plasma half-life,"The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91.0 +/- 5.6 and 59.7 +/- 5.4 hours, p less than 0.005), and the poor metabolizers had the lower clearance of diazepam than the extensive metabolizers (9.4 +/- 0.5 and 17.0 +/- 1.4 ml/min, p less than 0.001).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),h,59.7,149358,DB00829,Diazepam
,1505151,clearance,"The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91.0 +/- 5.6 and 59.7 +/- 5.4 hours, p less than 0.005), and the poor metabolizers had the lower clearance of diazepam than the extensive metabolizers (9.4 +/- 0.5 and 17.0 +/- 1.4 ml/min, p less than 0.001).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),[ml] / [min],9.4,149359,DB00829,Diazepam
,1505151,clearance,"The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91.0 +/- 5.6 and 59.7 +/- 5.4 hours, p less than 0.005), and the poor metabolizers had the lower clearance of diazepam than the extensive metabolizers (9.4 +/- 0.5 and 17.0 +/- 1.4 ml/min, p less than 0.001).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),[ml] / [min],17.0,149360,DB00829,Diazepam
,1505151,plasma half-life,"In addition, the plasma half-life of demethyldiazepam showed a statistically significant (p less than 0.001) difference between the extensive metabolizers (95.9 +/- 11.3 hours) and poor metabolizers (213.1 +/- 10.7 hours), and correlated with the log10 urinary excretion of 4-hydroxymephenytoin (rs = -0.615, p less than 0.01).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),h,95.9,149361,DB00829,Diazepam
,1505151,plasma half-life,"In addition, the plasma half-life of demethyldiazepam showed a statistically significant (p less than 0.001) difference between the extensive metabolizers (95.9 +/- 11.3 hours) and poor metabolizers (213.1 +/- 10.7 hours), and correlated with the log10 urinary excretion of 4-hydroxymephenytoin (rs = -0.615, p less than 0.01).",Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505151/),h,213.1,149362,DB00829,Diazepam
,24422409,Total analysis time,Total analysis time was 2 min.,"[Determination of chrysosplenetin, metabolic inhibitor of artemisinin, in rat plasma by UPLC-ms/MS and study on its pharmacokinetics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422409/),min,2,150324,DB00829,Diazepam
,24422409,recoveries,The assay was linear in the range 5-5 000 microg L-1 (r =0. 999 3) with recoveries in the range from 69.,"[Determination of chrysosplenetin, metabolic inhibitor of artemisinin, in rat plasma by UPLC-ms/MS and study on its pharmacokinetics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422409/),,69,150325,DB00829,Diazepam
,24422409,t1/2,"The t1/2 of CHR after intravenous injection was very short and that of low, medium, and high dosage was (17. 01 +/- 8. 06) , (24. 62 +/- 4. 59), (28. 46+/- 4. 63) min, respectively.","[Determination of chrysosplenetin, metabolic inhibitor of artemisinin, in rat plasma by UPLC-ms/MS and study on its pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422409/),min,17. 01,150326,DB00829,Diazepam
,24422409,t1/2,"The t1/2 of CHR after intravenous injection was very short and that of low, medium, and high dosage was (17. 01 +/- 8. 06) , (24. 62 +/- 4. 59), (28. 46+/- 4. 63) min, respectively.","[Determination of chrysosplenetin, metabolic inhibitor of artemisinin, in rat plasma by UPLC-ms/MS and study on its pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422409/),min,24. 62,150327,DB00829,Diazepam
,24422409,t1/2,"The t1/2 of CHR after intravenous injection was very short and that of low, medium, and high dosage was (17. 01 +/- 8. 06) , (24. 62 +/- 4. 59), (28. 46+/- 4. 63) min, respectively.","[Determination of chrysosplenetin, metabolic inhibitor of artemisinin, in rat plasma by UPLC-ms/MS and study on its pharmacokinetics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422409/),min,28. 46,150328,DB00829,Diazepam
<,9379349,tmax,In the search for a nasal formulation leading to a peak plasma concentration of diazepam at a tmax < or = 5 min bioavailability in rabbits has been studied after intranasal administration of the drug in ten vehicles of different polarity.,Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9379349/),min,5,151445,DB00829,Diazepam
,9379349,bioavailability,"The bioavailability, measured during the first 30 min, because periods after this are not relevant for acute treatment, was found to be between 49 and 62% for the four most promising vehicles, pure glycofurol 75, tetraethyleneglycol, poly(ethylene glycol) 200 and 30% glycofurol in tetraethyleneglycol.",Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9379349/),%,49 and 62,151446,DB00829,Diazepam
,9379349,bioavailability,"The bioavailability, measured during the first 30 min, because periods after this are not relevant for acute treatment, was found to be between 49 and 62% for the four most promising vehicles, pure glycofurol 75, tetraethyleneglycol, poly(ethylene glycol) 200 and 30% glycofurol in tetraethyleneglycol.",Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9379349/),%,30,151447,DB00829,Diazepam
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,407.10,151490,DB00829,Diazepam
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,389.20,151491,DB00829,Diazepam
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,285.08,151492,DB00829,Diazepam
,25734938,m/z,"The ion transitions monitored were set at m/z 407.10 → 389.20 and m/z 285.08 → 193.10 for GK and IS, respectively.",Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25734938/),,193.10,151493,DB00829,Diazepam
,24216164,flow rate,"Chromatographic separation was accomplished on an Agilent C18 column (2.1 mm × 150 mm, 5 µm), with 0.1% formic acid and acetonitrile (1:1) as the mobile phase at a flow rate of 0.5 mL/min.",Pharmacokinetic study on costunolide and dehydrocostuslactone after oral administration of traditional medicine Aucklandia lappa Decne. by LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216164/),[ml] / [min],0.5,155585,DB00829,Diazepam
,24216164,time to reach the maximum plasma concentration (Tmax),"The time to reach the maximum plasma concentration (Tmax) was 10.46 h for costunolide, 12.39 h dehydrocostuslactone.",Pharmacokinetic study on costunolide and dehydrocostuslactone after oral administration of traditional medicine Aucklandia lappa Decne. by LC/MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216164/),h,10.46,155586,DB00829,Diazepam
,24216164,time to reach the maximum plasma concentration (Tmax),"The time to reach the maximum plasma concentration (Tmax) was 10.46 h for costunolide, 12.39 h dehydrocostuslactone.",Pharmacokinetic study on costunolide and dehydrocostuslactone after oral administration of traditional medicine Aucklandia lappa Decne. by LC/MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216164/),h,12.39,155587,DB00829,Diazepam
,24216164,elimination half-time (t1/2),The elimination half-time (t1/2) of costunolide and dehydrocostuslactone was 5.54 ± 0.81 and 4.32 ± 0.71 (h).,Pharmacokinetic study on costunolide and dehydrocostuslactone after oral administration of traditional medicine Aucklandia lappa Decne. by LC/MS/MS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216164/),h,5.54,155588,DB00829,Diazepam
,24216164,elimination half-time (t1/2),The elimination half-time (t1/2) of costunolide and dehydrocostuslactone was 5.54 ± 0.81 and 4.32 ± 0.71 (h).,Pharmacokinetic study on costunolide and dehydrocostuslactone after oral administration of traditional medicine Aucklandia lappa Decne. by LC/MS/MS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216164/),h,4.32,155589,DB00829,Diazepam
,24216164,AUC,The AUC of costunolide and dehydrocostuslactone was 308.83 and 7884.51 respectively (ngh/mL).,Pharmacokinetic study on costunolide and dehydrocostuslactone after oral administration of traditional medicine Aucklandia lappa Decne. by LC/MS/MS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216164/),[ngh] / [ml],308.83,155590,DB00829,Diazepam
,24216164,AUC,The AUC of costunolide and dehydrocostuslactone was 308.83 and 7884.51 respectively (ngh/mL).,Pharmacokinetic study on costunolide and dehydrocostuslactone after oral administration of traditional medicine Aucklandia lappa Decne. by LC/MS/MS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216164/),[ngh] / [ml],7884.51,155591,DB00829,Diazepam
,6418547,plasma levels,The highest plasma levels of the parent compound (367 +/- 13 ng/ml) were found 3 min after administration.,"Disposition, distribution, plasma protein binding and biliary excretion of pinazepam after i.p. administration to rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418547/),[ng] / [ml],367,157015,DB00829,Diazepam
,6418547,volume of distribution,The volume of distribution and the clearance of the drug were 1315 ml and 7.23 ml/min respectively.,"Disposition, distribution, plasma protein binding and biliary excretion of pinazepam after i.p. administration to rat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418547/),ml,1315,157016,DB00829,Diazepam
,6418547,clearance,The volume of distribution and the clearance of the drug were 1315 ml and 7.23 ml/min respectively.,"Disposition, distribution, plasma protein binding and biliary excretion of pinazepam after i.p. administration to rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418547/),[ml] / [min],7.23,157017,DB00829,Diazepam
,6418547,association constant,The association constant was 2.60 X 10(3) l/mole and the number of sites 0.44 X 10(-6) sites/g.,"Disposition, distribution, plasma protein binding and biliary excretion of pinazepam after i.p. administration to rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418547/),[l] / [mole],2.60 X 10(3),157018,DB00829,Diazepam
,6418547,number of sites,The association constant was 2.60 X 10(3) l/mole and the number of sites 0.44 X 10(-6) sites/g.,"Disposition, distribution, plasma protein binding and biliary excretion of pinazepam after i.p. administration to rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6418547/),[sites] / [g],0.44 X 10(-6),157019,DB00829,Diazepam
,27405507,m/,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,612.1,158133,DB00829,Diazepam
,27405507,m/,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,280.2,158134,DB00829,Diazepam
,27405507,m/z,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,436.0,158135,DB00829,Diazepam
,27405507,m/z,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,235.1,158136,DB00829,Diazepam
,27405507,m/z,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,285.1,158137,DB00829,Diazepam
,27405507,m/z,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,193.1,158138,DB00829,Diazepam
,27405507,recoveries,The recoveries of the analytes were in the range of 98-103%.,Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),%,98-103,158139,DB00829,Diazepam
,15150671,terminal half-life,"The terminal half-life was 730+/-410 min, the AUC was 3130+/-425 microM min, and the clearance was 190+/-25 ml/min/m2.",Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150671/),min,730,158146,DB00829,Diazepam
,15150671,AUC,"The terminal half-life was 730+/-410 min, the AUC was 3130+/-425 microM min, and the clearance was 190+/-25 ml/min/m2.",Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150671/),min·μM,3130,158147,DB00829,Diazepam
,15150671,clearance,"The terminal half-life was 730+/-410 min, the AUC was 3130+/-425 microM min, and the clearance was 190+/-25 ml/min/m2.",Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150671/),[ml] / [m2·min],190,158148,DB00829,Diazepam
exceeding,6405081,half-life,Long acting benzodiazepines have half-life values usually exceeding 24 h.,[Benzodiazepines: significance of kinetics for therapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6405081/),h,24,158726,DB00829,Diazepam
,6405081,half-life,Intermediate and short-acting benzodiazepines have half-life values from 5-24 h and active metabolites are uncommon.,[Benzodiazepines: significance of kinetics for therapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6405081/),h,5-24,158727,DB00829,Diazepam
less,6405081,half-life,The half-life of ultrashort-acting benzodiazepines is less than 5 h.,[Benzodiazepines: significance of kinetics for therapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6405081/),h,5,158728,DB00829,Diazepam
,16085142,detection limit,"A detection limit of 0.10 ng/ml for lorazepam was achieved, and inter- and intra-run precisions of better than 4.4% (R.S.D.) were observed.",A fast and sensitive liquid chromatographic-tandem mass spectrometric method for assay of lorazepam and application to pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085142/),[ng] / [ml],0.10,159137,DB00829,Diazepam
longer,19015955,"t (1/2,z)","An apparent multiple dosing half-life (t (1/2, app)) was determined from peak and trough steady-state ratios and found to be significantly less than reported terminal t (1/2)s for eight orally dosed drugs with t (1/2,z) values longer than one day.",The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015955/),d,one,161202,DB00829,Diazepam
,28755970,total bioavailability,Pharmacokinetic data showed that the total bioavailability of RIN was 5.9 folds higher than that of IRN (23.4% vs. 4.0%).,Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,23.4,161501,DB00829,Diazepam
,28755970,total bioavailability,Pharmacokinetic data showed that the total bioavailability of RIN was 5.9 folds higher than that of IRN (23.4% vs. 4.0%).,Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,4.0,161502,DB00829,Diazepam
,28755970,hepatic availability,"The hepatic availability of RIN was 4.6 folds higher than that of IRN (46.9% vs. 10.3%), whereas the intestinal availability of RIN (48.1%) was comparable to that of IRN (42.7%).",Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,46.9,161503,DB00829,Diazepam
,28755970,hepatic availability,"The hepatic availability of RIN was 4.6 folds higher than that of IRN (46.9% vs. 10.3%), whereas the intestinal availability of RIN (48.1%) was comparable to that of IRN (42.7%).",Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,10.3,161504,DB00829,Diazepam
,28755970,intestinal availability,"The hepatic availability of RIN was 4.6 folds higher than that of IRN (46.9% vs. 10.3%), whereas the intestinal availability of RIN (48.1%) was comparable to that of IRN (42.7%).",Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,48.1,161505,DB00829,Diazepam
,28755970,intestinal availability,"The hepatic availability of RIN was 4.6 folds higher than that of IRN (46.9% vs. 10.3%), whereas the intestinal availability of RIN (48.1%) was comparable to that of IRN (42.7%).",Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,42.7,161506,DB00829,Diazepam
,2690330,volume of distribution,The volume of distribution is 0.3 litres/kg corresponding to the volume of extracellular water.,Omeprazole: pharmacokinetics and metabolism in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),[l] / [kg],0.3,161885,DB00829,Diazepam
less,2690330,half-life,"The half-life is less than 1 hour, and omeprazole is almost entirely cleared from plasma within 3-4 hours.",Omeprazole: pharmacokinetics and metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),h,1,161886,DB00829,Diazepam
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,35,161887,DB00829,Diazepam
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,60,161888,DB00829,Diazepam
,19488979,overall run time,The LC-MS/MS method on a RP-C18 column had an overall run time of 5.0 min and was linear (1/x weighted) over the range 0.5-50 ng/mL (R > 0.999).,Quantification of chlordesmethyldiazepam by liquid chromatography-tandem mass spectrometry: application to a cloxazolam bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488979/),min,5.0,162399,DB00829,Diazepam
,1577053,plasma clearance,"Individual pharmacokinetic parameters were calculated: plasma clearance was 3.9 ml.min-1, elimination half-life was 12.0 h.",Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577053/),[ml] / [min],3.9,162451,DB00829,Diazepam
,1577053,elimination half-life,"Individual pharmacokinetic parameters were calculated: plasma clearance was 3.9 ml.min-1, elimination half-life was 12.0 h.",Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577053/),h,12.0,162452,DB00829,Diazepam
,28547577,concentration,"The initial plasma pramipexole concentration was 34.2 ng/mL (therapeutic range 0.2 to 7 ng/mL), 9 h post-overdose.","Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28547577/),[ng] / [ml],34.2,162674,DB00829,Diazepam
,28547577,elimination half-life,Concentration time data fitted a one-compartment model with an estimated elimination half-life of 18 h.,"Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28547577/),h,18,162675,DB00829,Diazepam
,362051,half-life (T1/2(beta)),"While the normal half-life (T1/2(beta)) varies between 1 and 2 days, it can be increased to up to 80--100 h in subjects over 60 years of age.",[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),d,1 and 2,163625,DB00829,Diazepam
up to,362051,half-life (T1/2(beta)),"While the normal half-life (T1/2(beta)) varies between 1 and 2 days, it can be increased to up to 80--100 h in subjects over 60 years of age.",[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),h,80--100,163626,DB00829,Diazepam
,362051,hepatic clearance,"In patients with liver disease T1/2(beta) is about doubled, which is caused by a reduction (factor 2) of the normal hepatic clearance of 26 ml/min.",[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),[ml] / [min],26,163627,DB00829,Diazepam
,362051,T1/2(beta),The major metabolite desmethyldiazepam has a T1/2(beta) of 51 h and a Cl of 11 ml/min and accumulates after multiple doses of diazepam since its elimination is much slower than that of its parent compound.,[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),h,51,163628,DB00829,Diazepam
,362051,Cl,The major metabolite desmethyldiazepam has a T1/2(beta) of 51 h and a Cl of 11 ml/min and accumulates after multiple doses of diazepam since its elimination is much slower than that of its parent compound.,[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),[ml] / [min],11,163629,DB00829,Diazepam
,362051,T1/2(beta),In contrast to these findings oxazepam is excreted as glucuronide in the urine relatively fast and independently of the liver function with a T1/2(beta) of 5.5 h and a Cl of 130 ml/min.,[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),h,5.5,163630,DB00829,Diazepam
,362051,Cl,In contrast to these findings oxazepam is excreted as glucuronide in the urine relatively fast and independently of the liver function with a T1/2(beta) of 5.5 h and a Cl of 130 ml/min.,[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),[ml] / [min],130,163631,DB00829,Diazepam
,6339196,bioavailability,"However, the bioavailability of verapamil has been studied extensively; about 22% of an orally administered dose of verapamil is systemically available.",Calcium antagonists. Pharmacokinetic properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),%,22,163725,DB00829,Diazepam
,6339196,elimination half-lives,"The elimination half-lives of verapamil and diltiazem are about 8 and 5 hours, respectively.",Calcium antagonists. Pharmacokinetic properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),h,8,163726,DB00829,Diazepam
,6339196,elimination half-lives,"The elimination half-lives of verapamil and diltiazem are about 8 and 5 hours, respectively.",Calcium antagonists. Pharmacokinetic properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),h,5,163727,DB00829,Diazepam
,3954113,peak arterial plasma lidocaine concentration,"Despite a large total dose of topical lidocaine (5.3 +/- 2.1 mg/kg), the mean peak arterial plasma lidocaine concentration was low (0.6 +/- 2.1 micrograms/ml).",Cardiovascular responses and lidocaine absorption in fiberoptic-assisted awake intubation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954113/),[μg] / [ml],0.6,164985,DB00829,Diazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.2,165364,DB00829,Diazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.13,165365,DB00829,Diazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.14,165366,DB00829,Diazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.10,165367,DB00829,Diazepam
,14991686,chromatographic run time,The method had a chromatographic run time of 5.0 min and a linear calibration curve over the range 5.0-150 ng ml(-1) (r(2) > 0.9952).,Bromazepam determination in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry: a highly sensitive and specific tool for bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14991686/),min,5.0,165597,DB00829,Diazepam
,26689716,flow rate,"The analyte and IS were separated on an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm) with the mobile phase of acetonitrile and 1% formic acid in water with gradient elution at a flow rate of 0.4 mL/min.",UPLC-MS-MS Determination of Dihydrocodeine in Human Plasma and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26689716/),[ml] / [min],0.4,165624,DB00829,Diazepam
,26689716,overall run time,The overall run time was 4.0 min.,UPLC-MS-MS Determination of Dihydrocodeine in Human Plasma and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26689716/),min,4.0,165625,DB00829,Diazepam
,3082341,half-lives of elimination,"The mean half-lives of elimination came to 75.3 +/- 32.0 (SD) h (5-mg tablets), 66.5 +/- 21.0 (SD) h (10-mg tablets) and 78.4 +/- 33.2 (SD) h (10-mg drops).",Preliminary study of the pharmacokinetics of desmethyldiazepam administered as drops or tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082341/),h,75.3,166454,DB00829,Diazepam
,3082341,half-lives of elimination,"The mean half-lives of elimination came to 75.3 +/- 32.0 (SD) h (5-mg tablets), 66.5 +/- 21.0 (SD) h (10-mg tablets) and 78.4 +/- 33.2 (SD) h (10-mg drops).",Preliminary study of the pharmacokinetics of desmethyldiazepam administered as drops or tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082341/),h,66.5,166455,DB00829,Diazepam
,3082341,half-lives of elimination,"The mean half-lives of elimination came to 75.3 +/- 32.0 (SD) h (5-mg tablets), 66.5 +/- 21.0 (SD) h (10-mg tablets) and 78.4 +/- 33.2 (SD) h (10-mg drops).",Preliminary study of the pharmacokinetics of desmethyldiazepam administered as drops or tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082341/),h,78.4,166456,DB00829,Diazepam
,3082341,total plasma clearance,The total plasma clearance lay between 4.8 and 13.0 ml/min for the female and 12.4 and 24.3 ml/min for the male volunteers.,Preliminary study of the pharmacokinetics of desmethyldiazepam administered as drops or tablets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082341/),[ml] / [min],4.8 and 13.0,166457,DB00829,Diazepam
,3082341,total plasma clearance,The total plasma clearance lay between 4.8 and 13.0 ml/min for the female and 12.4 and 24.3 ml/min for the male volunteers.,Preliminary study of the pharmacokinetics of desmethyldiazepam administered as drops or tablets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082341/),[ml] / [min],12.4,166458,DB00829,Diazepam
,3082341,total plasma clearance,The total plasma clearance lay between 4.8 and 13.0 ml/min for the female and 12.4 and 24.3 ml/min for the male volunteers.,Preliminary study of the pharmacokinetics of desmethyldiazepam administered as drops or tablets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082341/),[ml] / [min],24.3,166459,DB00829,Diazepam
,3345616,total volume of distribution,The burned patients had increases in total volume of distribution (2.66 +/- 0.55 vs. 1.39 +/- 0.1 L/kg; P less than 0.02) and clearance (4.28 +/- 1.20 vs.,Lorazepam conjugation is unimpaired in burn trauma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),[l] / [kg],2.66,167606,DB00829,Diazepam
,3345616,total volume of distribution,The burned patients had increases in total volume of distribution (2.66 +/- 0.55 vs. 1.39 +/- 0.1 L/kg; P less than 0.02) and clearance (4.28 +/- 1.20 vs.,Lorazepam conjugation is unimpaired in burn trauma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),[l] / [kg],1.39,167607,DB00829,Diazepam
,3345616,clearance,The burned patients had increases in total volume of distribution (2.66 +/- 0.55 vs. 1.39 +/- 0.1 L/kg; P less than 0.02) and clearance (4.28 +/- 1.20 vs.,Lorazepam conjugation is unimpaired in burn trauma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),,4.28,167608,DB00829,Diazepam
,3345616,half-life,"1.16 +/- 0.1 ml/min/kg; P less than 0.01), whereas the half-life was significantly reduced in the burned group (9.6 +/- 1.3 vs. 13.9 +/- 0.9 hours; P less than 0.025).",Lorazepam conjugation is unimpaired in burn trauma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),h,9.6,167609,DB00829,Diazepam
,3345616,half-life,"1.16 +/- 0.1 ml/min/kg; P less than 0.01), whereas the half-life was significantly reduced in the burned group (9.6 +/- 1.3 vs. 13.9 +/- 0.9 hours; P less than 0.025).",Lorazepam conjugation is unimpaired in burn trauma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),h,13.9,167610,DB00829,Diazepam
,26684720,flow rate,"The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1mm×50mm, 1.7μm) using gradient elution with a mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of 0.4mL/min.","Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26684720/),[ml] / [min],0.4,170616,DB00829,Diazepam
,26684720,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 889.8→130.1 for ledipasvir, m/z 530.3→243.1 for sofosbuvir, m/z 261.5→113.1 for GS-331007 and m/z 285.2→193.1 for diazepam (IS) using a positive electrospray ionization interface.","Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26684720/),,261.5,170617,DB00829,Diazepam
,26684720,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 889.8→130.1 for ledipasvir, m/z 530.3→243.1 for sofosbuvir, m/z 261.5→113.1 for GS-331007 and m/z 285.2→193.1 for diazepam (IS) using a positive electrospray ionization interface.","Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26684720/),,113.1,170618,DB00829,Diazepam
,26684720,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 889.8→130.1 for ledipasvir, m/z 530.3→243.1 for sofosbuvir, m/z 261.5→113.1 for GS-331007 and m/z 285.2→193.1 for diazepam (IS) using a positive electrospray ionization interface.","Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26684720/),,285.2,170619,DB00829,Diazepam
,26684720,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 889.8→130.1 for ledipasvir, m/z 530.3→243.1 for sofosbuvir, m/z 261.5→113.1 for GS-331007 and m/z 285.2→193.1 for diazepam (IS) using a positive electrospray ionization interface.","Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26684720/),,193.1,170620,DB00829,Diazepam
,26684720,Total time,Total time for each chromatography was 3.0min.,"Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26684720/),min,3.0,170621,DB00829,Diazepam
,3709647,t 1/2,"Cisapride increased the rate of gastric emptying of 500 ml liquid containing diazepam 10 mg (t 1/2 C: 7.4 min, P: 14.9 min).",The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709647/),min,7.4,170681,DB00829,Diazepam
,3709647,t 1/2,"Cisapride increased the rate of gastric emptying of 500 ml liquid containing diazepam 10 mg (t 1/2 C: 7.4 min, P: 14.9 min).",The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709647/),min,14.9,170682,DB00829,Diazepam
,3709647,AUC 0-1 h,"The initial rate of absorption of diazepam contained in the drink was increased by C (AUC 0-1 h C: 328 micrograms h l-1, P: 253 micrograms h l-1, but there was no change in overall bioavailability.",The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709647/),[h·μg] / [l],328,170683,DB00829,Diazepam
,3709647,AUC 0-1 h,"The initial rate of absorption of diazepam contained in the drink was increased by C (AUC 0-1 h C: 328 micrograms h l-1, P: 253 micrograms h l-1, but there was no change in overall bioavailability.",The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709647/),[h·μg] / [l],253,170684,DB00829,Diazepam
,3083446,overall half-lives,"DZ rapidly disappeared from plasma and brain in parallel, with nearly identical overall half-lives of 0.88 and 0.89 h, respectively.",The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),h,0.88,170853,DB00829,Diazepam
,3083446,overall half-lives,"DZ rapidly disappeared from plasma and brain in parallel, with nearly identical overall half-lives of 0.88 and 0.89 h, respectively.",The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),h,0.89,170854,DB00829,Diazepam
,3083446,Apparent volume of distribution,Apparent volume of distribution was 19.3 1/kg and the apparent total clearance was 255 ml/kg/min.,The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),[1] / [kg],19.3,170855,DB00829,Diazepam
,3083446,apparent total clearance,Apparent volume of distribution was 19.3 1/kg and the apparent total clearance was 255 ml/kg/min.,The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),[ml] / [kg·min],255,170856,DB00829,Diazepam
,3083446,Free fractions,"Free fractions were 19.6% and 15.8% for DZ and DMDZ, respectively.",The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),%,19.6,170857,DB00829,Diazepam
,3083446,Free fractions,"Free fractions were 19.6% and 15.8% for DZ and DMDZ, respectively.",The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),%,15.8,170858,DB00829,Diazepam
,3083446,half-lives of disappearance,"Thereafter, DMDZ was likewise eliminated in parallel from both compartments, with nearly identical half-lives of disappearance from plasma (1.11 h) and brain (1.09 h).",The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),h,1.11,170859,DB00829,Diazepam
,3083446,half-lives of disappearance,"Thereafter, DMDZ was likewise eliminated in parallel from both compartments, with nearly identical half-lives of disappearance from plasma (1.11 h) and brain (1.09 h).",The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),h,1.09,170860,DB00829,Diazepam
,3083446,overall ratios,The overall ratios (mean +/- SE) were 4.5 +/- 0.1 for DZ and 3.5 +/- 0.2 for DMDZ.,The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),,4,170861,DB00829,Diazepam
,3083446,overall ratios,The overall ratios (mean +/- SE) were 4.5 +/- 0.1 for DZ and 3.5 +/- 0.2 for DMDZ.,The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083446/),,3.5,170862,DB00829,Diazepam
,7988100,terminal elimination half-life,"Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours.",Clinical pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988100/),h,15 to 20,171285,DB00829,Diazepam
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],3.1,171644,DB00829,Diazepam
,9084512,AD50s,"AD50s determined by the PPT in rabbits for morphine and nalbuphine were 3.1 and 8.4 mg/kg, respectively.",Paw pressure test in the rabbit: a new animal model for the study of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084512/),[mg] / [kg],8.4,171645,DB00829,Diazepam
,2874974,half-life,"Minimal impairment of psychomotor skills and mental acuity occurs in the morning after a bedtime dose of zopiclone, which has a short half-life of about 5 hours and no long acting metabolites.",Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874974/),h,5,173477,DB00829,Diazepam
,7650232,oral clearance (CL/f),"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[ml] / [h·kg],24,174662,DB00829,Diazepam
,7650232,oral clearance (CL/f),"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[ml] / [h·kg],26,174663,DB00829,Diazepam
,7650232,volume of distribution (Vz/f),"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[l] / [kg],0.85,174664,DB00829,Diazepam
,7650232,volume of distribution (Vz/f),"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[l] / [kg],0.99,174665,DB00829,Diazepam
,7650232,AUC,"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[h·ng] / [ml],5973,174666,DB00829,Diazepam
,7650232,AUC,"Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02).",Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),[h·ng] / [ml],5008,174667,DB00829,Diazepam
,7650232,Critical flicker fusion,Critical flicker fusion slightly decreased (P = .01) between placebo-diazepam (37.85 +/- 3.28 Hz) and venlafaxine-diazepam (37.09 +/- 4.13 Hz) treatments.,Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),hz,37.85,174668,DB00829,Diazepam
,7650232,Critical flicker fusion,Critical flicker fusion slightly decreased (P = .01) between placebo-diazepam (37.85 +/- 3.28 Hz) and venlafaxine-diazepam (37.09 +/- 4.13 Hz) treatments.,Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650232/),hz,37.09,174669,DB00829,Diazepam
,2879960,volume of distribution,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.27,175186,DB00829,Diazepam
,2879960,volume of distribution,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.23,175187,DB00829,Diazepam
,2879960,free fraction in serum,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.83,175188,DB00829,Diazepam
,2879960,free fraction in serum,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.80,175189,DB00829,Diazepam
,2879960,half-life,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,55,175190,DB00829,Diazepam
,2879960,half-life,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,61,175191,DB00829,Diazepam
,2879960,clearance,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.281,175192,DB00829,Diazepam
,2879960,clearance,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.247,175193,DB00829,Diazepam
,2879960,volume of distribution,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.29,175194,DB00829,Diazepam
,2879960,volume of distribution,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.34,175195,DB00829,Diazepam
,2879960,elimination half-life,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,55,175196,DB00829,Diazepam
,2879960,elimination half-life,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,59,175197,DB00829,Diazepam
,2879960,clearance,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.284,175198,DB00829,Diazepam
,2879960,clearance,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.276,175199,DB00829,Diazepam
,2879960,free fraction in serum,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.96,175200,DB00829,Diazepam
,2879960,free fraction in serum,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.92,175201,DB00829,Diazepam
,16952487,half-life [t((1/2))],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,45.1,175305,DB00829,Diazepam
,16952487,clearance [CL],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],1.38,175306,DB00829,Diazepam
,16952487,volume of distribution [V],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,90.1,175307,DB00829,Diazepam
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,35.7,175308,DB00829,Diazepam
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],1.3,175309,DB00829,Diazepam
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,123,175310,DB00829,Diazepam
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,4.87,175311,DB00829,Diazepam
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],21.2,175312,DB00829,Diazepam
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,145,175313,DB00829,Diazepam
,16952487,oral bioavailability [F],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),,0.23,175314,DB00829,Diazepam
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,3.31,175315,DB00829,Diazepam
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],20.4,175316,DB00829,Diazepam
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,75,175317,DB00829,Diazepam
,16952487,F,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),,0.22,175318,DB00829,Diazepam
<,16952487,F,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),%,1,175319,DB00829,Diazepam
,16952487,clearance,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],0.17,175320,DB00829,Diazepam
,16952487,clearance,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],0.26,175321,DB00829,Diazepam
,16952487,distribution,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,67,175322,DB00829,Diazepam
,16952487,distribution,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,17.9,175323,DB00829,Diazepam
,30086083,total run time,Daptomycin and diazepam as an internal standard were eluted with a total run time of 10 minutes.,Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086083/),min,10,175702,DB00829,Diazepam
,30086083,extraction recovery rates,"Their extraction recovery rates in nonfiltrated and ultrafiltrated plasma samples were 106.1% and 98.2%, respectively.",Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086083/),%,106.1,175703,DB00829,Diazepam
,30086083,extraction recovery rates,"Their extraction recovery rates in nonfiltrated and ultrafiltrated plasma samples were 106.1% and 98.2%, respectively.",Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086083/),%,98.2,175704,DB00829,Diazepam
,30086083,plasma concentration,"The plasma concentration ranges of total and free daptomycin in 15 infected patients were 3.01-34.1 and 0.39-3.64 mcg/mL, respectively.",Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086083/),[mcg] / [ml],3.01-34.1,175705,DB00829,Diazepam
,30086083,plasma concentration,"The plasma concentration ranges of total and free daptomycin in 15 infected patients were 3.01-34.1 and 0.39-3.64 mcg/mL, respectively.",Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086083/),[mcg] / [ml],0.39-3.64,175706,DB00829,Diazepam
,30086083,plasma protein binding rate,The plasma protein binding rate of daptomycin ranged from 80.8% to 94.9%.,Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086083/),%,80.8,175707,DB00829,Diazepam
,30086083,plasma protein binding rate,The plasma protein binding rate of daptomycin ranged from 80.8% to 94.9%.,Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30086083/),%,94.9,175708,DB00829,Diazepam
,33493742,flow rate,"The chromatographic separation was achieved on an Ultron ES-OVM column (150 × 2.0 mm, 5 μm) with acetonitrile-ammonium acetate (10 mM, pH 4.5) (22:78, v/v) at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for the enantioseparation and determination of clopidogrel bisulfate in beagle plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493742/),[ml] / [min],0.3,176338,DB00829,Diazepam
>,33493742,extraction recovery,The extraction recovery was >90.2 % and no obvious matrix effect was observed.,Development and validation of a LC-MS/MS method for the enantioseparation and determination of clopidogrel bisulfate in beagle plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493742/),%,90.2,176339,DB00829,Diazepam
,11339294,flow-rate,"The compounds were extracted using C18 Sep-Pak Vac 3cc (500 mg) cartridges and separated using isocratic mobile phase of methanol, acetonitrile and water (pH 3.2) (10:40:50) at a flow-rate of 0.5 ml/min in a period of 12 min, and UV detection ranging between 240 and 280 nm.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),[ml] / [min],0.5,176397,DB00829,Diazepam
,11339294,limits of detection,"The limits of detection for all analytes ranged between 20 and 50 ng/ml, while limits of quantitation were 100 ng/ml.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),[ng] / [ml],20 and 50,176398,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,79.1,176399,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.5,176400,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.9,176401,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,71.3,176402,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,77.7,176403,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,79.4,176404,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,83.1,176405,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,73.6,176406,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,74.3,176407,DB00829,Diazepam
,11339294,percentage extraction recoveries,"Average percentage extraction recoveries of five spiked plasma samples were 79.1+/-7.7, 83.5+/-6.4, 83.9+/-5.9, 71.3+/-6.0 and 77.7+/-5.6, and from urine 79.4+/-7.9, 83.1+/-6.9, 73.6+/-7.7, 74.3+/-7.1 and 77.6+/-5.9 for diazepam, N-desmethyldiazepam, temazepam, pyridostigmine bromide, and N-methyl-3-hydroxypyridinium bromide, respectively.","Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339294/),,77.6,176408,DB00829,Diazepam
,8701740,retention time,"The retention time for N-demethyldiazepam, oxazepam and internal standard were 4.85 min, 2.8 min and 8.5 min, respectively.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),min,4.85,177228,DB00829,Diazepam
,8701740,retention time,"The retention time for N-demethyldiazepam, oxazepam and internal standard were 4.85 min, 2.8 min and 8.5 min, respectively.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),min,2.8,177229,DB00829,Diazepam
,8701740,retention time,"The retention time for N-demethyldiazepam, oxazepam and internal standard were 4.85 min, 2.8 min and 8.5 min, respectively.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),min,8.5,177230,DB00829,Diazepam
,8701740,lower detection limits,The lower detection limits for oxazepam and N-demethyldiazepam were 10 ng.,[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),ng,10,177231,DB00829,Diazepam
,8701740,Tmax,"Its main pharmacokinetic parameters were: Tmax = 0.24 h, Cmax = 1211.78 ng.ml-1, T1/2 beta = 2.84 h, AUC = 1264 ng.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),h,0.24,177232,DB00829,Diazepam
,8701740,Cmax,"Its main pharmacokinetic parameters were: Tmax = 0.24 h, Cmax = 1211.78 ng.ml-1, T1/2 beta = 2.84 h, AUC = 1264 ng.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),[ng] / [ml],1211.78,177233,DB00829,Diazepam
,8701740,T1/2 beta,"Its main pharmacokinetic parameters were: Tmax = 0.24 h, Cmax = 1211.78 ng.ml-1, T1/2 beta = 2.84 h, AUC = 1264 ng.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),h,2.84,177234,DB00829,Diazepam
,8701740,AUC,"Its main pharmacokinetic parameters were: Tmax = 0.24 h, Cmax = 1211.78 ng.ml-1, T1/2 beta = 2.84 h, AUC = 1264 ng.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),ng,1264,177235,DB00829,Diazepam
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,88.3,177475,DB00829,Diazepam
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,40.8,177476,DB00829,Diazepam
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,127.8,177477,DB00829,Diazepam
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,59.0,177478,DB00829,Diazepam
,1868813,plasma levels,"""Active"" plasma levels ranged from approximately 300 ng/ml in the MES threshold test to approximately 1,300 ng/ml in the MES test.","Ralitoline: a reevaluation of anticonvulsant profile and determination of ""active"" plasma concentrations in comparison with prototype antiepileptic drugs in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868813/),[ng] / [ml],300,177484,DB00829,Diazepam
,1868813,plasma levels,"""Active"" plasma levels ranged from approximately 300 ng/ml in the MES threshold test to approximately 1,300 ng/ml in the MES test.","Ralitoline: a reevaluation of anticonvulsant profile and determination of ""active"" plasma concentrations in comparison with prototype antiepileptic drugs in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868813/),[ng] / [ml],"1,300",177485,DB00829,Diazepam
,8010009,T1/2 (alpha),"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),h,0.21,179229,DB00829,Diazepam
,8010009,T1/2 (beta),"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),h,2.2,179230,DB00829,Diazepam
,8010009,Ke,"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),1/[h],1.5,179231,DB00829,Diazepam
,8010009,K12,"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),1/[h],2.0,179232,DB00829,Diazepam
,8010009,K21,"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),1/[h],1.0,179233,DB00829,Diazepam
,8010009,V1,"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),[l] / [kg],3.1,179234,DB00829,Diazepam
,8010009,AUC,"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),[μg] / [h·ml],1.7,179235,DB00829,Diazepam
,8010009,lag time of reabsorption T',"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),h,0.25,179236,DB00829,Diazepam
,8010009,reabsorption rate constant Ka,"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),1/[h],3.5,179237,DB00829,Diazepam
,8010009,reabsorption rate Ra,"This model provides not only the ordinary pharmacokinetic parameters: T1/2 (alpha) = 0.21 +/- 0.15 h, T1/2 (beta) = 2.2 +/- 0.6 h, Ke = 1.5 +/- 0.6 h-1, K12 = 2.0 +/- 1.0 h-1, K21 = 1.0 +/- 0.4 h-1, V1 = 3.1 +/- 1.6 L.kg-1, AUC = 1.7 +/- 0.5 microgram.h-1.ml-1, but also the parameters of enterogastric circulation of diazepam: lag time of reabsorption T' = 0.25 +/- 0.24 h, reabsorption rate constant Ka = 3.5 +/- 1.4 h-1, reabsorption rate Ra = 24 +/- 7%.",[Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010009/),%,24,179238,DB00829,Diazepam
,22774843,pseudo-steady state concentrations,"Blood propofol concentrations during the infusion ranged between 1.52 and 7.65 μg/mL; pseudo-steady state concentrations 3.64-6.78 μg/mL, and concentrations on assuming standing position 0.75-1.40 μg/mL.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[μg] / [ml],3.64-6.78,179623,DB00829,Diazepam
,22774843,clearance,"Propofol clearance and volume of distribution were 31.4 (SD 6.1) mL/min/kg and 220.7 (132.0) mL/kg, respectively.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[ml] / [kg·min],31.4,179624,DB00829,Diazepam
,22774843,volume of distribution,"Propofol clearance and volume of distribution were 31.4 (SD 6.1) mL/min/kg and 220.7 (132.0) mL/kg, respectively.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[ml] / [kg],220.7,179625,DB00829,Diazepam
,13089,serum half-life (t0.5beta),"Pharmacokinetic analysis of the data according to a two-compartment open model with first-order absorption indicated that the serum half-life (t0.5beta) of nordiazepam, the major biotransformation product present in serum, was about 48 hours and served as a basis for the design of a multiple-dose steady-state study.",Steady-state bioavailability of two clorazepate dipotassium dosage forms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13089/),h,48,180381,DB00829,Diazepam
,13089,minimum steady-state serum levels,Multiple-dose administration of the tablet and divided-capsule regimen to two groups of subjects for ten days indicated each dosage form yielded similar minimum steady-state serum levels of about 0.6 micrograms/ml which plateaued following seven days of drug administration.,Steady-state bioavailability of two clorazepate dipotassium dosage forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13089/),[μg] / [ml],0.6,180382,DB00829,Diazepam
,7588138,volume of distribution,"Peak plasma temazepam concentrations were achieved rapidly (within 1 h post drug administration) and the estimated volume of distribution (mean: 1.13 1/kg), total clearance (mean: 1.6 ml/min/kg) and terminal elimination half-life (mean: 8 hours) were comparable to previously reported values in healthy subjects.",Pharmacokinetics of temazepam in male surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588138/),[1] / [kg],1.13,181288,DB00829,Diazepam
,7588138,total clearance,"Peak plasma temazepam concentrations were achieved rapidly (within 1 h post drug administration) and the estimated volume of distribution (mean: 1.13 1/kg), total clearance (mean: 1.6 ml/min/kg) and terminal elimination half-life (mean: 8 hours) were comparable to previously reported values in healthy subjects.",Pharmacokinetics of temazepam in male surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588138/),[ml] / [kg·min],1.6,181289,DB00829,Diazepam
,7588138,terminal elimination half-life,"Peak plasma temazepam concentrations were achieved rapidly (within 1 h post drug administration) and the estimated volume of distribution (mean: 1.13 1/kg), total clearance (mean: 1.6 ml/min/kg) and terminal elimination half-life (mean: 8 hours) were comparable to previously reported values in healthy subjects.",Pharmacokinetics of temazepam in male surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7588138/),h,8,181290,DB00829,Diazepam
,15175422,Rate of elimination (k(10)),"Rate of elimination (k(10)) for erythromycin and those with inhibitors was found to be similar (141 +/- 23 min), suggesting that elimination pathways were not altered.",Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175422/),min,141,181611,DB00829,Diazepam
,18508468,absorption rate,"In the gut sac, NADH had a concentration-independent absorption rate of about 5 percent and the in vivo laser-induced fluorescence spectroscopy revealed a relatively quick absorption of NADH starting after a few minute reaching a plateau (about 5 percent ) after 20-30 minutes.",Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18508468/),%,5,181677,DB00829,Diazepam
,2900012,time to reach peak concentration,"Compared with the fasting state, administration of CDDZ with food prolonged the time to reach peak concentration (1.5 vs.",Effect of food on absorption of chlordemethyldiazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900012/),,1.5,182428,DB00829,Diazepam
,2900012,absorption half-life,"6.8 h after dosage, p less than 0.01) and the absorption half-life (28 vs. 231 min, p less than 0.01).",Effect of food on absorption of chlordemethyldiazepam. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900012/),min,28,182429,DB00829,Diazepam
,2900012,absorption half-life,"6.8 h after dosage, p less than 0.01) and the absorption half-life (28 vs. 231 min, p less than 0.01).",Effect of food on absorption of chlordemethyldiazepam. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900012/),min,231,182430,DB00829,Diazepam
,2900012,elimination half-life,"Total area under the curve was not influenced, nor was CDDZ elimination half-life (84.2 vs. 88.7 h).",Effect of food on absorption of chlordemethyldiazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900012/),h,84.2,182431,DB00829,Diazepam
,2900012,elimination half-life,"Total area under the curve was not influenced, nor was CDDZ elimination half-life (84.2 vs. 88.7 h).",Effect of food on absorption of chlordemethyldiazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900012/),h,88.7,182432,DB00829,Diazepam
,8864311,half-life,"2. Following intravenous administration, the half-life and volume of distribution of 14C-labelled diazepam in the elderly were approximately twofold greater than corresponding estimates in younger subjects (mean +/- s.d., 71.5 +/- 27.6 vs 44.5 +/- 16.5 h and 1.39 +/- 0.32 vs 0.88 +/- 0.30 1 kg-1, respectively).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),h,71.5,185314,DB00829,Diazepam
,8864311,half-life,"2. Following intravenous administration, the half-life and volume of distribution of 14C-labelled diazepam in the elderly were approximately twofold greater than corresponding estimates in younger subjects (mean +/- s.d., 71.5 +/- 27.6 vs 44.5 +/- 16.5 h and 1.39 +/- 0.32 vs 0.88 +/- 0.30 1 kg-1, respectively).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),h,44.5,185315,DB00829,Diazepam
,8864311,volume of distribution,"2. Following intravenous administration, the half-life and volume of distribution of 14C-labelled diazepam in the elderly were approximately twofold greater than corresponding estimates in younger subjects (mean +/- s.d., 71.5 +/- 27.6 vs 44.5 +/- 16.5 h and 1.39 +/- 0.32 vs 0.88 +/- 0.30 1 kg-1, respectively).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),[1] / [kg],1.39,185316,DB00829,Diazepam
,8864311,volume of distribution,"2. Following intravenous administration, the half-life and volume of distribution of 14C-labelled diazepam in the elderly were approximately twofold greater than corresponding estimates in younger subjects (mean +/- s.d., 71.5 +/- 27.6 vs 44.5 +/- 16.5 h and 1.39 +/- 0.32 vs 0.88 +/- 0.30 1 kg-1, respectively).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),[1] / [kg],0.88,185317,DB00829,Diazepam
,8864311,Clearance,Clearance did not differ between the two groups (0.26 +/- 0.09 vs 0.29 +/- 0.09 ml min-1 kg-1).,Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),[ml] / [kg·min],0.26,185318,DB00829,Diazepam
,8864311,Clearance,Clearance did not differ between the two groups (0.26 +/- 0.09 vs 0.29 +/- 0.09 ml min-1 kg-1).,Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),[ml] / [kg·min],0.29,185319,DB00829,Diazepam
,8864311,clearance,"4. There were no age- or dosing-related differences in diazepam clearance (0.37 +/- 0.22 vs 0.32 +/- 0.18 ml min-1 kg-1, young vs elderly, single-dose; 0.37 +/- 0.11 vs 0.27 +/- 0.12 ml min-1 kg-1, young vs elderly, multiple-dose) and no age-related differences in the levels of accumulated 'benzodiazepine equivalents' (243.7 +/- 60.1 vs 288.0 +/- 125.8 ng ml-1, young vs elderly).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),[ml] / [kg·min],0.37,185320,DB00829,Diazepam
,8864311,clearance,"4. There were no age- or dosing-related differences in diazepam clearance (0.37 +/- 0.22 vs 0.32 +/- 0.18 ml min-1 kg-1, young vs elderly, single-dose; 0.37 +/- 0.11 vs 0.27 +/- 0.12 ml min-1 kg-1, young vs elderly, multiple-dose) and no age-related differences in the levels of accumulated 'benzodiazepine equivalents' (243.7 +/- 60.1 vs 288.0 +/- 125.8 ng ml-1, young vs elderly).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),[ml] / [kg·min],0.32,185321,DB00829,Diazepam
,8864311,clearance,"4. There were no age- or dosing-related differences in diazepam clearance (0.37 +/- 0.22 vs 0.32 +/- 0.18 ml min-1 kg-1, young vs elderly, single-dose; 0.37 +/- 0.11 vs 0.27 +/- 0.12 ml min-1 kg-1, young vs elderly, multiple-dose) and no age-related differences in the levels of accumulated 'benzodiazepine equivalents' (243.7 +/- 60.1 vs 288.0 +/- 125.8 ng ml-1, young vs elderly).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),[ml] / [kg·min],0.37,185322,DB00829,Diazepam
,8864311,clearance,"4. There were no age- or dosing-related differences in diazepam clearance (0.37 +/- 0.22 vs 0.32 +/- 0.18 ml min-1 kg-1, young vs elderly, single-dose; 0.37 +/- 0.11 vs 0.27 +/- 0.12 ml min-1 kg-1, young vs elderly, multiple-dose) and no age-related differences in the levels of accumulated 'benzodiazepine equivalents' (243.7 +/- 60.1 vs 288.0 +/- 125.8 ng ml-1, young vs elderly).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),[ml] / [kg·min],0.27,185323,DB00829,Diazepam
,8864311,clearance,"4. There were no age- or dosing-related differences in diazepam clearance (0.37 +/- 0.22 vs 0.32 +/- 0.18 ml min-1 kg-1, young vs elderly, single-dose; 0.37 +/- 0.11 vs 0.27 +/- 0.12 ml min-1 kg-1, young vs elderly, multiple-dose) and no age-related differences in the levels of accumulated 'benzodiazepine equivalents' (243.7 +/- 60.1 vs 288.0 +/- 125.8 ng ml-1, young vs elderly).",Disposition of diazepam in young and elderly subjects after acute and chronic dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864311/),ng,243.7,185324,DB00829,Diazepam
,19930799,flow rate,"Chromatographic separation was performed on a Narrow Bore C(18) column using methanol-10 mM ammonium acetate (68:32, v/v) as the mobile phase at the flow rate of 0.2 mL/min.",Simultaneous determination of omeprazole and domperidone in dog plasma by LC-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19930799/),[ml] / [min],0.2,186280,DB00829,Diazepam
,8599525,systemic availability,"Mean (+/- SD) diazepam concentrations in plasma after rectal administration were low in comparison with those obtained after IV administration, with systemic availability of only 7.4 (+/- 5.9) and 2.7 (+/- 3.2)% for the high and low dose, respectively.",Absorption of diazepam after its rectal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),%,7.4,186530,DB00829,Diazepam
,8599525,systemic availability,"Mean (+/- SD) diazepam concentrations in plasma after rectal administration were low in comparison with those obtained after IV administration, with systemic availability of only 7.4 (+/- 5.9) and 2.7 (+/- 3.2)% for the high and low dose, respectively.",Absorption of diazepam after its rectal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),%,2.7,186531,DB00829,Diazepam
,8599525,systemic availability,"Accounting for the total concentration of benzodiazepines (diazepam plus desmethyldiazepam and oxazepam) in plasma, systemic availability was 79.9 (+/- 20.7) and 66.0 (+/- 23.8)% for the high and low dosage, respectively.",Absorption of diazepam after its rectal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),%,79.9,186532,DB00829,Diazepam
,8599525,systemic availability,"Accounting for the total concentration of benzodiazepines (diazepam plus desmethyldiazepam and oxazepam) in plasma, systemic availability was 79.9 (+/- 20.7) and 66.0 (+/- 23.8)% for the high and low dosage, respectively.",Absorption of diazepam after its rectal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),%,66.0,186533,DB00829,Diazepam
,8599525,half-life,"After IV administration, diazepam concentration decreased, with a half-life of only 14 to 16 minutes, but desmethyldiazepam and oxazepam concentrations decreased more slowly, with a half-life of 2.2 to 2.8 hours and 3.5 to 5.1 hours, respectively.",Absorption of diazepam after its rectal administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),min,14 to 16,186534,DB00829,Diazepam
,8599525,half-life,"After IV administration, diazepam concentration decreased, with a half-life of only 14 to 16 minutes, but desmethyldiazepam and oxazepam concentrations decreased more slowly, with a half-life of 2.2 to 2.8 hours and 3.5 to 5.1 hours, respectively.",Absorption of diazepam after its rectal administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),h,2.2 to 2.8,186535,DB00829,Diazepam
,8599525,half-life,"After IV administration, diazepam concentration decreased, with a half-life of only 14 to 16 minutes, but desmethyldiazepam and oxazepam concentrations decreased more slowly, with a half-life of 2.2 to 2.8 hours and 3.5 to 5.1 hours, respectively.",Absorption of diazepam after its rectal administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),h,3.5 to 5.1,186536,DB00829,Diazepam
,12504914,electroconvulsive threshold,"(2S,2R)-4-Methylglutamic acid (SYM 2081), a potent selective agonist of GluR5 and GluR6 kainate receptor subtypes, applied at the dose of 15.5 mg/kg, equal to its CD(16) value (i.e., a dose required to induce convulsions in 16% of mice), significantly decreased the electroconvulsive threshold from 7.0 to 5.8 mA.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),m,7.0,186820,DB00829,Diazepam
,12504914,electroconvulsive threshold,"(2S,2R)-4-Methylglutamic acid (SYM 2081), a potent selective agonist of GluR5 and GluR6 kainate receptor subtypes, applied at the dose of 15.5 mg/kg, equal to its CD(16) value (i.e., a dose required to induce convulsions in 16% of mice), significantly decreased the electroconvulsive threshold from 7.0 to 5.8 mA.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),m,5,186821,DB00829,Diazepam
,12504914,ED(50),"The respective ED(50) values were increased from 18.5 to 23.8 mg/kg for phenobarbital, and from 11.7 to 14.7 mg/kg for diphenylhydantoin.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),[mg] / [kg],18.5 to 23.8,186822,DB00829,Diazepam
,12504914,ED(50),"The respective ED(50) values were increased from 18.5 to 23.8 mg/kg for phenobarbital, and from 11.7 to 14.7 mg/kg for diphenylhydantoin.",Low-affinity kainate receptor-mediated events reduce the protective activity of phenobarbital and diphenylhydantoin against maximal electroshock in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504914/),[mg] / [kg],11.7 to 14.7,186823,DB00829,Diazepam
,30956840,flow rate,"The chromatographic separation of jervine and IS was carried out on an UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm) with a flow rate of 0.4 mL/min.",A New UPLC-MS/MS Method Validated for Quantification of Jervine in Rat Plasma and the Study of Its Pharmacokinetics in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956840/),[ml] / [min],0.4,186846,DB00829,Diazepam
,30956840,retention times,"The retention times of jervine and the internal standard were 1.71 and 2.13 min, respectively.",A New UPLC-MS/MS Method Validated for Quantification of Jervine in Rat Plasma and the Study of Its Pharmacokinetics in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956840/),min,1.71,186847,DB00829,Diazepam
,30956840,retention times,"The retention times of jervine and the internal standard were 1.71 and 2.13 min, respectively.",A New UPLC-MS/MS Method Validated for Quantification of Jervine in Rat Plasma and the Study of Its Pharmacokinetics in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956840/),min,2.13,186848,DB00829,Diazepam
higher,30956840,recovery,"The recovery was higher than 90.3%, and the matrix effect was lower than 10%.",A New UPLC-MS/MS Method Validated for Quantification of Jervine in Rat Plasma and the Study of Its Pharmacokinetics in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956840/),%,90.3,186849,DB00829,Diazepam
,30956840,AUC(0-∞),"The primary pharmacokinetic parameters of jervine in this study were as follows: the AUC(0-∞) was 969.3 ± 277.7 ng/mL·h, the C max was 506.6 ± 192.8 ng/mL, the CL/F was 1.7 ± 0.5 L/h/kg, and the t 1/2 was 3.4 ± 1.2 h.",A New UPLC-MS/MS Method Validated for Quantification of Jervine in Rat Plasma and the Study of Its Pharmacokinetics in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956840/),[ng] / [h·ml],969.3,186850,DB00829,Diazepam
,30956840,C max,"The primary pharmacokinetic parameters of jervine in this study were as follows: the AUC(0-∞) was 969.3 ± 277.7 ng/mL·h, the C max was 506.6 ± 192.8 ng/mL, the CL/F was 1.7 ± 0.5 L/h/kg, and the t 1/2 was 3.4 ± 1.2 h.",A New UPLC-MS/MS Method Validated for Quantification of Jervine in Rat Plasma and the Study of Its Pharmacokinetics in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956840/),[ng] / [ml],506.6,186851,DB00829,Diazepam
,30956840,CL/F,"The primary pharmacokinetic parameters of jervine in this study were as follows: the AUC(0-∞) was 969.3 ± 277.7 ng/mL·h, the C max was 506.6 ± 192.8 ng/mL, the CL/F was 1.7 ± 0.5 L/h/kg, and the t 1/2 was 3.4 ± 1.2 h.",A New UPLC-MS/MS Method Validated for Quantification of Jervine in Rat Plasma and the Study of Its Pharmacokinetics in Rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956840/),[l] / [h·kg],1.7,186852,DB00829,Diazepam
,30956840,t 1/2,"The primary pharmacokinetic parameters of jervine in this study were as follows: the AUC(0-∞) was 969.3 ± 277.7 ng/mL·h, the C max was 506.6 ± 192.8 ng/mL, the CL/F was 1.7 ± 0.5 L/h/kg, and the t 1/2 was 3.4 ± 1.2 h.",A New UPLC-MS/MS Method Validated for Quantification of Jervine in Rat Plasma and the Study of Its Pharmacokinetics in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956840/),h,3.4,186853,DB00829,Diazepam
,3063133,respiratory rate,"Ventilation was performed mechanically during the entire operative period (N2O/O2 - FiO2:0.33, tidal volume 10 ml/kg, respiratory rate: 14/min).",[Response of human growth hormone to anesthesia induction with propofol]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063133/),1/[min],14,187266,DB00829,Diazepam
,16338280,area under the curve representing the concentration of diazepam over a 24-hour period (AUC(0-24)),"The PM subjects showed a larger area under the curve representing the concentration of diazepam over a 24-hour period (AUC(0-24)) (2088 +/- 378 ng/mL.h(-1), P = .0259), lower clearance of diazepam (0.049 +/- 0.009 L.h(-1).kg(-1), P = .0287), and longer emergence time (median, 18 minutes; 25th-75th percentile range, 13-21 minutes; P < .001) in comparison with subjects in the EM group (AUC(0-24), 1412 +/- 312 ng/mL; clearance, 0.074 +/- 0.018 L.h(-1).kg(-1); and emergence time, 10 minutes, 8-12 minutes [median and 25th-75th percentile range]).",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),[ml·ng] / [h],2088,187286,DB00829,Diazepam
,16338280,clearance,"The PM subjects showed a larger area under the curve representing the concentration of diazepam over a 24-hour period (AUC(0-24)) (2088 +/- 378 ng/mL.h(-1), P = .0259), lower clearance of diazepam (0.049 +/- 0.009 L.h(-1).kg(-1), P = .0287), and longer emergence time (median, 18 minutes; 25th-75th percentile range, 13-21 minutes; P < .001) in comparison with subjects in the EM group (AUC(0-24), 1412 +/- 312 ng/mL; clearance, 0.074 +/- 0.018 L.h(-1).kg(-1); and emergence time, 10 minutes, 8-12 minutes [median and 25th-75th percentile range]).",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),[l] / [h·kg],0.049,187287,DB00829,Diazepam
,16338280,emergence time,"The PM subjects showed a larger area under the curve representing the concentration of diazepam over a 24-hour period (AUC(0-24)) (2088 +/- 378 ng/mL.h(-1), P = .0259), lower clearance of diazepam (0.049 +/- 0.009 L.h(-1).kg(-1), P = .0287), and longer emergence time (median, 18 minutes; 25th-75th percentile range, 13-21 minutes; P < .001) in comparison with subjects in the EM group (AUC(0-24), 1412 +/- 312 ng/mL; clearance, 0.074 +/- 0.018 L.h(-1).kg(-1); and emergence time, 10 minutes, 8-12 minutes [median and 25th-75th percentile range]).",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),min,18,187288,DB00829,Diazepam
,16338280,AUC(0-24),"The PM subjects showed a larger area under the curve representing the concentration of diazepam over a 24-hour period (AUC(0-24)) (2088 +/- 378 ng/mL.h(-1), P = .0259), lower clearance of diazepam (0.049 +/- 0.009 L.h(-1).kg(-1), P = .0287), and longer emergence time (median, 18 minutes; 25th-75th percentile range, 13-21 minutes; P < .001) in comparison with subjects in the EM group (AUC(0-24), 1412 +/- 312 ng/mL; clearance, 0.074 +/- 0.018 L.h(-1).kg(-1); and emergence time, 10 minutes, 8-12 minutes [median and 25th-75th percentile range]).",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),[ng] / [ml],1412,187289,DB00829,Diazepam
,16338280,clearance,"The PM subjects showed a larger area under the curve representing the concentration of diazepam over a 24-hour period (AUC(0-24)) (2088 +/- 378 ng/mL.h(-1), P = .0259), lower clearance of diazepam (0.049 +/- 0.009 L.h(-1).kg(-1), P = .0287), and longer emergence time (median, 18 minutes; 25th-75th percentile range, 13-21 minutes; P < .001) in comparison with subjects in the EM group (AUC(0-24), 1412 +/- 312 ng/mL; clearance, 0.074 +/- 0.018 L.h(-1).kg(-1); and emergence time, 10 minutes, 8-12 minutes [median and 25th-75th percentile range]).",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),[l] / [h·kg],0.074,187290,DB00829,Diazepam
,16338280,emergence time,"The PM subjects showed a larger area under the curve representing the concentration of diazepam over a 24-hour period (AUC(0-24)) (2088 +/- 378 ng/mL.h(-1), P = .0259), lower clearance of diazepam (0.049 +/- 0.009 L.h(-1).kg(-1), P = .0287), and longer emergence time (median, 18 minutes; 25th-75th percentile range, 13-21 minutes; P < .001) in comparison with subjects in the EM group (AUC(0-24), 1412 +/- 312 ng/mL; clearance, 0.074 +/- 0.018 L.h(-1).kg(-1); and emergence time, 10 minutes, 8-12 minutes [median and 25th-75th percentile range]).",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),min,10,187291,DB00829,Diazepam
,16338280,emergence time,"The IM group also showed a longer emergence time (median, 13 minutes; 25th-75th percentile range, 9-20 minutes; P < .001) and a larger variation in this parameter in comparison with the EM group.",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),min,13,187292,DB00829,Diazepam
,16338280,mRNA level,"The mean value of the CYP3A4 mRNA level in the slow-emergence group (mean +/- SD, 4.80 +/- 3.99 x10(-10)) was significantly lower than that of the rapid-emergence group (mean +/- SD, 12.50 +/- 11.90 x10(-10)) (P = .0315).",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),,4.80,187293,DB00829,Diazepam
,16338280,mRNA level,"The mean value of the CYP3A4 mRNA level in the slow-emergence group (mean +/- SD, 4.80 +/- 3.99 x10(-10)) was significantly lower than that of the rapid-emergence group (mean +/- SD, 12.50 +/- 11.90 x10(-10)) (P = .0315).",CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338280/),,12.50,187294,DB00829,Diazepam
,6124406,ka,"Pinazepam was rapidly absorbed (ka = 2.77 hr-1) and converted into N-desmethyldiazepam, plasma levels of which were higher than those of parent compound shortly after administration.","Disposition, distribution, and liver first-pass effect of pinazepam in the rat. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124406/),1/[h],2.77,187673,DB00829,Diazepam
,6124406,elimination rate constants,The elimination rate constants were 0.20 hr-1 for pinazepam and 0.69 hr-1 for N-desmethyldiazepam.,"Disposition, distribution, and liver first-pass effect of pinazepam in the rat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124406/),1/[h],0.20,187674,DB00829,Diazepam
,6124406,elimination rate constants,The elimination rate constants were 0.20 hr-1 for pinazepam and 0.69 hr-1 for N-desmethyldiazepam.,"Disposition, distribution, and liver first-pass effect of pinazepam in the rat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124406/),1/[h],0.69,187675,DB00829,Diazepam
,6124406,plasma concentrations,"Ten minutes after dosing, the mean plasma concentrations of parent compound and metabolite, respectively, were 367.5 and 22.1 ng/ml in the portal vein and 9.8 and 40.7 ng/ml in the hepatic vein.","Disposition, distribution, and liver first-pass effect of pinazepam in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124406/),[ng] / [ml],367.5,187676,DB00829,Diazepam
,6124406,plasma concentrations,"Ten minutes after dosing, the mean plasma concentrations of parent compound and metabolite, respectively, were 367.5 and 22.1 ng/ml in the portal vein and 9.8 and 40.7 ng/ml in the hepatic vein.","Disposition, distribution, and liver first-pass effect of pinazepam in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124406/),[ng] / [ml],22.1,187677,DB00829,Diazepam
,6124406,plasma concentrations,"Ten minutes after dosing, the mean plasma concentrations of parent compound and metabolite, respectively, were 367.5 and 22.1 ng/ml in the portal vein and 9.8 and 40.7 ng/ml in the hepatic vein.","Disposition, distribution, and liver first-pass effect of pinazepam in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124406/),[ng] / [ml],9.8,187678,DB00829,Diazepam
,6124406,plasma concentrations,"Ten minutes after dosing, the mean plasma concentrations of parent compound and metabolite, respectively, were 367.5 and 22.1 ng/ml in the portal vein and 9.8 and 40.7 ng/ml in the hepatic vein.","Disposition, distribution, and liver first-pass effect of pinazepam in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124406/),[ng] / [ml],40.7,187679,DB00829,Diazepam
,2873990,Vmax,"Ciramadol glucuronidation was slower (Vmax, 1.56 vs. 5.40 nmol/min/mg of microsomal protein) in human than in dog liver microsomes.",Inhibition of ciramadol glucuronidation by benzodiazepines. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873990/),[nM] / [mg·min],1.56,187947,DB00829,Diazepam
,2873990,Vmax,"Ciramadol glucuronidation was slower (Vmax, 1.56 vs. 5.40 nmol/min/mg of microsomal protein) in human than in dog liver microsomes.",Inhibition of ciramadol glucuronidation by benzodiazepines. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873990/),[nM] / [mg·min],5.40,187948,DB00829,Diazepam
,9256974,Clearance,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [kg·min],5.06,188584,DB00829,Diazepam
,9256974,Clearance,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [kg·min],51,188585,DB00829,Diazepam
,9256974,Clearance,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [kg·min],8.64,188586,DB00829,Diazepam
,9256974,Clearance,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [kg·min],7.31,188587,DB00829,Diazepam
,9256974,Clearance,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [·kg·min],8.41,188588,DB00829,Diazepam
,9256974,free fraction,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [kg·min],51,188589,DB00829,Diazepam
,9256974,free fraction,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [kg·min],7.31,188590,DB00829,Diazepam
,9256974,free fraction,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [kg·min],83,188591,DB00829,Diazepam
,9256974,free fraction,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [·kg·min],8.41,188592,DB00829,Diazepam
,9256974,free fraction,"Clearance and free fraction values (mean +/- SEM) determined at 4 days (5.06 +/- 0.79 and 51 +/- 8 ml/kg/min, respectively) were significantly less than those obtained at 21 (8.64 +/- 0.95 and 87 +/- 11 ml/kg/min), 42 (7.31 +/- 0.82 and 83 +/- 10 ml/kg/min), and 84 (8.41 +/- 0.56 and 100 +/- 12 ml/kg/ min) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ml] / [·kg·min],100,188593,DB00829,Diazepam
,9256974,Volume of distribution,"Volume of distribution and unbound volume of distribution values determined at 4 days (1.57 +/- 0.11 and 16.0 +/- 1.7 L/kg, respectively) were significantly less than those found at 21 (2.66 +/- 0.33 and 26.8 +/- 3.9 L/kg), 42 (3.00 +/- 0.42 and 33.9 +/- 5.0 L/kg), and 84 (2.55 +/- 0.35 and 30.2 +/- 5.3 L/kg) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[l] / [kg],1.57,188594,DB00829,Diazepam
,9256974,Volume of distribution,"Volume of distribution and unbound volume of distribution values determined at 4 days (1.57 +/- 0.11 and 16.0 +/- 1.7 L/kg, respectively) were significantly less than those found at 21 (2.66 +/- 0.33 and 26.8 +/- 3.9 L/kg), 42 (3.00 +/- 0.42 and 33.9 +/- 5.0 L/kg), and 84 (2.55 +/- 0.35 and 30.2 +/- 5.3 L/kg) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[l] / [kg],2.66,188595,DB00829,Diazepam
,9256974,Volume of distribution,"Volume of distribution and unbound volume of distribution values determined at 4 days (1.57 +/- 0.11 and 16.0 +/- 1.7 L/kg, respectively) were significantly less than those found at 21 (2.66 +/- 0.33 and 26.8 +/- 3.9 L/kg), 42 (3.00 +/- 0.42 and 33.9 +/- 5.0 L/kg), and 84 (2.55 +/- 0.35 and 30.2 +/- 5.3 L/kg) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[l] / [kg],3.00,188596,DB00829,Diazepam
,9256974,unbound volume of distribution,"Volume of distribution and unbound volume of distribution values determined at 4 days (1.57 +/- 0.11 and 16.0 +/- 1.7 L/kg, respectively) were significantly less than those found at 21 (2.66 +/- 0.33 and 26.8 +/- 3.9 L/kg), 42 (3.00 +/- 0.42 and 33.9 +/- 5.0 L/kg), and 84 (2.55 +/- 0.35 and 30.2 +/- 5.3 L/kg) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[l] / [kg],16.0,188597,DB00829,Diazepam
,9256974,unbound volume of distribution,"Volume of distribution and unbound volume of distribution values determined at 4 days (1.57 +/- 0.11 and 16.0 +/- 1.7 L/kg, respectively) were significantly less than those found at 21 (2.66 +/- 0.33 and 26.8 +/- 3.9 L/kg), 42 (3.00 +/- 0.42 and 33.9 +/- 5.0 L/kg), and 84 (2.55 +/- 0.35 and 30.2 +/- 5.3 L/kg) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[l] / [kg],3.00,188598,DB00829,Diazepam
,9256974,unbound volume of distribution,"Volume of distribution and unbound volume of distribution values determined at 4 days (1.57 +/- 0.11 and 16.0 +/- 1.7 L/kg, respectively) were significantly less than those found at 21 (2.66 +/- 0.33 and 26.8 +/- 3.9 L/kg), 42 (3.00 +/- 0.42 and 33.9 +/- 5.0 L/kg), and 84 (2.55 +/- 0.35 and 30.2 +/- 5.3 L/kg) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[l] / [kg],33.9,188599,DB00829,Diazepam
,9256974,unbound volume of distribution,"Volume of distribution and unbound volume of distribution values determined at 4 days (1.57 +/- 0.11 and 16.0 +/- 1.7 L/kg, respectively) were significantly less than those found at 21 (2.66 +/- 0.33 and 26.8 +/- 3.9 L/kg), 42 (3.00 +/- 0.42 and 33.9 +/- 5.0 L/kg), and 84 (2.55 +/- 0.35 and 30.2 +/- 5.3 L/kg) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[l] / [kg],2.55,188600,DB00829,Diazepam
,9256974,unbound volume of distribution,"Volume of distribution and unbound volume of distribution values determined at 4 days (1.57 +/- 0.11 and 16.0 +/- 1.7 L/kg, respectively) were significantly less than those found at 21 (2.66 +/- 0.33 and 26.8 +/- 3.9 L/kg), 42 (3.00 +/- 0.42 and 33.9 +/- 5.0 L/kg), and 84 (2.55 +/- 0.35 and 30.2 +/- 5.3 L/kg) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[l] / [kg],30.2,188601,DB00829,Diazepam
,9256974,Peak plasma desmethyldiazepam concentration,"Peak plasma desmethyldiazepam concentration obtained at 4 days (22.7 +/- 2.4 ng/ml) was significantly lower than that obtained at 21 (36.1 +/- 4.5 ng/ml), 42 (38.3 +/- 4.8 ng/ml), and 84 (34.6 +/- 2.1 ng/ml) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ng] / [ml],22.7,188602,DB00829,Diazepam
,9256974,Peak plasma desmethyldiazepam concentration,"Peak plasma desmethyldiazepam concentration obtained at 4 days (22.7 +/- 2.4 ng/ml) was significantly lower than that obtained at 21 (36.1 +/- 4.5 ng/ml), 42 (38.3 +/- 4.8 ng/ml), and 84 (34.6 +/- 2.1 ng/ml) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ng] / [ml],36.1,188603,DB00829,Diazepam
,9256974,Peak plasma desmethyldiazepam concentration,"Peak plasma desmethyldiazepam concentration obtained at 4 days (22.7 +/- 2.4 ng/ml) was significantly lower than that obtained at 21 (36.1 +/- 4.5 ng/ml), 42 (38.3 +/- 4.8 ng/ml), and 84 (34.6 +/- 2.1 ng/ml) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ng] / [ml],38.3,188604,DB00829,Diazepam
,9256974,Peak plasma desmethyldiazepam concentration,"Peak plasma desmethyldiazepam concentration obtained at 4 days (22.7 +/- 2.4 ng/ml) was significantly lower than that obtained at 21 (36.1 +/- 4.5 ng/ml), 42 (38.3 +/- 4.8 ng/ml), and 84 (34.6 +/- 2.1 ng/ml) days.",Age-related changes in the pharmacokinetic disposition of diazepam in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256974/),[ng] / [ml],34.6,188605,DB00829,Diazepam
,6137019,bioavailability,The bioavailability was almost 100% after IM administration.,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),%,100,189043,DB00829,Diazepam
,6137019,plasma half lives,The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),h,2.42,189044,DB00829,Diazepam
,6137019,plasma half lives,The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),h,46.0,189045,DB00829,Diazepam
,6137019,plasma half lives,The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),h,2.29,189046,DB00829,Diazepam
,6137019,plasma half lives,The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).,Pharmacokinetics of chlorazepate after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6137019/),h,45.1,189047,DB00829,Diazepam
,8368611,maximal nordiazepam concentrations,"After a single oral dose of clorazepate, maximal nordiazepam concentrations ranged from 569.6 to 1,387.9 ng/ml (mean, 880.2 +/- 248.9 ng/ml) and were detected 16.8 to 131.4 minutes (mean, 85.2 +/- 36 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],"569.6 to 1,387.9",189693,DB00829,Diazepam
,8368611,maximal nordiazepam concentrations,"After a single oral dose of clorazepate, maximal nordiazepam concentrations ranged from 569.6 to 1,387.9 ng/ml (mean, 880.2 +/- 248.9 ng/ml) and were detected 16.8 to 131.4 minutes (mean, 85.2 +/- 36 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],880.2,189694,DB00829,Diazepam
,8368611,maximal nordiazepam concentrations,"After administration of phenobarbital for 44 consecutive days, maximal nordiazepam concentrations were significantly (P < 0.01) lower, ranging from 209.6 to 698.5 ng/ml (mean, 399.3 +/- 155.6 ng/ml) at 68.4 to 145.8 minutes (mean, 93 +/- 25.8 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],209.6 to 698.5,189695,DB00829,Diazepam
,8368611,maximal nordiazepam concentrations,"After administration of phenobarbital for 44 consecutive days, maximal nordiazepam concentrations were significantly (P < 0.01) lower, ranging from 209.6 to 698.5 ng/ml (mean, 399.3 +/- 155.6 ng/ml) at 68.4 to 145.8 minutes (mean, 93 +/- 25.8 minutes) after dosing.",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ng] / [ml],39,189696,DB00829,Diazepam
,8368611,area under the curve (AUC),"Mean area under the curve (AUC) on day 1 (mean, 3.37 +/- 0.598 ng.min/ml) was significantly (P < 0.001) greater than AUC on day 44 (1.66 +/- 0.308 ng.min/ml).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[min·ng] / [ml],3.37,189697,DB00829,Diazepam
,8368611,AUC,"Mean area under the curve (AUC) on day 1 (mean, 3.37 +/- 0.598 ng.min/ml) was significantly (P < 0.001) greater than AUC on day 44 (1.66 +/- 0.308 ng.min/ml).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[min·ng] / [ml],1.66,189698,DB00829,Diazepam
,8368611,Oral clearance,"Oral clearance was significantly (P < 0.01) greater on day 44 (12.44 +/- 2.55 ml/min/kg), compared with that on day 1 (6.16 +/- 1.35 ml/min/kg).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ml] / [kg·min],12.44,189699,DB00829,Diazepam
,8368611,Oral clearance,"Oral clearance was significantly (P < 0.01) greater on day 44 (12.44 +/- 2.55 ml/min/kg), compared with that on day 1 (6.16 +/- 1.35 ml/min/kg).",Effects of a 44-day administration of phenobarbital on disposition of clorazepate in dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368611/),[ml] / [kg·min],6.16,189700,DB00829,Diazepam
,8513847,CL,Ciprofloxacin pretreatment significantly reduced diazepam CL (without ciprofloxacin: 19.5 ml.h-1 kg-1; with ciprofloxacin: 12.3 ml.h-1 kg-1).,The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),[ml] / [h·kg],19.5,189791,DB00829,Diazepam
,8513847,CL,Ciprofloxacin pretreatment significantly reduced diazepam CL (without ciprofloxacin: 19.5 ml.h-1 kg-1; with ciprofloxacin: 12.3 ml.h-1 kg-1).,The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),[ml] / [h·kg],12.3,189792,DB00829,Diazepam
,8513847,t1/2,"Diazepam t1/2 was also prolonged (without ciprofloxacin: 36.7 h; with ciprofloxacin: 71.1 h), but volume of distribution was unaltered (without ciprofloxacin: 1.1 l.kg-1; with ciprofloxacin: 1.1 l.kg-1).",The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),h,36.7,189793,DB00829,Diazepam
,8513847,t1/2,"Diazepam t1/2 was also prolonged (without ciprofloxacin: 36.7 h; with ciprofloxacin: 71.1 h), but volume of distribution was unaltered (without ciprofloxacin: 1.1 l.kg-1; with ciprofloxacin: 1.1 l.kg-1).",The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),h,71.1,189794,DB00829,Diazepam
,8513847,volume of distribution,"Diazepam t1/2 was also prolonged (without ciprofloxacin: 36.7 h; with ciprofloxacin: 71.1 h), but volume of distribution was unaltered (without ciprofloxacin: 1.1 l.kg-1; with ciprofloxacin: 1.1 l.kg-1).",The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513847/),[l] / [kg],1.1,189795,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,2.6,189846,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,15.8,189847,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,22.3,189848,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,16.3,189849,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,3.2,189850,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,0.8,189851,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,7.5,189852,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,7.7,189853,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,16.0,189854,DB00829,Diazepam
,20848732,Half-lives,"Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2.6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice.",The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848732/),h,1.5,189855,DB00829,Diazepam
,2960465,central compartment concentration,"At that point, an infusion of sufentanil, aimed to reach a central compartment concentration of 5 ng.",Sufentanil disposition during cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960465/),ng,5,190294,DB00829,Diazepam
,2960465,Plasma concentrations,Plasma concentrations of sufentanil reached 3.8 +/- 0.4 ng.,Sufentanil disposition during cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960465/),ng,3.8,190295,DB00829,Diazepam
,24604775,elimination half-life,"Based on this study, diclazepam has an approximate elimination half-life of 42 h and is metabolized into the pharmacologically active benzodiazepines delorazepam, lorazepam, and lormetazepam which can be detected in urine for 6, 19, and 11 days, respectively, when applying the presented LC-MS/MS method.",Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24604775/),h,42,191172,DB00829,Diazepam
,1127104,t 1/2 (beta),"In the normal individuals, the terminal plasma half-life of diazepam, (t 1/2 (B)) exhibited a striking age-dependence; at 20 yr the t 1/2 (beta) was about 20 h, but it increased linearly with age to about 90 h at 80 yr.",The effects of age and liver disease on the disposition and elimination of diazepam in adult man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127104/),h,20,191630,DB00829,Diazepam
,1127104,t 1/2 (beta),"In the normal individuals, the terminal plasma half-life of diazepam, (t 1/2 (B)) exhibited a striking age-dependence; at 20 yr the t 1/2 (beta) was about 20 h, but it increased linearly with age to about 90 h at 80 yr.",The effects of age and liver disease on the disposition and elimination of diazepam in adult man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127104/),h,90,191631,DB00829,Diazepam
,1127104,plasma clearance,The plasma clearance of diazepam in the majority of the normal subjects was between 20 and 32 ml/min and showed no significant age-dependence.,The effects of age and liver disease on the disposition and elimination of diazepam in adult man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127104/),[ml] / [min],20 and 32,191632,DB00829,Diazepam
,1127104,plasma binding,"Additionally, neither the plasma binding (97.4 plus or minus 1.2%, mean plus or minus SD) nor the blood/plasma concentration ratio (0.58 plus or minus 0.16) of diazepam showed any age-related changes (P greater than 0.05).",The effects of age and liver disease on the disposition and elimination of diazepam in adult man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127104/),%,97.4,191633,DB00829,Diazepam
,1127104,blood/plasma concentration ratio,"Additionally, neither the plasma binding (97.4 plus or minus 1.2%, mean plus or minus SD) nor the blood/plasma concentration ratio (0.58 plus or minus 0.16) of diazepam showed any age-related changes (P greater than 0.05).",The effects of age and liver disease on the disposition and elimination of diazepam in adult man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127104/),,0.58,191634,DB00829,Diazepam
,1127104,half-life,"Patients with cirrhosis showed a more than twofold prolongation in the half-life of diazepam (105.6 plus or minus 15.2 vs. 46.6 plus or minus 14.2 h, P less than 0.001).",The effects of age and liver disease on the disposition and elimination of diazepam in adult man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127104/),h,105.6,191635,DB00829,Diazepam
,1127104,half-life,"Patients with cirrhosis showed a more than twofold prolongation in the half-life of diazepam (105.6 plus or minus 15.2 vs. 46.6 plus or minus 14.2 h, P less than 0.001).",The effects of age and liver disease on the disposition and elimination of diazepam in adult man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127104/),h,46.6,191636,DB00829,Diazepam
,31965188,k01_HL,"Pharmacokinetics of diazepam in oral fluid conformed to a two-compartment model, and k01_HL, k12_HL, k10_HL were 0.7 ± 1.1, 31.4 ± 68.5, 12.1 ± 11.6 h, respectively, nordazepam conformed to an one-compartment model, and k01_HL, k10_HL were 41.5 ± 44.8, 282.3 ± 365.5 h, respectively.",An Experimental Pharmacokinetics Study of Diazepam and Its Metabolites in Oral Fluid of Chinese Population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31965188/),h,0.7,192079,DB00829,Diazepam
,31965188,k12_HL,"Pharmacokinetics of diazepam in oral fluid conformed to a two-compartment model, and k01_HL, k12_HL, k10_HL were 0.7 ± 1.1, 31.4 ± 68.5, 12.1 ± 11.6 h, respectively, nordazepam conformed to an one-compartment model, and k01_HL, k10_HL were 41.5 ± 44.8, 282.3 ± 365.5 h, respectively.",An Experimental Pharmacokinetics Study of Diazepam and Its Metabolites in Oral Fluid of Chinese Population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31965188/),h,31.4,192080,DB00829,Diazepam
,31965188,k12_HL,"Pharmacokinetics of diazepam in oral fluid conformed to a two-compartment model, and k01_HL, k12_HL, k10_HL were 0.7 ± 1.1, 31.4 ± 68.5, 12.1 ± 11.6 h, respectively, nordazepam conformed to an one-compartment model, and k01_HL, k10_HL were 41.5 ± 44.8, 282.3 ± 365.5 h, respectively.",An Experimental Pharmacokinetics Study of Diazepam and Its Metabolites in Oral Fluid of Chinese Population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31965188/),h,12.1,192081,DB00829,Diazepam
,31965188,k10_HL,"Pharmacokinetics of diazepam in oral fluid conformed to a two-compartment model, and k01_HL, k12_HL, k10_HL were 0.7 ± 1.1, 31.4 ± 68.5, 12.1 ± 11.6 h, respectively, nordazepam conformed to an one-compartment model, and k01_HL, k10_HL were 41.5 ± 44.8, 282.3 ± 365.5 h, respectively.",An Experimental Pharmacokinetics Study of Diazepam and Its Metabolites in Oral Fluid of Chinese Population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31965188/),h,12.1,192082,DB00829,Diazepam
,31965188,k01_HL,"Pharmacokinetics of diazepam in oral fluid conformed to a two-compartment model, and k01_HL, k12_HL, k10_HL were 0.7 ± 1.1, 31.4 ± 68.5, 12.1 ± 11.6 h, respectively, nordazepam conformed to an one-compartment model, and k01_HL, k10_HL were 41.5 ± 44.8, 282.3 ± 365.5 h, respectively.",An Experimental Pharmacokinetics Study of Diazepam and Its Metabolites in Oral Fluid of Chinese Population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31965188/),h,41.5,192083,DB00829,Diazepam
,31965188,k10_HL,"Pharmacokinetics of diazepam in oral fluid conformed to a two-compartment model, and k01_HL, k12_HL, k10_HL were 0.7 ± 1.1, 31.4 ± 68.5, 12.1 ± 11.6 h, respectively, nordazepam conformed to an one-compartment model, and k01_HL, k10_HL were 41.5 ± 44.8, 282.3 ± 365.5 h, respectively.",An Experimental Pharmacokinetics Study of Diazepam and Its Metabolites in Oral Fluid of Chinese Population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31965188/),h,282.3,192084,DB00829,Diazepam
,11849195,maximum plasma diazepam concentrations,"Median maximum plasma diazepam concentrations of 634 (range 402-1507) ng ml(-1) and 423 (range 112-1953) ng ml(-1) were achieved at 5 and 25 min following i.v. and p.r. administration, respectively.",Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11849195/),[ng] / [ml],634,192345,DB00829,Diazepam
,11849195,maximum plasma diazepam concentrations,"Median maximum plasma diazepam concentrations of 634 (range 402-1507) ng ml(-1) and 423 (range 112-1953) ng ml(-1) were achieved at 5 and 25 min following i.v. and p.r. administration, respectively.",Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11849195/),[ng] / [ml],423,192346,DB00829,Diazepam
,11849195,concentrations,"However, nine children treated with i.v. and all those treated with p.r. diazepam had a recurrence of convulsions occurring at median plasma diazepam concentrations of 157 (range: 67-169) and 172 (range: 74-393) ng ml(-1) , respectively.",Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11849195/),[ng] / [ml],157,192347,DB00829,Diazepam
,11849195,concentrations,"However, nine children treated with i.v. and all those treated with p.r. diazepam had a recurrence of convulsions occurring at median plasma diazepam concentrations of 157 (range: 67-169) and 172 (range: 74-393) ng ml(-1) , respectively.",Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11849195/),[ng] / [ml],172,192348,DB00829,Diazepam
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,1.50,192764,DB00829,Diazepam
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,2.06,192765,DB00829,Diazepam
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,231.2,193838,DB00829,Diazepam
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,346.9,193839,DB00829,Diazepam
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,285.1,193840,DB00829,Diazepam
,33176242,m,"The mass transition ion pairs were m/z 231.2 → 185.0, 346.9 → 198.2, 285.1 → 193.1 and 382.2 → 281.2 for NAP, ESOM, diazepam (IS for NAP) and celecoxib (IS for ESOM), respectively.",Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33176242/),,382.2,193841,DB00829,Diazepam
,11470209,analytical run time,The analytical run time was 5 min.,The simultaneous determination of diazepam and its three metabolites in dog plasma by high-performance liquid chromatography with mass spectroscopy detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11470209/),min,5,194420,DB00829,Diazepam
,15688985,half-life,"After DZ administration, a fast absorption phase was observed with a plasma Cmax value 1 hour after, followed by a rapid concentration decrease, with a half-life of 1 hour, indicating that, besides elimination, a fast distribution to other organs and tissues and/or hepatic metabolism occurred.",Vitreous humour as a complementary sample to blood for the detection/confirmation of diazepam: ante-mortem and post-mortem studies in an animal model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15688985/),h,1,194600,DB00829,Diazepam
,15688985,DZ ratio,The plasma/VH DZ ratio calculated at this time was 10.,Vitreous humour as a complementary sample to blood for the detection/confirmation of diazepam: ante-mortem and post-mortem studies in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15688985/),,10,194601,DB00829,Diazepam
,8644048,initial peak,Plasma chloroquine levels showed an initial peak of 6.7 mumol/l.,[Chloroquine poisoning]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8644048/),[μM] / [l],6.7,194903,DB00829,Diazepam
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,35.3,195854,DB00829,Diazepam
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,37.3,195855,DB00829,Diazepam
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],28.2,195856,DB00829,Diazepam
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],26.7,195857,DB00829,Diazepam
,22078155,C(max),"The mean C(max) of 78 (40) ng/mL was reached 44 minutes after IN administration, whereas the mean C(max) was 51 (5) ng/mL after IV administration.","Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),[ng] / [ml],78,198585,DB00829,Diazepam
,22078155,C(max),"The mean C(max) of 78 (40) ng/mL was reached 44 minutes after IN administration, whereas the mean C(max) was 51 (5) ng/mL after IV administration.","Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),[ng] / [ml],51,198586,DB00829,Diazepam
,22078155,C(t,The mean estimated C(t=5 min) was 31.4 (28.1) ng/mL after IN administration.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),[ng] / [ml],5,198587,DB00829,Diazepam
,22078155,C(t,The mean estimated C(t=5 min) was 31.4 (28.1) ng/mL after IN administration.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),[ng] / [ml],31.4,198588,DB00829,Diazepam
,22078155,elimination t(½),The elimination t(½) was 1.9 (0.41) hours for IN midazolam and 2.3 (0.19) hours for IV midazolam.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),h,1.9,198589,DB00829,Diazepam
,22078155,elimination t(½),The elimination t(½) was 1.9 (0.41) hours for IN midazolam and 2.3 (0.19) hours for IV midazolam.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),h,2.3,198590,DB00829,Diazepam
,22078155,bioavailability,The bioavailability of IN midazolam was 82%.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),%,82,198591,DB00829,Diazepam
,17622531,TGI,"Antitumor activity was highly significant in both human hormone-independent breast (MDA-MB-231) and prostate (PC-3) xenografts, resulting in TGI of 72 and 100%, respectively.","Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17622531/),%,72,200664,DB00829,Diazepam
,17622531,TGI,"Antitumor activity was highly significant in both human hormone-independent breast (MDA-MB-231) and prostate (PC-3) xenografts, resulting in TGI of 72 and 100%, respectively.","Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17622531/),%,100,200665,DB00829,Diazepam
,27071281,recovery,The applied analitycal method showed excellent recovery (94.65%).,Determination of flumazenil in serum by liquid chromatography-mass spectrometry: Application to kinetics study in acute diazepam overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27071281/),%,94.65,201137,DB00829,Diazepam
,1572756,area under the plasma concentration-time curve,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[h·ng] / [ml],"4,910",201527,DB00829,Diazepam
,1572756,area under the plasma concentration-time curve,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[h·ng] / [ml],"5,581",201528,DB00829,Diazepam
,1572756,peak concentrations,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[ng] / [ml],40,201529,DB00829,Diazepam
,1572756,peak concentrations,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[ng] / [ml],47,201530,DB00829,Diazepam
,8905790,time of the maximal plasma concentration,"The time of the maximal plasma concentration and the elimination half-life of zotepine in 14 volunteers were about 4 hours and 21 hours, respectively, which were found to be much longer than previously reported data.",[Pharmacokinetics of zotepine and various factors affecting that of zotepine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905790/),h,4,203781,DB00829,Diazepam
,8905790,elimination half-life,"The time of the maximal plasma concentration and the elimination half-life of zotepine in 14 volunteers were about 4 hours and 21 hours, respectively, which were found to be much longer than previously reported data.",[Pharmacokinetics of zotepine and various factors affecting that of zotepine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8905790/),h,21,203782,DB00829,Diazepam
,26663385,flow rate,"Periplocymarin was analyzed on a C18 column with isocratic eluted mobile phase composed of methanol and water (containing 0.1% formic acid) at a flow rate of 0.2 mL/min (73:27, v/v).",Quantitative determination of periplocymarin in rat plasma and tissue by LC-MS/MS: application to pharmacokinetic and tissue distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663385/),[ml] / [min],0.2,203855,DB00829,Diazepam
,26663385,m/z,"The MS/MS ion transitions monitored were m/z 535.3→355.1 and 285.1→193.0 for periplocymarin and diazepam, respectively.",Quantitative determination of periplocymarin in rat plasma and tissue by LC-MS/MS: application to pharmacokinetic and tissue distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663385/),,535.3,203856,DB00829,Diazepam
,26663385,m/z,"The MS/MS ion transitions monitored were m/z 535.3→355.1 and 285.1→193.0 for periplocymarin and diazepam, respectively.",Quantitative determination of periplocymarin in rat plasma and tissue by LC-MS/MS: application to pharmacokinetic and tissue distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663385/),,355.1,203857,DB00829,Diazepam
,26663385,m/z,"The MS/MS ion transitions monitored were m/z 535.3→355.1 and 285.1→193.0 for periplocymarin and diazepam, respectively.",Quantitative determination of periplocymarin in rat plasma and tissue by LC-MS/MS: application to pharmacokinetic and tissue distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663385/),,285.1,203858,DB00829,Diazepam
>,26663385,Recoveries,Recoveries in plasma and tissue were >90%.,Quantitative determination of periplocymarin in rat plasma and tissue by LC-MS/MS: application to pharmacokinetic and tissue distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663385/),%,90,203859,DB00829,Diazepam
,8846617,oral bioavailability,"Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism.",Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,50,204181,DB00829,Diazepam
,8846617,terminal elimination half-life,Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state.,Overview of the pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),h,12 to 15,204182,DB00829,Diazepam
,8846617,Plasma protein binding,Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.,Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,77,204183,DB00829,Diazepam
,7862714,ED50,AMPH injected acutely at a dose of 50 mg/kg significantly reduced anticonvulsant action of DZP elevating ED50 from 10.9 (control) to 15.9 mg/kg (p < 0.01).,Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],10.9,205057,DB00829,Diazepam
,7862714,ED50,AMPH injected acutely at a dose of 50 mg/kg significantly reduced anticonvulsant action of DZP elevating ED50 from 10.9 (control) to 15.9 mg/kg (p < 0.01).,Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],15.9,205058,DB00829,Diazepam
,7862714,ED50,"Chronic treatment with AMPH resulted in further increase of ED50 of DZP, which was 20.2 mg/kg, and this elevation was significant not only when compared with saline-treated animals, but also with acute and 3-day administration of the xanthine (p < 0.01, 0.05, and 0.001, respectively).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],20.2,205059,DB00829,Diazepam
,7862714,ED50,"On the other hand, chronic treatment with AMPH decreased convulsive activity of AMPH elevating ED50 for induction of clonic seizures from 218 to 252 mg/kg (p < 0.01).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],218,205060,DB00829,Diazepam
,7862714,ED50,"On the other hand, chronic treatment with AMPH decreased convulsive activity of AMPH elevating ED50 for induction of clonic seizures from 218 to 252 mg/kg (p < 0.01).",Influence of chronic aminophylline on antielectroshock activity of diazepam and aminophylline-induced convulsions in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7862714/),[mg] / [kg],252,205061,DB00829,Diazepam
,19863908,Half-life,"Half-life value of 61,8 h was found, being much longer than already published hexobarbital half-lives (between 3.2 h and 6.9 h).",[Human toxicokinetic of hexobarbital after acute multi-drug intoxication]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863908/),h,"61,8",206338,DB00829,Diazepam
,19863908,half-lives,"Half-life value of 61,8 h was found, being much longer than already published hexobarbital half-lives (between 3.2 h and 6.9 h).",[Human toxicokinetic of hexobarbital after acute multi-drug intoxication]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863908/),h,3.2,206339,DB00829,Diazepam
,19863908,half-lives,"Half-life value of 61,8 h was found, being much longer than already published hexobarbital half-lives (between 3.2 h and 6.9 h).",[Human toxicokinetic of hexobarbital after acute multi-drug intoxication]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863908/),h,6.9,206340,DB00829,Diazepam
,6425492,total body clearance,The total body clearance of diazepam (4.72 +/- 2.45 mL/min/kg) is approximately six times that of nordiazepam (0.85 +/- 0.25 mL/min/kg).,Pharmacokinetics of diazepam and nordiazepam in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425492/),[ml] / [kg·min],4.72,206609,DB00829,Diazepam
,6425492,total body clearance,The total body clearance of diazepam (4.72 +/- 2.45 mL/min/kg) is approximately six times that of nordiazepam (0.85 +/- 0.25 mL/min/kg).,Pharmacokinetics of diazepam and nordiazepam in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425492/),[ml] / [kg·min],0.85,206610,DB00829,Diazepam
,7628184,oral clearance,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[ml] / [min],34.4,207703,DB00829,Diazepam
,7628184,oral clearance,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[ml] / [min],25.2,207704,DB00829,Diazepam
,7628184,AUC,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[μg] / [h·l],8794,207705,DB00829,Diazepam
,7628184,AUC,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[mg] / [h·l],"16,358",207706,DB00829,Diazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.44,208117,DB00829,Diazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.47,208118,DB00829,Diazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],9.6,208119,DB00829,Diazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],7.1,208120,DB00829,Diazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.96,208121,DB00829,Diazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],1.08,208122,DB00829,Diazepam
,6133268,serum half-life,It achieves peak serum levels in 0.7 to 2.1 hours and has a serum half-life of 12 to 15 hours.,"Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133268/),h,12 to 15,208971,DB00829,Diazepam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,24 to 48,209320,DB00829,Diazepam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,"4,5",209321,DB00829,Diazepam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,"2,5",209322,DB00829,Diazepam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],30,209323,DB00829,Diazepam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],250,209324,DB00829,Diazepam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],450,209325,DB00829,Diazepam
,6114680,V1,"On the other hand, all three drugs were found to have nearly the same volumes of distribution (V1: 25 l, VdSS: 80-100 l).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),l,25,209326,DB00829,Diazepam
,6114680,VdSS,"On the other hand, all three drugs were found to have nearly the same volumes of distribution (V1: 25 l, VdSS: 80-100 l).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),l,80-100,209327,DB00829,Diazepam
,6114680,biological halflife,"Of the 3 benzodiazepines investigated, diazepam reveals extremely complex pharmacokinetic effects which vary the duration of pharmacological responses very widely; besides drug interaction, enzyme induction and -inhibition it gives rise to the active metabolite N-desmethyl-diazepam (biological halflife 50 to 120 hours).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,50 to 120,209328,DB00829,Diazepam
,1425620,tmax,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,1.9,210774,DB00829,Diazepam
,1425620,absolute bioavailability,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),%,60,210775,DB00829,Diazepam
,1425620,terminal elimination half-life,Its terminal elimination half-life is 3.5 h and it is extensively hepatically metabolized.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,3.5,210776,DB00829,Diazepam
,1425620,Plasma clearance,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [h·kg],0.38,210777,DB00829,Diazepam
,1425620,volume of distribution,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [kg],1.8,210778,DB00829,Diazepam
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,35.3,211889,DB00829,Diazepam
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,30.1,211890,DB00829,Diazepam
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,37.3,211891,DB00829,Diazepam
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],28.2,211892,DB00829,Diazepam
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],26.5,211893,DB00829,Diazepam
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],26.7,211894,DB00829,Diazepam
,964287,biological half-life (T/2),The mean biological half-life (T/2) of diazepam was increased five-fold in patients with cirrhosis compared to the controls (164 hours vs. 32.1 hours).,Pharmacokinetics of diazepam in disordered liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/964287/),h,164,212243,DB00829,Diazepam
,964287,biological half-life (T/2),The mean biological half-life (T/2) of diazepam was increased five-fold in patients with cirrhosis compared to the controls (164 hours vs. 32.1 hours).,Pharmacokinetics of diazepam in disordered liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/964287/),h,32.1,212244,DB00829,Diazepam
,2906643,volume of distribution (Vd),"Mean kinetic variables were volume of distribution (Vd), 90 liters; elimination half-life (t1/2), 93 hours; and clearance, 12.3 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),l,90,213155,DB00829,Diazepam
,2906643,elimination half-life (t1/2),"Mean kinetic variables were volume of distribution (Vd), 90 liters; elimination half-life (t1/2), 93 hours; and clearance, 12.3 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),h,93,213156,DB00829,Diazepam
,2906643,clearance,"Mean kinetic variables were volume of distribution (Vd), 90 liters; elimination half-life (t1/2), 93 hours; and clearance, 12.3 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),[ml] / [min],12.3,213157,DB00829,Diazepam
,2906643,Vd,"Mean kinetic variables were Vd, 180 liters; t1/2, 83 hours; and clearance, 28 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),l,180,213158,DB00829,Diazepam
,2906643,t1/2,"Mean kinetic variables were Vd, 180 liters; t1/2, 83 hours; and clearance, 28 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),h,83,213159,DB00829,Diazepam
,2906643,clearance,"Mean kinetic variables were Vd, 180 liters; t1/2, 83 hours; and clearance, 28 mL/min.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),[ml] / [min],28,213160,DB00829,Diazepam
,2906643,systemic availability,"After oral administration of DMDZ in tablet form (10 mg), or of clorazepate dipotassium in capsule form (15 mg), systemic availability of DMDZ from each of the oral dosage forms was not significantly different from 100%.","Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906643/),%,100,213161,DB00829,Diazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,4.9,216455,DB00829,Diazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,9.2,216456,DB00829,Diazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,1.0,216457,DB00829,Diazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,6.2,216458,DB00829,Diazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,2.4,216459,DB00829,Diazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],2.37,216460,DB00829,Diazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],0.935,216461,DB00829,Diazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],27.9,216462,DB00829,Diazepam
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],44.7,216463,DB00829,Diazepam
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],305.2,216464,DB00829,Diazepam
,6707886,bioavailability (F),"The bioavailability (F) values of I at dosage levels 0.1, 0.5, 1.0, and 5.0 mg/kg were 0.49, 0.75, 0.77, and 0.83, respectively.",Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707886/),,0.49,216866,DB00829,Diazepam
,6707886,bioavailability (F),"The bioavailability (F) values of I at dosage levels 0.1, 0.5, 1.0, and 5.0 mg/kg were 0.49, 0.75, 0.77, and 0.83, respectively.",Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707886/),,0.75,216867,DB00829,Diazepam
,6707886,bioavailability (F),"The bioavailability (F) values of I at dosage levels 0.1, 0.5, 1.0, and 5.0 mg/kg were 0.49, 0.75, 0.77, and 0.83, respectively.",Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707886/),,0.77,216868,DB00829,Diazepam
,6707886,bioavailability (F),"The bioavailability (F) values of I at dosage levels 0.1, 0.5, 1.0, and 5.0 mg/kg were 0.49, 0.75, 0.77, and 0.83, respectively.",Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707886/),,0.83,216869,DB00829,Diazepam
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,5.2,217311,DB00829,Diazepam
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,8.3,217312,DB00829,Diazepam
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,9.6,217313,DB00829,Diazepam
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,11.6,217314,DB00829,Diazepam
less,23106955,total run time,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,15,217315,DB00829,Diazepam
,9673833,half-life,"Its half-life in children over 12 months is reported to be 0.8 to 1.8 hours, with a clearance of 4.7 to 19.7 ml/min/kg.",Clinical pharmacology of midazolam in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673833/),h,0.8 to 1.8,217533,DB00829,Diazepam
,9673833,clearance,"Its half-life in children over 12 months is reported to be 0.8 to 1.8 hours, with a clearance of 4.7 to 19.7 ml/min/kg.",Clinical pharmacology of midazolam in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673833/),[ml] / [kg·min],4.7 to 19.7,217534,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,96.8,219091,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,96.6,219092,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,96.0,219093,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,95.9,219094,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,89.9,219095,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,94.7,219096,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,91.3,219097,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,78.6,219098,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,86.3,219099,DB00829,Diazepam
,789856,binding,"The binding of D and desmethyldiazepam has been determined at therapeutic concentrations by equilibrium dialysis in man (96.8 and 96.6%, respectively), dog (96.0 and 95.9%), rabbit (89.9 and 94.7%), guinea pig (91.3 and 78.6%) and rat (86.3 and 90.5%).","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),%,90.5,219100,DB00829,Diazepam
,789856,T1/2(beta),"T1/2(beta) and the rates of drug clearance were characteristic figures for each species: from 1.1 hours and 81.6 ml/min/kg in the rat to 32.9 hours and 0.35 ml/min/kg in man, whereas T1/2(alpha), the half-life of distribution, varied only approximately 3-fold (0.3-1.0 hours) in the different species.","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),h,1.1,219101,DB00829,Diazepam
,789856,T1/2(beta),"T1/2(beta) and the rates of drug clearance were characteristic figures for each species: from 1.1 hours and 81.6 ml/min/kg in the rat to 32.9 hours and 0.35 ml/min/kg in man, whereas T1/2(alpha), the half-life of distribution, varied only approximately 3-fold (0.3-1.0 hours) in the different species.","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),[ml] / [kg·min],81.6,219102,DB00829,Diazepam
,789856,T1/2(beta),"T1/2(beta) and the rates of drug clearance were characteristic figures for each species: from 1.1 hours and 81.6 ml/min/kg in the rat to 32.9 hours and 0.35 ml/min/kg in man, whereas T1/2(alpha), the half-life of distribution, varied only approximately 3-fold (0.3-1.0 hours) in the different species.","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),h,32.9,219103,DB00829,Diazepam
,789856,T1/2(beta),"T1/2(beta) and the rates of drug clearance were characteristic figures for each species: from 1.1 hours and 81.6 ml/min/kg in the rat to 32.9 hours and 0.35 ml/min/kg in man, whereas T1/2(alpha), the half-life of distribution, varied only approximately 3-fold (0.3-1.0 hours) in the different species.","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),[ml] / [kg·min],0.35,219104,DB00829,Diazepam
,789856,rates of drug clearance,"T1/2(beta) and the rates of drug clearance were characteristic figures for each species: from 1.1 hours and 81.6 ml/min/kg in the rat to 32.9 hours and 0.35 ml/min/kg in man, whereas T1/2(alpha), the half-life of distribution, varied only approximately 3-fold (0.3-1.0 hours) in the different species.","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),[ml] / [kg·min],81.6,219105,DB00829,Diazepam
,789856,rates of drug clearance,"T1/2(beta) and the rates of drug clearance were characteristic figures for each species: from 1.1 hours and 81.6 ml/min/kg in the rat to 32.9 hours and 0.35 ml/min/kg in man, whereas T1/2(alpha), the half-life of distribution, varied only approximately 3-fold (0.3-1.0 hours) in the different species.","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),[ml] / [kg·min],0.35,219106,DB00829,Diazepam
,789856,half-life of distribution,"T1/2(beta) and the rates of drug clearance were characteristic figures for each species: from 1.1 hours and 81.6 ml/min/kg in the rat to 32.9 hours and 0.35 ml/min/kg in man, whereas T1/2(alpha), the half-life of distribution, varied only approximately 3-fold (0.3-1.0 hours) in the different species.","Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/789856/),h,0.3-1.0,219107,DB00829,Diazepam
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],1.1,220371,DB00829,Diazepam
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],37.4,220372,DB00829,Diazepam
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],0.7,220373,DB00829,Diazepam
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],3.2,220374,DB00829,Diazepam
,27469324,hepatocellularity,"The hepatocellularity for minipig was determined as 124 Mcells/g liver, similar to the values reported for human.",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[Mcells] / [g],124,220375,DB00829,Diazepam
,9113346,"dissociation constant, Kd,1","The highest binding affinity for dansylsarcosine was observed with HSA (dissociation constant, Kd,1 = 0.5 microM), while it was lowest in the mouse (Kd,1 = 18 microM).",Determination of protein binding of troglitazone stereoisomers by fluorometric titration. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113346/),μM,0.5,221049,DB00829,Diazepam
,9113346,"Kd,1","The highest binding affinity for dansylsarcosine was observed with HSA (dissociation constant, Kd,1 = 0.5 microM), while it was lowest in the mouse (Kd,1 = 18 microM).",Determination of protein binding of troglitazone stereoisomers by fluorometric titration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113346/),μM,18,221050,DB00829,Diazepam
,9113346,Ki,"The Ki values for KK and ddY mouse plasma and mouse and rat albumin were in the range 2-15 microM, and there were no large variations among stereoisomers, the maximum differences being twofold.",Determination of protein binding of troglitazone stereoisomers by fluorometric titration. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113346/),μM,2-15,221051,DB00829,Diazepam
,24783509,m,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,453.3,221398,DB00829,Diazepam
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,447.2,221399,DB00829,Diazepam
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,327.4,221400,DB00829,Diazepam
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,285.1,221401,DB00829,Diazepam
,24783509,m/z,"The detector was operated in selected Reaction-monitoring mode at m/z 453.3-->230.1 for repaglinide, m/z 447.2-->327.4 for pravastatin sodium and m/z 285.1-->192.9 for diazepam as the internal standard.",[Simultaneous determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and its application on pharmacokinetic interactions study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783509/),,192.9,221402,DB00829,Diazepam
,12742689,ICRs,The ICRs ranged from 0.002 (flunitrazepam) to 0.049 (flurazepam).,A study into the rate of incorporation of eight benzodiazepines into rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742689/),,0.002,222417,DB00829,Diazepam
,12742689,ICRs,The ICRs ranged from 0.002 (flunitrazepam) to 0.049 (flurazepam).,A study into the rate of incorporation of eight benzodiazepines into rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742689/),,0.049,222418,DB00829,Diazepam
,6434219,elimination t1/2,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,58,222575,DB00829,Diazepam
,6434219,elimination t1/2,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,49,222576,DB00829,Diazepam
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.20,222577,DB00829,Diazepam
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.24,222578,DB00829,Diazepam
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),,168,222579,DB00829,Diazepam
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),,168,222580,DB00829,Diazepam
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[μg] / [h·ml],5.63,222581,DB00829,Diazepam
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[μg] / [h·ml],4.81,222582,DB00829,Diazepam
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,13.2,222583,DB00829,Diazepam
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,12.7,222584,DB00829,Diazepam
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.33,222585,DB00829,Diazepam
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.36,222586,DB00829,Diazepam
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,15.9,222587,DB00829,Diazepam
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,18.5,222588,DB00829,Diazepam
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.1,222589,DB00829,Diazepam
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.8,222590,DB00829,Diazepam
,1817958,half-life (t 1/2 alpha),After intravenous administration initial distribution was rapid with a mean half-life (t 1/2 alpha) of 0.06 +/- 0.03 h followed by a terminal half-life (t 1/2 beta or gamma) of 1.5 +/- 0.3 h.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),h,0.06,222906,DB00829,Diazepam
,1817958,terminal half-life (t 1/2 beta or,After intravenous administration initial distribution was rapid with a mean half-life (t 1/2 alpha) of 0.06 +/- 0.03 h followed by a terminal half-life (t 1/2 beta or gamma) of 1.5 +/- 0.3 h.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),h,1.5,222907,DB00829,Diazepam
,1817958,gamma),After intravenous administration initial distribution was rapid with a mean half-life (t 1/2 alpha) of 0.06 +/- 0.03 h followed by a terminal half-life (t 1/2 beta or gamma) of 1.5 +/- 0.3 h.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),h,1.5,222908,DB00829,Diazepam
,1817958,Volume of distribution,Volume of distribution was 0.62 +/- 0.27 l/kg.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),[l] / [kg],0.62,222909,DB00829,Diazepam
,1817958,terminal half-life,Mean terminal half-life was 2.8 +/- 1.7 h.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),h,2.8,222910,DB00829,Diazepam
,1817958,absolute bioavailability,The absolute bioavailability of intramuscular midazolam was calculated in 11 patients as 87 +/- 18%.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),%,87,222911,DB00829,Diazepam
,17847064,limit of detection (LOD),The limit of detection (LOD) was 0.3 ng/ml.,Development and validation of a gas chromatography-mass spectrometry method for the determination of phenazopyridine in rat plasma: application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847064/),[ng] / [ml],0.3,225038,DB00829,Diazepam
>,17847064,recoveries,The recoveries for all samples were >90%.,Development and validation of a gas chromatography-mass spectrometry method for the determination of phenazopyridine in rat plasma: application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847064/),%,90,225039,DB00829,Diazepam
,17847064,T(max),"The main pharmacokinetic parameters obtained were T(max) = (0.35+/-0.01) h, C(max) = (0.396+/-0.079) microg/ml, AUC = (0.373+/-0.065) h microg/ml and CL = (94.2+/-5.9) ml/g/h.",Development and validation of a gas chromatography-mass spectrometry method for the determination of phenazopyridine in rat plasma: application to the pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847064/),h,0.35,225040,DB00829,Diazepam
,17847064,C(max),"The main pharmacokinetic parameters obtained were T(max) = (0.35+/-0.01) h, C(max) = (0.396+/-0.079) microg/ml, AUC = (0.373+/-0.065) h microg/ml and CL = (94.2+/-5.9) ml/g/h.",Development and validation of a gas chromatography-mass spectrometry method for the determination of phenazopyridine in rat plasma: application to the pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847064/),[μg] / [ml],0.396,225041,DB00829,Diazepam
,17847064,AUC,"The main pharmacokinetic parameters obtained were T(max) = (0.35+/-0.01) h, C(max) = (0.396+/-0.079) microg/ml, AUC = (0.373+/-0.065) h microg/ml and CL = (94.2+/-5.9) ml/g/h.",Development and validation of a gas chromatography-mass spectrometry method for the determination of phenazopyridine in rat plasma: application to the pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847064/),[h·μg] / [ml],0.373,225042,DB00829,Diazepam
,17847064,CL,"The main pharmacokinetic parameters obtained were T(max) = (0.35+/-0.01) h, C(max) = (0.396+/-0.079) microg/ml, AUC = (0.373+/-0.065) h microg/ml and CL = (94.2+/-5.9) ml/g/h.",Development and validation of a gas chromatography-mass spectrometry method for the determination of phenazopyridine in rat plasma: application to the pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17847064/),[ml] / [g·h],94.2,225043,DB00829,Diazepam
,27262994,flow rate,"The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1mm×50mm, 1.7μm) using gradient elution with a mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of 0.4mL/min.","Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),[ml] / [min],0.4,226496,DB00829,Diazepam
,27262994,m,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 299.2→150.1 for vortioxetine, m/z 407.2→100.3 for carvedilol, m/z 423.2→100.1 for 4-hydroxyphenyl carvedilol and m/z 285.2→193.1 for diazepam (IS) using a positive electrospray ionization interface.","Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),,423.2,226497,DB00829,Diazepam
,27262994,Total time,Total time for each chromatograph was 3.0min.,"Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),min,3.0,226498,DB00829,Diazepam
,2567646,volume of distribution,The volume of distribution of alprazolam and triazolam is approximately 1L.,Pharmacokinetics of the newer benzodiazepines. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),l,1,228435,DB00829,Diazepam
,2567646,elimination half-life,"Mean alprazolam elimination half-life in healthy adult subjects ranges from 9.5 to 12 hours; liver disease prolongs alprazolam elimination, but renal insufficiency does not.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,9.5 to 12,228436,DB00829,Diazepam
,2567646,elimination half-life,"The elimination half-life of triazolam ranges between 1.8 and 5.9 hours, while that of the conjugated metabolites is short, approximately 3.8 hours.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,1.8 and 5.9,228437,DB00829,Diazepam
,2567646,elimination half-life,"The elimination half-life of triazolam ranges between 1.8 and 5.9 hours, while that of the conjugated metabolites is short, approximately 3.8 hours.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,3.8,228438,DB00829,Diazepam
,11381567,brain:plasma partition coefficient,"For diazepam, the estimated brain:plasma partition coefficient was 2.67, and the first and second compartments filled with half-lives of 2.2 and 0.5 min, respectively.",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),,2.67,228911,DB00829,Diazepam
,11381567,half-lives,"For diazepam, the estimated brain:plasma partition coefficient was 2.67, and the first and second compartments filled with half-lives of 2.2 and 0.5 min, respectively.",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),min,2.2,228912,DB00829,Diazepam
,11381567,half-lives,"For diazepam, the estimated brain:plasma partition coefficient was 2.67, and the first and second compartments filled with half-lives of 2.2 and 0.5 min, respectively.",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),min,0.5,228913,DB00829,Diazepam
,11381567,half-lives,"The changes in cerebral blood flow were best described by a previously published a dynamic model that incorporated long half-lives for drug dissociation from the benzodiazepine receptor (13.3 and 5.5 min for midazolam and diazepam, respectively).",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),min,13.3,228914,DB00829,Diazepam
,11381567,half-lives,"The changes in cerebral blood flow were best described by a previously published a dynamic model that incorporated long half-lives for drug dissociation from the benzodiazepine receptor (13.3 and 5.5 min for midazolam and diazepam, respectively).",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),min,5.5,228915,DB00829,Diazepam
,9839087,distribution volume,"At steady-state, acamprosate has a moderate distribution volume of about 20L.",Clinical pharmacokinetics of acamprosate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),l,20,229746,DB00829,Diazepam
,9839087,terminal,The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion.,Clinical pharmacokinetics of acamprosate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),h,3,229747,DB00829,Diazepam
,9839087,accumulation ratio,"The pharmacokinetics of acamprosate administered as an enteric-coated tablets are time- and dose-independent, and its accumulation ratio is about 2.4 at steady-state.",Clinical pharmacokinetics of acamprosate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),,2.4,229748,DB00829,Diazepam
,3877295,terminal half-life,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),min,286,230796,DB00829,Diazepam
,3877295,clearance,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),[ml] / [min],1803,230797,DB00829,Diazepam
,3877295,volume of distribution,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),l,755,230798,DB00829,Diazepam
,23561287,absolute bioavailability,Exposure following administration of DZP IN solution (absolute bioavailability - 97%) was greater than the IN suspension (absolute bioavailability - 67%).,A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23561287/),%,97,231969,DB00829,Diazepam
,23561287,absolute bioavailability,Exposure following administration of DZP IN solution (absolute bioavailability - 97%) was greater than the IN suspension (absolute bioavailability - 67%).,A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23561287/),%,67,231970,DB00829,Diazepam
,23561287,Cmaxvalues,"Mean Cmaxvalues for the suspension and solution formulations were 221 ng/mL and 272 ng/mL, respectively.",A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23561287/),[ng] / [ml],221,231971,DB00829,Diazepam
,23561287,Cmaxvalues,"Mean Cmaxvalues for the suspension and solution formulations were 221 ng/mL and 272 ng/mL, respectively.",A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23561287/),[ng] / [ml],272,231972,DB00829,Diazepam
,23561287,time to maximum concentration (Tmax),"Median time to maximum concentration (Tmax) was 1h and 1.5h for suspension and solution formulation, respectively.",A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23561287/),h,1,231973,DB00829,Diazepam
,23561287,time to maximum concentration (Tmax),"Median time to maximum concentration (Tmax) was 1h and 1.5h for suspension and solution formulation, respectively.",A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23561287/),h,1.5,231974,DB00829,Diazepam
,26670364,flow rate,The separation was achieved on a µ-Bondapak C18 HPLC column using sodium acetate buffer solution (0.01 M)/acetonitrile (58/42 v/v) at pH 5 ± 0.1 and flow rate of 1.9 mL/min.,A Rapid and Sensitive HPLC Method for Quantitation of Paclitaxel in Biological Samples using Liquid-Liquid Extraction and UV Detection: Application to Pharmacokinetics and Tissues Distribution Study of Paclitaxel Loaded Targeted Polymeric Micelles in Tumor Bearing Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670364/),[ml] / [min],1.9,234562,DB00829,Diazepam
,26670364,recoveries,The mean recoveries of the drug after plasma extraction was 87.4% ± 3.6 while those of tissue homogenates ranged from 62.1± 4.5 to 75.5± 3.2 depending on the type of tissues studied.,A Rapid and Sensitive HPLC Method for Quantitation of Paclitaxel in Biological Samples using Liquid-Liquid Extraction and UV Detection: Application to Pharmacokinetics and Tissues Distribution Study of Paclitaxel Loaded Targeted Polymeric Micelles in Tumor Bearing Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670364/),%,87.4,234563,DB00829,Diazepam
,26670364,recoveries,The mean recoveries of the drug after plasma extraction was 87.4% ± 3.6 while those of tissue homogenates ranged from 62.1± 4.5 to 75.5± 3.2 depending on the type of tissues studied.,A Rapid and Sensitive HPLC Method for Quantitation of Paclitaxel in Biological Samples using Liquid-Liquid Extraction and UV Detection: Application to Pharmacokinetics and Tissues Distribution Study of Paclitaxel Loaded Targeted Polymeric Micelles in Tumor Bearing Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670364/),%,62.1,234564,DB00829,Diazepam
,26670364,recoveries,The mean recoveries of the drug after plasma extraction was 87.4% ± 3.6 while those of tissue homogenates ranged from 62.1± 4.5 to 75.5± 3.2 depending on the type of tissues studied.,A Rapid and Sensitive HPLC Method for Quantitation of Paclitaxel in Biological Samples using Liquid-Liquid Extraction and UV Detection: Application to Pharmacokinetics and Tissues Distribution Study of Paclitaxel Loaded Targeted Polymeric Micelles in Tumor Bearing Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670364/),%,75.5,234565,DB00829,Diazepam
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.7,235671,DB00829,Diazepam
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,10.9,235672,DB00829,Diazepam
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.46,235673,DB00829,Diazepam
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.72,235674,DB00829,Diazepam
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,58,235675,DB00829,Diazepam
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,39,235676,DB00829,Diazepam
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.42,235677,DB00829,Diazepam
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.30,235678,DB00829,Diazepam
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.8,235679,DB00829,Diazepam
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,15.3,235680,DB00829,Diazepam
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.03,235681,DB00829,Diazepam
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.07,235682,DB00829,Diazepam
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.66,235683,DB00829,Diazepam
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.60,235684,DB00829,Diazepam
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.8,235685,DB00829,Diazepam
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.5,235686,DB00829,Diazepam
,6827475,LD50,"In an animal model used to assess the effect of cimetidine on acetaminophen toxicity, the LD50 of acetaminophen alone in Charles River CD-1 mice was 480 mg/kg (95% confidence interval: 436-528 mg/kg).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[mg] / [kg],480,235687,DB00829,Diazepam
,32292480,m/z,"Under the positive ion electrospray ionization (ESI) source conditions, the mass transfer pairs of enasidenib were monitored by multiple reaction monitoring (MRM) to be m/z 474.2 ⟶ 456.1 and m/z 474.2 ⟶ 267.0, and the IS mass transfer pairs were m/z 285.0 ⟶ 154.0.",Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32292480/),⟶,474.2,236058,DB00829,Diazepam
,32292480,m/z,"Under the positive ion electrospray ionization (ESI) source conditions, the mass transfer pairs of enasidenib were monitored by multiple reaction monitoring (MRM) to be m/z 474.2 ⟶ 456.1 and m/z 474.2 ⟶ 267.0, and the IS mass transfer pairs were m/z 285.0 ⟶ 154.0.",Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32292480/),⟶,456.1,236059,DB00829,Diazepam
,32292480,m/z,"Under the positive ion electrospray ionization (ESI) source conditions, the mass transfer pairs of enasidenib were monitored by multiple reaction monitoring (MRM) to be m/z 474.2 ⟶ 456.1 and m/z 474.2 ⟶ 267.0, and the IS mass transfer pairs were m/z 285.0 ⟶ 154.0.",Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32292480/),⟶,474.2,236060,DB00829,Diazepam
,32292480,m/z,"Under the positive ion electrospray ionization (ESI) source conditions, the mass transfer pairs of enasidenib were monitored by multiple reaction monitoring (MRM) to be m/z 474.2 ⟶ 456.1 and m/z 474.2 ⟶ 267.0, and the IS mass transfer pairs were m/z 285.0 ⟶ 154.0.",Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32292480/),⟶,267.0,236061,DB00829,Diazepam
,32292480,m/z,"Under the positive ion electrospray ionization (ESI) source conditions, the mass transfer pairs of enasidenib were monitored by multiple reaction monitoring (MRM) to be m/z 474.2 ⟶ 456.1 and m/z 474.2 ⟶ 267.0, and the IS mass transfer pairs were m/z 285.0 ⟶ 154.0.",Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32292480/),⟶,285.0,236062,DB00829,Diazepam
,32292480,m/z,"Under the positive ion electrospray ionization (ESI) source conditions, the mass transfer pairs of enasidenib were monitored by multiple reaction monitoring (MRM) to be m/z 474.2 ⟶ 456.1 and m/z 474.2 ⟶ 267.0, and the IS mass transfer pairs were m/z 285.0 ⟶ 154.0.",Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32292480/),⟶,154.0,236063,DB00829,Diazepam
,32095471,flow rate,"After liquid-liquid extraction (LLE) using 1.2 ml of ethyl acetate:n-hexane (80:20, v/v), diazepam and IS were eluted on a Phenomenex Cadenza CD-C18 column (150 × 3.0 mm, 3 µm) with an isocratic mobile phase (10 mM ammonium acetate in water:methanol [5:95, v/v]) at a flow rate of 0.4 mL/min.",Development of a simple and sensitive HPLC-MS/MS method for determination of diazepam in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095471/),[ml] / [min],0.4,236129,DB00829,Diazepam
,32095471,peak retention time,"The peak retention time was 2.32 min for diazepam and 2.01 min for IS, respectively.",Development of a simple and sensitive HPLC-MS/MS method for determination of diazepam in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095471/),min,2.32,236130,DB00829,Diazepam
,32095471,peak retention time,"The peak retention time was 2.32 min for diazepam and 2.01 min for IS, respectively.",Development of a simple and sensitive HPLC-MS/MS method for determination of diazepam in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095471/),min,2.01,236131,DB00829,Diazepam
>,32095471,S/N,"The lower limit of quantitation (LLOQ) was 0.5 ng/mL (S/N > 10) using 50 µL of plasma, and no interferences were observed in chromatograms.",Development of a simple and sensitive HPLC-MS/MS method for determination of diazepam in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095471/),,10,236132,DB00829,Diazepam
,2896126,volume of distribution,"Mean kinetic variables for intravenous chlordesmethyldiazepam were: volume of distribution, 1.71 l.kg-1; elimination half-life, 113 h; total clearance, 0.21 ml.min-1.kg-1; cumulative excretion of lorazepam glucuronide 24.2% of the dose.",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),[l] / [kg],1.71,236519,DB00829,Diazepam
,2896126,elimination half-life,"Mean kinetic variables for intravenous chlordesmethyldiazepam were: volume of distribution, 1.71 l.kg-1; elimination half-life, 113 h; total clearance, 0.21 ml.min-1.kg-1; cumulative excretion of lorazepam glucuronide 24.2% of the dose.",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),h,113,236520,DB00829,Diazepam
,2896126,total clearance,"Mean kinetic variables for intravenous chlordesmethyldiazepam were: volume of distribution, 1.71 l.kg-1; elimination half-life, 113 h; total clearance, 0.21 ml.min-1.kg-1; cumulative excretion of lorazepam glucuronide 24.2% of the dose.",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),[ml] / [kg·min],0.21,236521,DB00829,Diazepam
,2896126,lag time,"Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops).",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),min,15.5,236522,DB00829,Diazepam
,2896126,lag time,"Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops).",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),min,4.2,236523,DB00829,Diazepam
,2896126,apparent absorption half-life,"Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops).",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),h,1.5,236524,DB00829,Diazepam
,2896126,apparent absorption half-life,"Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops).",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),h,1.1,236525,DB00829,Diazepam
,2896126,Bioavailability,Bioavailability was 77% for tablets and 79% for drops.,Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),%,77,236526,DB00829,Diazepam
,2896126,Bioavailability,Bioavailability was 77% for tablets and 79% for drops.,Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),%,79,236527,DB00829,Diazepam
,31380858,run time,"LC separation was achieved on Waters XBrige C18 column (50 mm × 2.1 mm, 3.5 μm) under gradient conditions in a run time of 5 min.","A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31380858/),min,5,236744,DB00829,Diazepam
,31380858,m,"Multiple reaction monitoring transitions were at m/z 408.2 → 339.2 for ANL, 558.2 → 433.2 for CER, 441.0 → 138.0 for IBR, 285.0 → 193.1 for diazepam (internal standard), respectively.","A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31380858/),,408.2,236745,DB00829,Diazepam
,31380858,m,"Multiple reaction monitoring transitions were at m/z 408.2 → 339.2 for ANL, 558.2 → 433.2 for CER, 441.0 → 138.0 for IBR, 285.0 → 193.1 for diazepam (internal standard), respectively.","A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31380858/),,339.2,236746,DB00829,Diazepam
,31380858,m,"Multiple reaction monitoring transitions were at m/z 408.2 → 339.2 for ANL, 558.2 → 433.2 for CER, 441.0 → 138.0 for IBR, 285.0 → 193.1 for diazepam (internal standard), respectively.","A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31380858/),,558.2,236747,DB00829,Diazepam
,31380858,m,"Multiple reaction monitoring transitions were at m/z 408.2 → 339.2 for ANL, 558.2 → 433.2 for CER, 441.0 → 138.0 for IBR, 285.0 → 193.1 for diazepam (internal standard), respectively.","A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31380858/),,441.0,236748,DB00829,Diazepam
,31380858,m,"Multiple reaction monitoring transitions were at m/z 408.2 → 339.2 for ANL, 558.2 → 433.2 for CER, 441.0 → 138.0 for IBR, 285.0 → 193.1 for diazepam (internal standard), respectively.","A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31380858/),,285.0,236749,DB00829,Diazepam
,6125154,elimination half-life,"Values of elimination half-life were 6.5, 7.0, and 17.8 h, respectively.",Electron capture GLC analysis of the thienodiazepine clotiazepam. Preliminary pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125154/),h,6.5,236869,DB00829,Diazepam
,6125154,elimination half-life,"Values of elimination half-life were 6.5, 7.0, and 17.8 h, respectively.",Electron capture GLC analysis of the thienodiazepine clotiazepam. Preliminary pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125154/),h,7.0,236870,DB00829,Diazepam
,6125154,elimination half-life,"Values of elimination half-life were 6.5, 7.0, and 17.8 h, respectively.",Electron capture GLC analysis of the thienodiazepine clotiazepam. Preliminary pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125154/),h,17.8,236871,DB00829,Diazepam
,30230386,zeta potential,"MME2 composed of oleic acid (5), surfactant mixture (50), water (45), and chitosan (0.5) showed size of 96.45 nm, PDI 0.21 and zeta potential 13.52 mV.","Brain targeting of chitosan-based diazepam mucoadhesive microemulsions via nasal route: formulation optimization, characterization, pharmacokinetic and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30230386/),mv,13.52,237022,DB00829,Diazepam
,30230386,flux,MME2 showed significantly high flux of 846.96 ± 34 µg/cm2/h and AUCbrain 1206.49 ± 145.8.,"Brain targeting of chitosan-based diazepam mucoadhesive microemulsions via nasal route: formulation optimization, characterization, pharmacokinetic and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30230386/),[μg] / [cm2·h],846.96,237023,DB00829,Diazepam
,30230386,AUCbrain,MME2 showed significantly high flux of 846.96 ± 34 µg/cm2/h and AUCbrain 1206.49 ± 145.8.,"Brain targeting of chitosan-based diazepam mucoadhesive microemulsions via nasal route: formulation optimization, characterization, pharmacokinetic and pharmacodynamic evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30230386/),,1206.49,237024,DB00829,Diazepam
,30230386,drug targeting efficiency,The drug targeting efficiency (314%) and direct nose-to-brain transport (68.1%) of MME2 were significantly high compared to Calmpose (i.v) and ME.,"Brain targeting of chitosan-based diazepam mucoadhesive microemulsions via nasal route: formulation optimization, characterization, pharmacokinetic and pharmacodynamic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30230386/),%,314,237025,DB00829,Diazepam
,3621584,relative oral/intramuscular bioavailability,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),%,13,237079,DB00829,Diazepam
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.6,237080,DB00829,Diazepam
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.7,237081,DB00829,Diazepam
,3621584,steady-state concentrations,"The relative oral/intramuscular bioavailability of amitriptyline was only 13%, and the steady-state concentrations of this drug on four consecutive days were acutely subtherapeutic (i.e., 3.6, 3.7, 3.9, and 3.7 micrograms/L).",Decreased drug absorption in a patient with Behçet's syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621584/),μ,3.9,237082,DB00829,Diazepam
,19801,plasma half-life (t1/2),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),h,53,237710,DB00829,Diazepam
,19801,elimination coefficient (Kbeta),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),1/[h],0.0147,237711,DB00829,Diazepam
,19801,elimination coefficient (Kbeta),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),[ng] / [ml],884,237712,DB00829,Diazepam
,19801,concentration (Css),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),1/[h],0.0147,237713,DB00829,Diazepam
,19801,apparent volume of distribution (Vbeta),"The plasma half-life (t1/2), the elimination coefficient (Kbeta), the concentration (Css), and the apparent volume of distribution (Vbeta) were calculated at steady state, and the mean values +/- SEM were 53 +/- 6 h, 0.0147 +/- 0.0013 h-1, 884 +/- 73 ng/ml, and 1.13 +/- 0.08 1/kg, respectively.",Pharmacokinetics of N-desmethyldiazepam in healthy volunteers after single daily doses of dipotassium chlorazepate. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801/),[1] / [kg],1.13,237714,DB00829,Diazepam
,2908106,ED50,"The ED50 of the drug was 12 mg/kg at 1 min against pentetrazole-induced convulsions (45 mg/kg i.v.), it reached a minimum at 1 h (2.0 mg/kg) and rose to 2.7 mg/kg at 2 h.","Clorazepate, correlation between metabolism and anticonvulsant activity. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908106/),[mg] / [kg],12,239133,DB00829,Diazepam
,2908106,ED50,"The ED50 of the drug was 12 mg/kg at 1 min against pentetrazole-induced convulsions (45 mg/kg i.v.), it reached a minimum at 1 h (2.0 mg/kg) and rose to 2.7 mg/kg at 2 h.","Clorazepate, correlation between metabolism and anticonvulsant activity. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908106/),[mg] / [kg],2.7,239134,DB00829,Diazepam
more,26149247,Recoveries,Recoveries of galangin and IS were more than 78.3%.,Determination of galangin in rat plasma by UPLC and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149247/),%,78.3,239329,DB00829,Diazepam
,1783998,maximum serum concentration,The average maximum serum concentration (50 ng/mL) was reached in 29 min.,Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ng] / [ml],50,240801,DB00829,Diazepam
,1783998,volume of distribution,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[l] / [kg],1.5,240802,DB00829,Diazepam
,1783998,systemic clearance,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[l] / [kg],1.5,240803,DB00829,Diazepam
,1783998,systemic clearance,"The volume of distribution and systemic clearance, assuming 100% bioavailability, were 1.5 L/kg and 19.4 mL/min/kg, respectively.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ml] / [kg·min],19.4,240804,DB00829,Diazepam
,1783998,maximum concentration,"The percentage of diazepam unbound to serum proteins was 4.6% and, therefore, the maximum concentration of free diazepam was 2.3 ng/mL.",Pharmacokinetics of diazepam intramuscularly administered to rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783998/),[ng] / [ml],2.3,240805,DB00829,Diazepam
,3871765,half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,1-3,240991,DB00829,Diazepam
,3871765,plasma half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,7-15,240992,DB00829,Diazepam
,10677836,retention times,"The assay produces sharp peaks with retention times of 6.2 and 15 min for rifampin and diazepam, respectively.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),min,6.2,241328,DB00829,Diazepam
,10677836,retention times,"The assay produces sharp peaks with retention times of 6.2 and 15 min for rifampin and diazepam, respectively.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),min,15,241329,DB00829,Diazepam
,10677836,detection limits,"The detection limits for rifampin were 0.5 microgram/mL for plasma, 0.015 microgram/mL for BAL supernatants, and 0.03 microgram/mL for AC suspensions.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),[μg] / [ml],0.5,241330,DB00829,Diazepam
,10677836,detection limits,"The detection limits for rifampin were 0.5 microgram/mL for plasma, 0.015 microgram/mL for BAL supernatants, and 0.03 microgram/mL for AC suspensions.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),[μg] / [ml],0.015,241331,DB00829,Diazepam
,10677836,detection limits,"The detection limits for rifampin were 0.5 microgram/mL for plasma, 0.015 microgram/mL for BAL supernatants, and 0.03 microgram/mL for AC suspensions.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),[μg] / [ml],0.03,241332,DB00829,Diazepam
,7226707,Vdssl/kg,"While the free fraction of diazepam was identical in both races (0.02), volume of distribution at steady state (Vdss) was different when calculated as absolute volume (Vdss = 76.55 +/- 9.63 l in Caucasians and 54.96 +/- 4.55 l in Orientals, p = 0.04) and marginally significant when corrected for body weight (Vdssl/kg = 1.10 +/- 0.11 in Caucasian and 0.88 +/- 0.05 in Orientals, p = 0.07).",Diazepam effects and kinetics in Caucasians and Orientals. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226707/),,1.10,241902,DB00829,Diazepam
,7226707,Vdssl/kg,"While the free fraction of diazepam was identical in both races (0.02), volume of distribution at steady state (Vdss) was different when calculated as absolute volume (Vdss = 76.55 +/- 9.63 l in Caucasians and 54.96 +/- 4.55 l in Orientals, p = 0.04) and marginally significant when corrected for body weight (Vdssl/kg = 1.10 +/- 0.11 in Caucasian and 0.88 +/- 0.05 in Orientals, p = 0.07).",Diazepam effects and kinetics in Caucasians and Orientals. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226707/),,0.88,241903,DB00829,Diazepam
,7226707,t 1/2,"total body clearance (Cl), but not elimination half-life (t 1/2), was higher in Caucasians than Orientals, p less than 0.01; t 1/2 = 37.70 +2- 5.53 hr in Caucasians and 41.77 +/- 3.80 in Orientals).",Diazepam effects and kinetics in Caucasians and Orientals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226707/),h,37.70,241904,DB00829,Diazepam
,7226707,t 1/2,"total body clearance (Cl), but not elimination half-life (t 1/2), was higher in Caucasians than Orientals, p less than 0.01; t 1/2 = 37.70 +2- 5.53 hr in Caucasians and 41.77 +/- 3.80 in Orientals).",Diazepam effects and kinetics in Caucasians and Orientals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226707/),,41.77,241905,DB00829,Diazepam
,10719906,relative recoveries,The relative recoveries of nifedipine from plasma ranged from 91.0-107.3% whereas extraction recoveries were 88.6-93.3%.,Liquid chromatographic assay of nifedipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719906/),%,91.0-107.3,246019,DB00829,Diazepam
,10719906,extraction recoveries,The relative recoveries of nifedipine from plasma ranged from 91.0-107.3% whereas extraction recoveries were 88.6-93.3%.,Liquid chromatographic assay of nifedipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719906/),%,88.6-93.3,246020,DB00829,Diazepam
,8563769,S/R ratios,"The ratios of (S) to (R) glucuronide metabolites (S/R ratios) were 3.87 +/- 0.79 (mean +/- SD) and 3.52 +/- 0.60 in urine and plasma, respectively.",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),,3.87,246143,DB00829,Diazepam
,8563769,S/R ratios,"The ratios of (S) to (R) glucuronide metabolites (S/R ratios) were 3.87 +/- 0.79 (mean +/- SD) and 3.52 +/- 0.60 in urine and plasma, respectively.",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),,3.52,246144,DB00829,Diazepam
,8563769,half-life,"In these two atypical subjects, the half-life of (R,S) oxazepam was also markedly longer (14.7 and 15.9 h) than in the other subjects (8.1 +/- 3.2 h).",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),h,14.7,246145,DB00829,Diazepam
,8563769,half-life,"In these two atypical subjects, the half-life of (R,S) oxazepam was also markedly longer (14.7 and 15.9 h) than in the other subjects (8.1 +/- 3.2 h).",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),h,15.9,246146,DB00829,Diazepam
,8563769,half-life,"In these two atypical subjects, the half-life of (R,S) oxazepam was also markedly longer (14.7 and 15.9 h) than in the other subjects (8.1 +/- 3.2 h).",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),h,8.1,246147,DB00829,Diazepam
,8563769,apparent antimode,"The S/R-glucuronide ratio in 8 h pooled urine was bimodally distributed, with 10% of all subjects possessing ratios below an apparent antimode of 1.9.",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),,1.9,246148,DB00829,Diazepam
,6772370,Volume of distribution,"Volume of distribution of total DMDZ (range, 1.33 to 6.30 l/kg) and of unbound DMDZ after correction for protein binding (range, 43 to 243 l/kg) was larger in women than in men of all ages, and in the elderly as opposed to the young.",Desmethyldiazepam kinetics in the elderly after oral prazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6772370/),[l] / [kg],1.33 to 6.30,248494,DB00829,Diazepam
,6772370,protein binding,"Volume of distribution of total DMDZ (range, 1.33 to 6.30 l/kg) and of unbound DMDZ after correction for protein binding (range, 43 to 243 l/kg) was larger in women than in men of all ages, and in the elderly as opposed to the young.",Desmethyldiazepam kinetics in the elderly after oral prazepam. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6772370/),[l] / [kg],43 to 243,248495,DB00829,Diazepam
,6772370,Elimination half-life,"Elimination half-life (range, 29 to 224 hr) rose with age in men (r = 0.66, p < 0.01) but not in women (r = -0.02).",Desmethyldiazepam kinetics in the elderly after oral prazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6772370/),h,29 to 224,248496,DB00829,Diazepam
,6772370,Clearance of unbound,"Clearance of unbound DMDZ (range, 2.9 to 31.2 ml/min/kg) was greater in women than in men of all ages, and declined with age in men (r = -0.40) but not in women (r = -0.06).",Desmethyldiazepam kinetics in the elderly after oral prazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6772370/),[ml] / [kg·min],2.9 to 31.2,248497,DB00829,Diazepam
,42427,half-life,"The elimination of diazepam was significantly altered having a half-life of 37 h before and 18 h afterwards combined with a significant increase in total body clearance after the induction period, although the volume of distribution remained unaltered.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,37,249060,DB00829,Diazepam
,42427,half-life,"The elimination of diazepam was significantly altered having a half-life of 37 h before and 18 h afterwards combined with a significant increase in total body clearance after the induction period, although the volume of distribution remained unaltered.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,18,249061,DB00829,Diazepam
,42427,half-life,"The formation of the main metabolite N-desmethyldiazepam was not changed, but its elimination was increased having a half-life of 139 or 58 h respectively.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,139,249062,DB00829,Diazepam
,42427,half-life,"The formation of the main metabolite N-desmethyldiazepam was not changed, but its elimination was increased having a half-life of 139 or 58 h respectively.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,58,249063,DB00829,Diazepam
,6747022,Absolute bioavailability,Absolute bioavailability of DZ-SR averaged 0.98 +/- 0.06.,Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747022/),,0.98,250391,DB00829,Diazepam
,2858217,elimination half-life,"For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,43,251538,DB00829,Diazepam
,2858217,elimination half-life,"For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,38,251539,DB00829,Diazepam
,2858217,total clearance,"For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],0.41,251540,DB00829,Diazepam
,2858217,total clearance,"For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],0.47,251541,DB00829,Diazepam
,2858217,half-life,"Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,18,251542,DB00829,Diazepam
,2858217,half-life,"Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,12,251543,DB00829,Diazepam
,2858217,total clearance,"Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],0.8,251544,DB00829,Diazepam
,2858217,total clearance,"Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],1.3,251545,DB00829,Diazepam
,2858217,half-life,Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1).,"Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,13.4,251546,DB00829,Diazepam
,2858217,half-life,Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1).,"Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,13.5,251547,DB00829,Diazepam
,2858217,clearance,Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1).,"Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],1.5,251548,DB00829,Diazepam
,2858217,clearance,Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1).,"Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],1.4,251549,DB00829,Diazepam
,24925268,flow rate,The flow rate was set at 1.0 mL/min with a split ratio of 3:2.,Development and validation of an LC-MS/MS method for the determination of mesalazine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24925268/),[ml] / [min],1.0,253542,DB00829,Diazepam
,19231138,t(max),"Following the 5 and 10mg doses, the median t(max) were 20 and 30min and the mean C(max) were 134.3+/-62 and 247.6+/-61ng/mL.",Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231138/),min,20,253546,DB00829,Diazepam
,19231138,t(max),"Following the 5 and 10mg doses, the median t(max) were 20 and 30min and the mean C(max) were 134.3+/-62 and 247.6+/-61ng/mL.",Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231138/),min,30,253547,DB00829,Diazepam
,19231138,C(max),"Following the 5 and 10mg doses, the median t(max) were 20 and 30min and the mean C(max) were 134.3+/-62 and 247.6+/-61ng/mL.",Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231138/),[ng] / [ml],134.3,253548,DB00829,Diazepam
,19231138,C(max),"Following the 5 and 10mg doses, the median t(max) were 20 and 30min and the mean C(max) were 134.3+/-62 and 247.6+/-61ng/mL.",Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231138/),[ng] / [ml],247.6,253549,DB00829,Diazepam
,19231138,bioavailability,Estimated bioavailability was 75% for both doses.,Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231138/),%,75,253550,DB00829,Diazepam
,19231138,tolerability,Pain scores of 2 and 2.3 were observed following the 5 and 10mg doses; tolerability scores were 4.4 and 4.7.,Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231138/),,4.4,253551,DB00829,Diazepam
,19231138,tolerability,Pain scores of 2 and 2.3 were observed following the 5 and 10mg doses; tolerability scores were 4.4 and 4.7.,Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19231138/),,4.7,253552,DB00829,Diazepam
,7149375,Total body clearances,"Total body clearances of diazepam were between 6.94 and 9.56 ml/min/kg, and the half-life values between 2.52 and 21.6 hours.",Pharmacodynamic and pharmacokinetic properties of diazepam in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149375/),[ml] / [kg·min],6.94 and 9.56,253633,DB00829,Diazepam
,7149375,half-life,"Total body clearances of diazepam were between 6.94 and 9.56 ml/min/kg, and the half-life values between 2.52 and 21.6 hours.",Pharmacodynamic and pharmacokinetic properties of diazepam in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149375/),h,2.52 and 21.6,253634,DB00829,Diazepam
,7149375,volume of distribution at steady state,The volume of distribution at steady state was 1.56 to 2.94 L/kg.,Pharmacodynamic and pharmacokinetic properties of diazepam in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149375/),[l] / [kg],1.56 to 2.94,253635,DB00829,Diazepam
,10613621,plasma elimination half-life,The plasma elimination half-life values of diazepam (84.0 +/- 13.7 hours) and desmethyldiazepam (176.0 +/- 28.9 hours) in subjects of ml/ml were significantly longer than those (62.9 +/- 9.8 hours for diazepam; 132.1 +/- 24.9 hours for desmethyldiazepam; both P < .01) in subjects of wt/ml or those (20.0 +/- 10.8 hours for diazepam; 99.2.+/- 21.7 hours for desmethyldiazepam; both P < .01) in subjects of wt/wt.,Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),h,84.0,253793,DB00829,Diazepam
,10613621,plasma elimination half-life,The plasma elimination half-life values of diazepam (84.0 +/- 13.7 hours) and desmethyldiazepam (176.0 +/- 28.9 hours) in subjects of ml/ml were significantly longer than those (62.9 +/- 9.8 hours for diazepam; 132.1 +/- 24.9 hours for desmethyldiazepam; both P < .01) in subjects of wt/ml or those (20.0 +/- 10.8 hours for diazepam; 99.2.+/- 21.7 hours for desmethyldiazepam; both P < .01) in subjects of wt/wt.,Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),h,176.0,253794,DB00829,Diazepam
,10613621,plasma elimination half-life,The plasma elimination half-life values of diazepam (84.0 +/- 13.7 hours) and desmethyldiazepam (176.0 +/- 28.9 hours) in subjects of ml/ml were significantly longer than those (62.9 +/- 9.8 hours for diazepam; 132.1 +/- 24.9 hours for desmethyldiazepam; both P < .01) in subjects of wt/ml or those (20.0 +/- 10.8 hours for diazepam; 99.2.+/- 21.7 hours for desmethyldiazepam; both P < .01) in subjects of wt/wt.,Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),h,62.9,253795,DB00829,Diazepam
,10613621,plasma elimination half-life,The plasma elimination half-life values of diazepam (84.0 +/- 13.7 hours) and desmethyldiazepam (176.0 +/- 28.9 hours) in subjects of ml/ml were significantly longer than those (62.9 +/- 9.8 hours for diazepam; 132.1 +/- 24.9 hours for desmethyldiazepam; both P < .01) in subjects of wt/ml or those (20.0 +/- 10.8 hours for diazepam; 99.2.+/- 21.7 hours for desmethyldiazepam; both P < .01) in subjects of wt/wt.,Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),h,132.1,253796,DB00829,Diazepam
,10613621,plasma elimination half-life,The plasma elimination half-life values of diazepam (84.0 +/- 13.7 hours) and desmethyldiazepam (176.0 +/- 28.9 hours) in subjects of ml/ml were significantly longer than those (62.9 +/- 9.8 hours for diazepam; 132.1 +/- 24.9 hours for desmethyldiazepam; both P < .01) in subjects of wt/ml or those (20.0 +/- 10.8 hours for diazepam; 99.2.+/- 21.7 hours for desmethyldiazepam; both P < .01) in subjects of wt/wt.,Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),h,20.0,253797,DB00829,Diazepam
,10613621,plasma elimination half-life,The plasma elimination half-life values of diazepam (84.0 +/- 13.7 hours) and desmethyldiazepam (176.0 +/- 28.9 hours) in subjects of ml/ml were significantly longer than those (62.9 +/- 9.8 hours for diazepam; 132.1 +/- 24.9 hours for desmethyldiazepam; both P < .01) in subjects of wt/ml or those (20.0 +/- 10.8 hours for diazepam; 99.2.+/- 21.7 hours for desmethyldiazepam; both P < .01) in subjects of wt/wt.,Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),h,99.2.,253798,DB00829,Diazepam
,10613621,clearance,"As expected, the slowest mean clearance of diazepam was observed in the ml/ml subjects (2.8 +/- 0.9 mL/min) and the fastest in the wt/wt subjects (19.5 +/- 9.8 mL/min), with the wt/ml heterozygotes having an intermediate value (7.2 +/- 2.6 mL/min).",Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),[ml] / [min],2.8,253799,DB00829,Diazepam
,10613621,clearance,"As expected, the slowest mean clearance of diazepam was observed in the ml/ml subjects (2.8 +/- 0.9 mL/min) and the fastest in the wt/wt subjects (19.5 +/- 9.8 mL/min), with the wt/ml heterozygotes having an intermediate value (7.2 +/- 2.6 mL/min).",Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),[ml] / [min],19.5,253800,DB00829,Diazepam
,10613621,clearance,"As expected, the slowest mean clearance of diazepam was observed in the ml/ml subjects (2.8 +/- 0.9 mL/min) and the fastest in the wt/wt subjects (19.5 +/- 9.8 mL/min), with the wt/ml heterozygotes having an intermediate value (7.2 +/- 2.6 mL/min).",Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613621/),[ml] / [min],7.2,253801,DB00829,Diazepam
,18796223,limit of detection,The limit of detection is 0.3 ng/mL.,Determination of phenazopyridine in human plasma by GC-MS and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796223/),[ng] / [ml],0.3,254609,DB00829,Diazepam
more,18796223,Extraction efficiency,"Extraction efficiency is more than 90%, and recoveries are in the range of 92.65-96.21%.",Determination of phenazopyridine in human plasma by GC-MS and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796223/),%,90,254610,DB00829,Diazepam
,18796223,recoveries,"Extraction efficiency is more than 90%, and recoveries are in the range of 92.65-96.21%.",Determination of phenazopyridine in human plasma by GC-MS and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796223/),%,92.65-96.21,254611,DB00829,Diazepam
less,10794928,T(max)'s,Both DZ and CZ were absorbed very rapidly from 1% SGC/60% PG-30% EtOH-10% Water after IN single application; the T(max)'s were less than 2 min.,Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),min,2,255791,DB00829,Diazepam
,10794928,peak time,The absorption rate of MCA was relatively slower with the peak time of 13-32 min.,Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),min,13-32,255792,DB00829,Diazepam
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,77,255793,DB00829,Diazepam
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,45,255794,DB00829,Diazepam
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,79,255795,DB00829,Diazepam
,964288,"elimination half-life, T1/2(beta)","In younger patients (n = 5, age 29 - 35 years) the elimination half-life, T1/2(beta), of D was 33.9 +/- 10.6 h (mean +/- S.D.) after the single dose.",Comparison of the pharmacokinetics of diazepam after single and subchronic doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/964288/),h,33.9,258110,DB00829,Diazepam
,964288,T1/2(beta),After subchronic dosage in all patients T1/2(beta) showed a modest but significant prolongation (paired t-test p less than 0.01) to 52.9 +/- 17.4 h.,Comparison of the pharmacokinetics of diazepam after single and subchronic doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/964288/),h,52.9,258111,DB00829,Diazepam
,964288,total plasma clearance (Cl),"It was caused by a significant decrease (p = 0.016) in total plasma clearance (Cl), from 26.0 +/- 10.8 ml/min.",Comparison of the pharmacokinetics of diazepam after single and subchronic doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/964288/),[ml] / [min],26.0,258112,DB00829,Diazepam
,964288,T1/2(beta),"After pretreating rabbits with DD and maintaining a high DD plasma level, there was prolongation of T1/2(beta) from 2.7 h to 5.2 h, with a corresponding decrease of Cl from 101.6 ml/min to 23.4 ml/min.",Comparison of the pharmacokinetics of diazepam after single and subchronic doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/964288/),h,2.7,258113,DB00829,Diazepam
,964288,T1/2(beta),"After pretreating rabbits with DD and maintaining a high DD plasma level, there was prolongation of T1/2(beta) from 2.7 h to 5.2 h, with a corresponding decrease of Cl from 101.6 ml/min to 23.4 ml/min.",Comparison of the pharmacokinetics of diazepam after single and subchronic doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/964288/),h,5.2,258114,DB00829,Diazepam
,964288,Cl,"After pretreating rabbits with DD and maintaining a high DD plasma level, there was prolongation of T1/2(beta) from 2.7 h to 5.2 h, with a corresponding decrease of Cl from 101.6 ml/min to 23.4 ml/min.",Comparison of the pharmacokinetics of diazepam after single and subchronic doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/964288/),[ml] / [min],101.6,258115,DB00829,Diazepam
,964288,Cl,"After pretreating rabbits with DD and maintaining a high DD plasma level, there was prolongation of T1/2(beta) from 2.7 h to 5.2 h, with a corresponding decrease of Cl from 101.6 ml/min to 23.4 ml/min.",Comparison of the pharmacokinetics of diazepam after single and subchronic doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/964288/),[ml] / [min],23.4,258116,DB00829,Diazepam
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,53.7,258187,DB00829,Diazepam
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,42.3,258188,DB00829,Diazepam
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,73.9,258189,DB00829,Diazepam
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,52.6,258190,DB00829,Diazepam
,9278198,75% recovery,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258191,DB00829,Diazepam
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258192,DB00829,Diazepam
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,66.8,258193,DB00829,Diazepam
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,114.9,258194,DB00829,Diazepam
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,76.1,258195,DB00829,Diazepam
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],2.66,258196,DB00829,Diazepam
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],3.70,258197,DB00829,Diazepam
,9278198,redistribution (,"The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258198,DB00829,Diazepam
,9278198,"t1/2,lambda1","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258199,DB00829,Diazepam
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,16.8,258200,DB00829,Diazepam
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,143,258201,DB00829,Diazepam
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,92,258202,DB00829,Diazepam
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.25,258203,DB00829,Diazepam
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.16,258204,DB00829,Diazepam
,6124654,volume of distribution,"After a single 20-mg intravenous dose of CZP, mean kinetic variables for DMDZ were: volume of distribution, 1.24 l/kg; elimination half-life, 65 h; total clearance, 0.24 ml/min/kg.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),[l] / [kg],1.24,258525,DB00829,Diazepam
,6124654,elimination half-life,"After a single 20-mg intravenous dose of CZP, mean kinetic variables for DMDZ were: volume of distribution, 1.24 l/kg; elimination half-life, 65 h; total clearance, 0.24 ml/min/kg.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),h,65,258526,DB00829,Diazepam
,6124654,total clearance,"After a single 20-mg intravenous dose of CZP, mean kinetic variables for DMDZ were: volume of distribution, 1.24 l/kg; elimination half-life, 65 h; total clearance, 0.24 ml/min/kg.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),[ml] / [kg·min],0.24,258527,DB00829,Diazepam
,6124654,peak plasma level,"After oral administration of 20 mg CZP, appearance of DMDZ in the circulation was rapid; the mean peak plasma level was 356 ng/ml, reached an average of 0.9 h after dosage.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),[ng] / [ml],356,258528,DB00829,Diazepam
,6124654,peak DMDZ levels,"Mean peak DMDZ levels were 290 ng/ml, reaching an average of 2.7 h after dosage.","Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124654/),[ng] / [ml],290,258529,DB00829,Diazepam
,21721594,time to reach C(max) (t(max)),The median time to reach C(max) (t(max)) was consistent at 1 hour for each dose.,"Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21721594/),h,1,260285,DB00829,Diazepam
,21721594,overall bioavailability,"The geometric mean ratio (diazepam autoinjector/diazepam rectal gel) and 90% confidence intervals for diazepam C(max) and AUC(last) were 0.94 (0.84, 1.05) and 1.14 (1.08, 1.21), respectively, indicating that the overall bioavailability of the diazepam autoinjector was approximately 14% higher than that of diazepam rectal gel.","Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21721594/),%,14,260286,DB00829,Diazepam
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,100.8,261726,DB00829,Diazepam
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,219.9,261727,DB00829,Diazepam
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,34.7,261728,DB00829,Diazepam
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,103.1,261729,DB00829,Diazepam
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,30.8,261730,DB00829,Diazepam
,8904619,plasma elimination half-lives,"3. The plasma elimination half-lives of diazepam (100.8 +/- 32.3 h) and desmethyldiazepam (219.9 +/- 62.7 h) in PMs were significantly longer than those (34.7 +/- 23.0 h for diazepam, 103.1 +/- 25.9 h for desmethyldiazepam) of the 17 phenotyped extensive metabolizers (EM), and those (30.8 +/- 24.9 h for diazepam, 103.1 +/- 27.5 h for desmethyldiazepam) of the five genotyped EMs.",The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8904619/),h,103.1,261731,DB00829,Diazepam
,16531476,unbound fractions,"Both molecules were very highly bound to plasma proteins in all the tested species with unbound fractions in plasma in the range of 0.4 to 1.8% and 0.2 to 1.2% for deferasirox and Fe-[ICL670]2, respectively; binding of the iron complex was either similar or higher in all the species.","In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531476/),%,0.4 to 1.8,261788,DB00829,Diazepam
,16531476,unbound fractions,"Both molecules were very highly bound to plasma proteins in all the tested species with unbound fractions in plasma in the range of 0.4 to 1.8% and 0.2 to 1.2% for deferasirox and Fe-[ICL670]2, respectively; binding of the iron complex was either similar or higher in all the species.","In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531476/),%,0.2 to 1.2,261789,DB00829,Diazepam
,16531476,fraction,The high plasma protein binding was in line with a distribution mainly into the plasma fraction of blood; the fraction in plasma was around 100% for Fe-[ICL670]2 in all the species and 65 to 95% for deferasirox depending on the species.,"In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531476/),%,100,261790,DB00829,Diazepam
,16531476,fraction,The high plasma protein binding was in line with a distribution mainly into the plasma fraction of blood; the fraction in plasma was around 100% for Fe-[ICL670]2 in all the species and 65 to 95% for deferasirox depending on the species.,"In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531476/),%,65 to 95,261791,DB00829,Diazepam
,7357789,volume of distribution (Vd),"Based upon total (bound + free) diazepam concentrations, volume of distribution (Vd) ranged from 0.7 to 4.7 l/kg, and became larger both with increasing age and with female sex.",Diazepam disposition determinants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[l] / [kg],0.7 to 4.7,262614,DB00829,Diazepam
,7357789,Clearances,"Clearances of total (bound + free) diazepam in young and elderly females were nearly identical (0.51 and 0.48 ml/min/kg), but clearance was higher in young than elderly males (0.39 and 0.24 ml/min/kg, p less than 0.01).",Diazepam disposition determinants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[ml] / [kg·min],0.51,262615,DB00829,Diazepam
,7357789,Clearances,"Clearances of total (bound + free) diazepam in young and elderly females were nearly identical (0.51 and 0.48 ml/min/kg), but clearance was higher in young than elderly males (0.39 and 0.24 ml/min/kg, p less than 0.01).",Diazepam disposition determinants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[ml] / [kg·min],0.48,262616,DB00829,Diazepam
,7357789,clearance,"Clearances of total (bound + free) diazepam in young and elderly females were nearly identical (0.51 and 0.48 ml/min/kg), but clearance was higher in young than elderly males (0.39 and 0.24 ml/min/kg, p less than 0.01).",Diazepam disposition determinants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[ml] / [kg·min],0.39,262617,DB00829,Diazepam
,7357789,clearance,"Clearances of total (bound + free) diazepam in young and elderly females were nearly identical (0.51 and 0.48 ml/min/kg), but clearance was higher in young than elderly males (0.39 and 0.24 ml/min/kg, p less than 0.01).",Diazepam disposition determinants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[ml] / [kg·min],0.24,262618,DB00829,Diazepam
,7357789,unbound fraction,"The unbound fraction of diazepam in plasma (range, 0.9% to 2.7%) did not depend on sex, but was greater in the elderly than in the young.",Diazepam disposition determinants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),%,0.9,262619,DB00829,Diazepam
,7357789,unbound fraction,"The unbound fraction of diazepam in plasma (range, 0.9% to 2.7%) did not depend on sex, but was greater in the elderly than in the young.",Diazepam disposition determinants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),%,2.7,262620,DB00829,Diazepam
,7357789,Clearance of unbound diazepam (intrinsic clearance),"Clearance of unbound diazepam (intrinsic clearance) tended to be higher in the females than in the males of both age groups, and was higher in the young than in the elderly of both sexes (male: 29.9 and 14.9 ml/min/kg, p less than 0.005; female: 43.6 and 28.0 ml/min/kg, p less than 0.05).",Diazepam disposition determinants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[ml] / [kg·min],29.9,262621,DB00829,Diazepam
,7357789,Clearance of unbound diazepam (intrinsic clearance),"Clearance of unbound diazepam (intrinsic clearance) tended to be higher in the females than in the males of both age groups, and was higher in the young than in the elderly of both sexes (male: 29.9 and 14.9 ml/min/kg, p less than 0.005; female: 43.6 and 28.0 ml/min/kg, p less than 0.05).",Diazepam disposition determinants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[ml] / [kg·min],14.9,262622,DB00829,Diazepam
,7357789,Clearance of unbound diazepam (intrinsic clearance),"Clearance of unbound diazepam (intrinsic clearance) tended to be higher in the females than in the males of both age groups, and was higher in the young than in the elderly of both sexes (male: 29.9 and 14.9 ml/min/kg, p less than 0.005; female: 43.6 and 28.0 ml/min/kg, p less than 0.05).",Diazepam disposition determinants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[ml] / [kg·min],43.6,262623,DB00829,Diazepam
,7357789,Clearance of unbound diazepam (intrinsic clearance),"Clearance of unbound diazepam (intrinsic clearance) tended to be higher in the females than in the males of both age groups, and was higher in the young than in the elderly of both sexes (male: 29.9 and 14.9 ml/min/kg, p less than 0.005; female: 43.6 and 28.0 ml/min/kg, p less than 0.05).",Diazepam disposition determinants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357789/),[ml] / [kg·min],28.0,262624,DB00829,Diazepam
,33480487,time to reach the maximum plasma concentration (Tmax),The time to reach the maximum plasma concentration (Tmax) was markedly shorter with intra- rectal administration (45±26 min) than with intragastric administration (270±99 min).,Comparison of pharmacokinetics of intragastrically and intrarectally administered levetiracetam tablets in healthy non-epileptic dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480487/),min,45,262971,DB00829,Diazepam
,33480487,time to reach the maximum plasma concentration (Tmax),The time to reach the maximum plasma concentration (Tmax) was markedly shorter with intra- rectal administration (45±26 min) than with intragastric administration (270±99 min).,Comparison of pharmacokinetics of intragastrically and intrarectally administered levetiracetam tablets in healthy non-epileptic dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480487/),min,270,262972,DB00829,Diazepam
no more,29128277,recovery,"The recovery was no more than 77.06%, and the matrix effect, stability, dilution integrity tests were all satisfied the currently criterion.","A fast, sensitive, and high throughput method for the determination of esomeprazole in dog plasma by UHPLC-MS/MS: Application to formulation development of the compound preparation of esomeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128277/),%,77.06,264504,DB00829,Diazepam
more,8704938,Extraction recovery,Extraction recovery from serum proved to be more than 86%.,Simple high-performance liquid chromatographic separation of oxazepam and its diastereoisomeric glucuronides in serum. Applications in a pharmacokinetic study in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704938/),%,86,264657,DB00829,Diazepam
,3239381,penetration,"The penetration of diazepam and oxazepam from maternal serum to placental tissue in a 4 h period after drug administration was 31.5% and 49%, respectively, indicating a rapid transfer.",Pharmacokinetics and distribution of diazepam and oxazepam in early pregnancy. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239381/),%,31.5,264711,DB00829,Diazepam
,3239381,penetration,"The penetration of diazepam and oxazepam from maternal serum to placental tissue in a 4 h period after drug administration was 31.5% and 49%, respectively, indicating a rapid transfer.",Pharmacokinetics and distribution of diazepam and oxazepam in early pregnancy. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239381/),%,49,264712,DB00829,Diazepam
,26332539,time to Cmax (Tmax,"Increasing USL261 dose corresponded with increases in midazolam area under the concentration time curve (AUC) and maximum observed plasma concentration (Cmax ), with all doses demonstrating rapid median time to Cmax (Tmax ; 10-12 min).","Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332539/),min,10-12,265521,DB00829,Diazepam
,26332539,relative bioavailability,"USL261 also demonstrated increased absorption, with a 134% relative bioavailability, compared with the same MDZ-inj IN dose.","Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332539/),%,134,265522,DB00829,Diazepam
,31477360,heart rate,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],115,265920,DB00829,Diazepam
,31477360,respirations,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],18,265921,DB00829,Diazepam
,31477360,half-life,Serial concentrations demonstrated apparent first-order elimination with a half-life of 11.6 h.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265922,DB00829,Diazepam
,31477360,apparent,The apparent 11.6 hour half-life of hydroxychloroquine was shorter than previously described.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265923,DB00829,Diazepam
,1424419,plasma elimination half-life,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),h,26.0,268808,DB00829,Diazepam
,1424419,clearance,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),[ml] / [h·kg],22.5,268809,DB00829,Diazepam
,1424419,volume of distribution,"During the placebo session, the plasma elimination half-life, clearance, and volume of distribution of diazepam were 26.0 +/- 1.6 hours, 22.5 +/- 1.1 ml/hr/kg, and 0.82 +/- 0.04 L/kg, respectively.",Influence of lansoprazole treatment on diazepam plasma concentrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424419/),[l] / [kg],0.82,268810,DB00829,Diazepam
,19630071,flow rate,"After protein precipitation of 200 microL plasma with methanol, dipyridamole and diazepam (internal standard) were chromatographed on an Ultimate XB-C(18) (50 x 2.1 mm i.d, 3 microm) column with the mobile phase consisting of methanol-ammonium acetate (5 mM; 80 : 20, v/v) at a flow rate of 0.25 mL/min.",Quantitative determination of dipyridamole in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19630071/),[ml] / [min],0.25,269725,DB00829,Diazepam
,19630071,retention times,"The retention times of dipyridamole and diazepam were 1.4 and 1.2 min, respectively.",Quantitative determination of dipyridamole in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19630071/),min,1.4,269726,DB00829,Diazepam
,19630071,retention times,"The retention times of dipyridamole and diazepam were 1.4 and 1.2 min, respectively.",Quantitative determination of dipyridamole in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19630071/),min,1.2,269727,DB00829,Diazepam
,2514810,Peak plasma diazepam concentrations,"Peak plasma diazepam concentrations were significantly lower for NeoCalme vs Valium (247 vs 394 ng ml-1, p less than 0.001) and reached significantly later after the dose (1.62 vs 0.98 h, p less than 0.001).",Bioinequivalence of a generic brand of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514810/),[ng] / [ml],247,270314,DB00829,Diazepam
,2514810,Peak plasma diazepam concentrations,"Peak plasma diazepam concentrations were significantly lower for NeoCalme vs Valium (247 vs 394 ng ml-1, p less than 0.001) and reached significantly later after the dose (1.62 vs 0.98 h, p less than 0.001).",Bioinequivalence of a generic brand of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514810/),[ng] / [ml],394,270315,DB00829,Diazepam
,2514810,Peak plasma diazepam concentrations,"Peak plasma diazepam concentrations were significantly lower for NeoCalme vs Valium (247 vs 394 ng ml-1, p less than 0.001) and reached significantly later after the dose (1.62 vs 0.98 h, p less than 0.001).",Bioinequivalence of a generic brand of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514810/),,0,270316,DB00829,Diazepam
,2514810,Total area under the plasma concentration curve (AUC),"Total area under the plasma concentration curve (AUC) was also significantly lower for NeoCalme (6614 vs 7552 ng ml-1 x h, p less than 0.001), although AUC ratios for NeoCalme divided by Valium satisfied the '75-75' guidelines.",Bioinequivalence of a generic brand of diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514810/),[h·ng] / [ml],6614,270317,DB00829,Diazepam
,2514810,Total area under the plasma concentration curve (AUC),"Total area under the plasma concentration curve (AUC) was also significantly lower for NeoCalme (6614 vs 7552 ng ml-1 x h, p less than 0.001), although AUC ratios for NeoCalme divided by Valium satisfied the '75-75' guidelines.",Bioinequivalence of a generic brand of diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514810/),[h·ng] / [ml],7552,270318,DB00829,Diazepam
,6119204,half life of elimination (t1/2 beta),The half life of elimination (t1/2 beta) was significantly longer in the non-smoking volunteers than in the smokers: 54.7 +17.7 versus 29.8 +9.9 h (p less than 0.05).,Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119204/),h,54.7,271576,DB00829,Diazepam
,6119204,half life of elimination (t1/2 beta),The half life of elimination (t1/2 beta) was significantly longer in the non-smoking volunteers than in the smokers: 54.7 +17.7 versus 29.8 +9.9 h (p less than 0.05).,Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119204/),h,29.8,271577,DB00829,Diazepam
,6119204,Peak plasma concentrations (Cmax),"Peak plasma concentrations (Cmax) were higher in non-smokers than in smokers, 413 +106 micrograms/l and 245 +50 micrograms/l, respectively (p less than 0.05).",Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119204/),[μg] / [l],413,271578,DB00829,Diazepam
,6119204,Peak plasma concentrations (Cmax),"Peak plasma concentrations (Cmax) were higher in non-smokers than in smokers, 413 +106 micrograms/l and 245 +50 micrograms/l, respectively (p less than 0.05).",Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119204/),[μg] / [l],245,271579,DB00829,Diazepam
,7955810,peak plasma diazepam concentrations,"Compared with the control session, concurrent fluvoxamine intake was associated with increased mean peak plasma diazepam concentrations (from 108 to 143 ng/ml, geometric means, difference not significant), with a marked reduction in apparent oral diazepam clearance (from 0.40 to 0.14 ml/min/kg; p < 0.01) and with a prolongation in diazepam half-life (from 51 to 118 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),[ng] / [ml],108 to 143,272077,DB00829,Diazepam
,7955810,apparent oral diazepam clearance,"Compared with the control session, concurrent fluvoxamine intake was associated with increased mean peak plasma diazepam concentrations (from 108 to 143 ng/ml, geometric means, difference not significant), with a marked reduction in apparent oral diazepam clearance (from 0.40 to 0.14 ml/min/kg; p < 0.01) and with a prolongation in diazepam half-life (from 51 to 118 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),[ml] / [kg·min],0.,272078,DB00829,Diazepam
,7955810,apparent oral diazepam clearance,"Compared with the control session, concurrent fluvoxamine intake was associated with increased mean peak plasma diazepam concentrations (from 108 to 143 ng/ml, geometric means, difference not significant), with a marked reduction in apparent oral diazepam clearance (from 0.40 to 0.14 ml/min/kg; p < 0.01) and with a prolongation in diazepam half-life (from 51 to 118 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),[ml] / [kg·min],0,272079,DB00829,Diazepam
,7955810,half-life,"Compared with the control session, concurrent fluvoxamine intake was associated with increased mean peak plasma diazepam concentrations (from 108 to 143 ng/ml, geometric means, difference not significant), with a marked reduction in apparent oral diazepam clearance (from 0.40 to 0.14 ml/min/kg; p < 0.01) and with a prolongation in diazepam half-life (from 51 to 118 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),h,51 to 118,272080,DB00829,Diazepam
,7955810,time required,"Although peak plasma N-desmethyldiazepam levels were similar in the two sessions, the time required for the metabolite to reach a peak was longer during fluvoxamine intake than in the control session (206 versus 62 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),h,206,272081,DB00829,Diazepam
,7955810,time required,"Although peak plasma N-desmethyldiazepam levels were similar in the two sessions, the time required for the metabolite to reach a peak was longer during fluvoxamine intake than in the control session (206 versus 62 hours; p < 0.01).",Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955810/),h,62,272082,DB00829,Diazepam
,18499386,run time,"The analyte and internal standard (diazepam) were extracted from plasma (100 microl) by liquid-liquid extraction and separated on a C18 column using 10mM ammonium acetate buffer: methanol (15:85, v/v) as mobile phase in a run time of 3.0 min.",A rapid and sensitive LC-MS/MS assay to quantify yonkenafil in rat plasma with application to preclinical pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499386/),min,3.0,272852,DB00829,Diazepam
,18499386,limit of detection,The assay was linear over the concentration range 1.0-1000 ng/ml with a limit of detection of 0.20 ng/ml.,A rapid and sensitive LC-MS/MS assay to quantify yonkenafil in rat plasma with application to preclinical pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499386/),[ng] / [ml],0.20,272853,DB00829,Diazepam
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,118,273139,DB00829,Diazepam
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,310,273140,DB00829,Diazepam
,26519619,m/z,"The monitored transitions were set at m/z 391.14→271.10 for GL and m/z 285.08→193.10 for IS, respectively.",Pharmacokinetics and tissue distribution study of ginkgolide L in rats by ultra-high performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26519619/),,391.14,274070,DB00829,Diazepam
,26519619,m/z,"The monitored transitions were set at m/z 391.14→271.10 for GL and m/z 285.08→193.10 for IS, respectively.",Pharmacokinetics and tissue distribution study of ginkgolide L in rats by ultra-high performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26519619/),,271.10,274071,DB00829,Diazepam
,26519619,m/z,"The monitored transitions were set at m/z 391.14→271.10 for GL and m/z 285.08→193.10 for IS, respectively.",Pharmacokinetics and tissue distribution study of ginkgolide L in rats by ultra-high performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26519619/),,285.08,274072,DB00829,Diazepam
,26519619,m/z,"The monitored transitions were set at m/z 391.14→271.10 for GL and m/z 285.08→193.10 for IS, respectively.",Pharmacokinetics and tissue distribution study of ginkgolide L in rats by ultra-high performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26519619/),,193.10,274073,DB00829,Diazepam
,9091281,Elimination half-life (t1/2 beta),Elimination half-life (t1/2 beta) after a dose of 0.05-0.08 mg/kg (30-50 mg Diazepam per horse) was 7.5 to 13.2 h.,[Kinetics of elimination of diazepam after intravenous injection in horses]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091281/),h,7.5 to 13.2,274223,DB00829,Diazepam
,9091281,Total clearance (Cltot),Total clearance (Cltot) between 1.86 and 3.44 ml/min/kg was detected and apparent volume of distribution in steady state (Vdiss) was 1.98 to 2.25 l/kg.,[Kinetics of elimination of diazepam after intravenous injection in horses]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091281/),[ml] / [kg·min],1.86 and 3.44,274224,DB00829,Diazepam
,9091281,apparent volume of distribution in steady state (Vdiss),Total clearance (Cltot) between 1.86 and 3.44 ml/min/kg was detected and apparent volume of distribution in steady state (Vdiss) was 1.98 to 2.25 l/kg.,[Kinetics of elimination of diazepam after intravenous injection in horses]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091281/),[l] / [kg],1.98 to 2.25,274225,DB00829,Diazepam
,9091281,elimination half-life,Its elimination half-life was 14-16.5 hours.,[Kinetics of elimination of diazepam after intravenous injection in horses]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091281/),h,14-16.5,274226,DB00829,Diazepam
